Editorial Board

Cancer Studies and Molecular Medicine - Open Journal

Sajeed Abdul Rahuman, DNB, DMRT, MD, MBBS, MRC

Associate Professor
Regional Cancer Centre
Medical College Campus
Thiruvananthapuram 695011, Kerala, India

BiographyResearch InterestScientific ActivitiesPublications
Education and Training

• (2013) Phd Scholar Radiobiology, Faculty of Medicine, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (2002) DNB, Radiotherapy, Regional Cancer Centre, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (2001) Regional Cancer Centre, Trivandrum, University of Kerala, MD, Nov 2001, Radiotherapy Thiruvananthapuram, Kerala 695034, India
• (2000) DMRT, Radiotherapy, Regional Cancer Centre, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India
• (1993) MBBS, Govt. Medical College, Trivandrum, University of Kerala, Thiruvananthapuram, Kerala 695034, India

Professional Experience

•(2013-Present) Associate Professor, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2013-Present) Member, Faculty of Medicine, University of Kerala, Thiruvananthapuram
•(2010-2013) Assistant Professor, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2004-2010) Lecturer in Radiotherapy, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram
•(2003-2004) Specialist in Oncology, Insurance Medical Service
•(2002-2003) Research Medical Officer, Regional Cancer Centre( Deputation from Insurance Medical Service)
•(2001-2002) Assistant Insurance Medical Officer, Insurance Medical Service
•(1995-1996) Assistant Surgeon, Kerala Government Health Service

His research interests include: Clinical Radiobiology, Molecular Biology, Nano Medicine, Targeted Therapy.

Scientific papers published in indexed journals:


1. Sajeed A, Stephenson J, Beegum TR, Rasheed RA. Graves ophthalmopathy- Response to pulse intravenous methyl prednisolone and retro orbital radiation. Transworld Medical Journal. 2013; 1(3): 93-96.
2. Sajeed A, Geetha N, Mathews A, Jayasree K, Lijeesh AL, Haridas L. Rhabdomyosarcoma arising from mediastinal germ cell tumor - report of two cases. Transworld Medical Journal. 2013; 1(4): 141-143.
3. Sajeed A. Multicentric Epithelioid Hemangioendothelioma-An Entity with Danger of Misdiagnosis-A case report. Journal of Case Reports in Practice (JCRP). 2014; 2(3): 77-79.

Jian Pan, PhD

Associate Professor
Department of Hematology and Oncology
Childrens Hospital of Soochow University
303 Jingde Rd, Ping Jiang Qu, Suzhou, Jiangsu, China

BiographyResearch InterestScientific ActivitiesPublications

•(2001-2005) B.Sc. Biology , NanJing University, Jiansu Province, PR China
•(2005-2010) Ph.D. Immulogy, State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China


•(2010- Present) Associate professor, Department of Hematology and Oncology, Childrens Hospital of Soochow University, Suzhou, China
•(2010-Present) A guest professor of Translational Research Center, Second Hospital, The Second Clinical School, Nanjing Medical University, Nanjing, China
•8 years of extensive experiences in molecular oncology, hematology, leukemia and cell biologically associated research

His research interests include: Molecular oncology, hematology, leukemia and cell biologically associated research.

1. Wang NN, Li ZH, Zhao H, et al. Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells. International journal of molecular sciences. 2015; 16: 1266-1292. doi: 10.3390/ijms16011266
2. Tao YF, Xu LX, Lu J, et al. Early B-cell factor 3 ( EBF3 ) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia. J Exp Clin Cancer Res. 2015; 34: 4. doi: 10.1186/s13046-014-0118-1
3. Xu L, Li Z, Tao Y, et al. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway. J Exp Clin Cancer Res 2014; 33: 108. doi: 10.1186/s13046-014-0108-3
4. Pang L, Liang Y, Pan J, Wang JR, Chai YH, Zhao WL. Clinical Features and Prognostic Significance of TCF3-PBX1 Fusion Gene in Chinese Children with Acute Lymphoblastic Leukemia by Using a Modified ALL-BFM-95 Protocol. Pediatric hematology and oncology. 2014. doi: 10.3109/08880018.2014.983625
5. Cao L, Wang N, Pan J, et al. Effect of DNA methylation on the proliferation of leukemia cells regulated by miR-34b. Zhonghua er ke za zhi. Chinese journal of pediatrics. 2014; 52: 840-845. doi:
6. Tao YF, Li ZH, Wang NN, Fang F, Xu LX, Pan J. Tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia. Leukemia & lymphoma 2015; 1-14. doi: 10.3109/10428194.2015.1011157
7. Wu SY, Fan J, Hong D, et al. C3aR1 gene overexpressed at initial stage of AML-M2 patients predicting a short term survival. Leukemia & lymphoma 2014; 1-7. doi: 10.3109/10428194.2014.986481
8. Tao YF, Xu LX, Lu J, et al. Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation. Journal of translational medicine 2014; 12: 182. doi: 10.1186/1479-5876-12-182
9. Tao YF, Hu SY, Lu J, et al. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients. International journal of molecular medicine 2014; 34: 1505-1515. doi: 10.3892/ijmm.2014.1966
10. Ma W, Zhang T, Pan J, et al. Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy. Oncology reports 2014; 32: 1601-1609. doi: 10.3892/or.2014.3348
11. Fang F, Pan J Xu L, Su G, Li G, Wang J. Association between angiotensin-converting enzyme gene insertion/deletion polymorphism and pancreatitis risk: A meta-analysis. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2014; pii: 1470320314539827. doi: 10.1177/1470320314539827
12. Yan-Fang T, Jian N, Jun L, et al. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML). BMC medical genetics 2013; 14: 74. doi: 10.1186/1471-2350-14-74
13. Wang N, Pan J, Cao L, et al. The expression and clinical significance of miR-203 in pediatric acute leukemia. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2013; 34:777-781. doi: 10.3760/cma.j.issn.0253-2727.2013.09.009
14. Tao YF, Pang L, Du XJ, et al. Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. International journal of molecular sciences 2013; 14: 3376-3394. doi: 10.3390/ijms14023376
15. Sun L, Chen L, Pan J, et al. Functional Screen for Secreted Proteins by Monoclonal Antibody Library and Identification of Mac-2 Binding Protein (Mac-2BP) as a Potential Therapeutic Target and Biomarker for Lung Cancer. Molecular & cellular proteomics : MCP 2013; 12: 395-406. doi: 10.1074/mcp.M112.020784
16. Li Y, Yan J Li M, et al. Addition of SNAP to perinatal risk factors improves the prediction of bronchopulmonary dysplasia or death in critically ill preterm infants. BMC pediatrics 2013; 13: 138. doi: 10.1186/1471-2431-13-138
17. Li Y, Xiao Z, Yan J, et al. Urine erythropoietin level is associated with kidney and brain injury in critically ill neonates. Neonatology 2013; 104: 87-94. doi: 10.1159/000350546
18. Li Y, Li X, Zhou X, et al. Impact of sepsis on the urinary level of interleukin-18 and cystatin C in critically ill neonates. Pediatr Nephrol 2013; 28: 135-144. doi: 10.1007/s00467-012-2285-7
19. Hu S, Wang Y, Wu S, et al. Homology modeling and molecular dynamics studies of Wilms tumor gene 1 frameshift mutations in exon 7. Biomedical reports 2013; 1: 702-706. doi: 10.3892/br.2013.149
20. Zhao WL, Nie SS, Xu YY, et al. Expression of two subtype molecules of CD133 in childhood with B linage acute lymphoblastic leukemia and its clinical significance. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 2012; 20: 536-540. doi:
21. Yan-Fang T, Dong W, Li P, et al. Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays. Cancer Cell Int 2012; 12: 40. doi: 10.1186/1475-2867-12-40
22. Wen-Li Z, Jian W, Yan-Fang T, et al. Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines. J Exp Clin Cancer Res 2012; 31: 92. doi: 10.1186/1756-9966-31-92
23. Tao YF, Lu J, Du XJ, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC cancer 2012; 12: 619. doi: 10.1186/1471-2407-12-619
24. Sun L, Pan J, Peng L, et al. Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis. Annals of surgical oncology 2012; 19: 2411-2419. doi: 10.1245/s10434-011-2177-2
25. Jian P, Yan WS, Chao SL, et al. Promoter of TFPI-2 is hypermethylated in Chinese pediatric acute myeloid leukemia. Journal of pediatric hematology/oncology 2012; 34: 43-46. doi: 10.1097/MPH.0b013e3182277276
26. Sun L, Hu H, Peng L, et al. P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. The American journal of pathology 2011; 179: 380-390. doi: 10.1016/j.ajpath.2011.03.046
27. Pan J, Tao YF, Zhou Z, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. Journal of translational medicine 2011; 9: 157. doi: 10.1186/1479-5876-9-157
28. Pan J, Sun LC, Tao YF, et al. ATP synthase ecto-alpha-subunit: a novel therapeutic target for breast cancer. Journal of translational medicine 2011; 9: 211. doi: 10.1186/1479-5876-9-211
29. Jian P, Yanfang T, Zhuan Z, Jian W, Xueming Z, Jian N. MMP28 (epilysin) as a novel promoter of invasion and metastasis in gastric cancer. BMC cancer 2011; 11: 200. doi: 10.1186/1471-2407-11-200
30. Jian P, Li ZW, Fang TY, et al. Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663. Journal of hematology & oncology 2011; 4: 20. doi: 10.1186/1756-8722-4-20
31. Pan J, Hu H, Zhou Z, et al. Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncology reports 2010; 24: 105-112. doi: 10.3892/or_00000834
32. Ran Y, Pan J, Hu H, et al. A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Hum Gene Ther 2009; 20: 41-49. doi: 10.1089/hum.2008.129
33. Peng L, Ran YL, Hu H, et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009; 30: 1660-1669. doi: 10.1093/carcin/bgp178
34. Hu H, Sun L, Guo C, et al. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 2009; 15: 5485-5493. doi: 10.1158/1078-0432.CCR-08-2491
35. Hu H, Ran Y, Zhang Y, et al. Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Molecular & cellular proteomics : MCP 2009; 8: 816-826. doi: 10.1074/mcp.M800331-MCP200
36. Zhou Z, Ran YL, Hu H, et al. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis 2008; 25: 537-548. doi: 10.1007/s10585-008-9168-0
37. Ran Y, Hu H, Zhou Z, et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14: 2696-2700. doi: 10.1158/1078-0432.CCR-07-2021
38. Ran Y, Hu H, Hu D, et al. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14: 6538-6545. doi: 10.1158/1078-0432.CCR-08-0476

Ramon V. Tiu, MD

Medical Advisor-Early Phase Oncology
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 4628, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Tiu completed his Internal Medicine, Hematology and Oncology training at the Cleveland Clinic. He was an Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Department of Translational Hematology and Oncology Research at the Cleveland Clinic in Cleveland, Ohio from 2010 to 2014. He is board certified in Internal Medicine, Hematology and Oncology and involved in both Clinical and Translational research. He began employment with Eli Lilly and Company on January 19, 2015.

His research interests include: Molecular hematology and Molecular pathogenesis of myeloid neoplasia including Myelodysplastic syndromes and myeloproliferative neoplasms and bone marrow failure syndromes.


• (2015) American Association for Cancer Research
• (2014) Nitric Oxide Society
• (2008) American Society of Clinical Oncology
• (2007) American Society of Hematology



• (2012) Scott Hamilton CARES grant recipient
Pathology and Laboratory Medicine Institute Research Grant
Primary Investigator: Dr. Shashirekha Shetty. Co-investigator: Ramon Tiu
American Cancer Society Pilot Grant
• (2011) First ASH Advocacy Leadership Institute
• (2010) Clinical and Translational Science Collaborative Annual Pilot Award
Aplastic Anemia & MDS International Foundation Research Grant Awardee Torry Yahn Research Fund


• (2009) European Hematology Association/American Society of Hematology First Translational Research Training in Hematology Celgene Future Leaders in Hematology Award/Clinical Research in Hematology MDS Foundation 5th Annual Young Investigators Grant American Association for Cancer Research Methods of Clinical Cancer Research Workshop Cancer Education Consortium Molecular and Translational Oncology Workshop Travel Grant
• (2008) Mayo Clinic Hematology/Oncology Fellows Research Awards recipient, Amelia Islands, Florida
• (2007) American Society of Hematology Travel Award, Atlanta, Georgia "Tito Bastianello" Young Investigator Award 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy
• (2005) Honorable Mention 10th annual Cleveland Clinic Internal Medicine Resident Research Scholar Competition – “Epsilon aminocaproic acid is effective in controlling thrombocytopenic hemorrhage in patients with hematologic malignancies”
• (2000/2001) Overall Most Outstanding Intern of Cardinal Santos Medical Center Most Outstanding Intern of the Department of Pediatrics Most Outstanding Intern of the Department of Rehabilitation Medicine

1. Visconte V, Tabarroki A, Hasrouni E, et al. Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Leuk Lymphoma. 2015; 1-11.
2. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015. doi: 10.1182/blood-2014-10-607341
3. Saunthararajah Y, Sekeres M, Advani A, et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest. 2015. doi: 10.1172/JCI78789
4. Ornstein MC, Mukherjee S, Keng M, et al. Impact of vancomycinresistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. Leuk Lymphoma. 2015; 1-7. doi: 10.3109/10428194.2014.1003557
5. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014; 49(4): 216-227. doi: 10.5045/br.2014.49.4.216
6. Al-Issa K, Visconte V, Rogers HJ, Dembla V, Lichtin AE, Tiu RV. Cyclosporine dependent Pure Red Cell Aplasia: a case presentation. Blood Cells, Molecules and Diseases. 2015; 54(3): 281-283. doi: 10.1016/j.bcmd.2014.11.013
7. Gerace C, Visconte V, Romero-Marrero C, et al. Clinical course of a patient with symptomatic primary myelofibrosis and hepatitis C treated with ruxoltinib. Clinical Leukemia, Lymphoma & Myeloma. 2014.
8. Chatterjee A, Ghosh J, Ramdas B, et al. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014; 9(4): 1333-1348. doi: 10.1016/j.celrep.2014.10.039
9. de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research. 2014.
10. Visconte V, Tabarroki A, Gerace C, et al. Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal from non-clonal sideroblastic anemia. Leuk Lymphoma. 2014; 14: 1-3.
11. Visconte V, Tabarroki A, Zhang L, et al. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. Journal of Hematology and Oncology. 2014; 7(1): 89. doi: 10.1186/s13045-014-0089-x
12. Stein BL, Moliterno AR, Tiu RV. Polycythemia Vera Disease Burden: Contributing Factors, Impact on Quality of Life, and Emerging Treatment Options. Annals of Hematology. 2014; 93(12): 1965-1976. doi: 10.1007/s00277-014-2205-y
13. Tabarroki A, Visconte V, Rogers HJ, et al. Modified dose escalation of Ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis. Leukemia Research. 2014.
14. Visconte V, Avishai N, Mahfouz R, et al. Distinct iron architecture in SF3B1 mutant Myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 2014.
15. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia (aCML) BCR-ABL1-negative is clinicopathologically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U): a Bone Marrow Pathology Group study. Blood. 2014. doi: 10.1182/blood-2014-02-553800
16. Estephan F, Rogers HJ, Visconte V, et al. Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib. Leukemia & Lymphoma. 2014; 17: 1-3.
17. Visconte V, Tabarroki A, Zhang L, et al. Molecular characterization of myeloid neoplasms harboring isochromosome 17q abnormality. Am J Hematology. 2014.
18. Tabarroki A, Saunthararajah Y, Visconte V, et al. Ruxolitinib in combination with hypomethylating agents; clinical responsis in symptomatic myelofibrosis patients with cytopenias and elevated blast counts. Leukemia & Lymphoma. 2014.
19. Mukherjee S, Reddy CA, Ciezki JP, et al. Risk of Developing Myelodysplastic Syndromes in Prostate Cancer Patients Definitively Treated With Radiation. J Natl Cancer Inst. 2014. doi: 10.1093/jnci/djt462
20. Shivarov V, Ivanova M, Tiu RV. Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications. Blood Cancer J. 2014; 4: e185. doi: 10.1038/bcj.2014.7
21. Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage are associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014. doi: 10.3324/haematol.2013.096420
22. Tabarroki A, Tiu RV. Molecular Genetics of Myelofibrosis and its associated Disease Phenotypes. Translational Medicine UniSa. 2014; 8: 53-64.
23. Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014. doi: 10.1038/leu.2014.5
24. Tiu RV, Sekeres MA. Making sense of the myelodysplastic/myeloproliferative. Neoplasms overlap syndromes. Curr Opin Hematol. 2014; 21(2): 131-140. doi: 10.1097/MOH.0000000000000021
25. Visconte V, Selleri C, Maciejewski JP, Tiu RV. Molecular Pathogenesis of Myelodysplastic Syndromes. Translational Medicine UniSa. 2014; 8: 19-30.
26. Radivoyevitch T, Jankovic GM, Tiu RV, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2013. doi: 10.1007/s00411-013-0507-4
27. Liu Y, Tabarroki A, Billings S, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5- azacitidine. Leuk Lymphoma. 2014; 55(2): 447-449. doi: 10.3109/10428194.2013.802315
28. Ai J, Visconte V, Rogers HJ, Sekeres MA, Tiu RV. Pure red Cell Aplasia in a Patient with Cri- Du-Chat. International Blood Research & Reviews. 2013; 2(1): 2321-7219. doi: 10.9734/IBRR/2014/6978#sthash.bUGiJDsI.dpuf
29. Ai J, Tiu RV. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor–resistant BCR-ABL1 mutations. Ther Adv Hematol. 2014; 5(4): 107-120.
30. Martin H, Mali RS, Ma P, et al. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013; 123(10): 4449-4463. doi: 10.1172/JCI67509
31. Ornstein MC, Mukherjee S, Mohan S, et al. Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML. Am J Hematol. 2013. doi: 10.1002/ajh.23605
32. Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leuk Res. 2013; 37(11): 1445-1450. doi: 10.1016/j.leukres.2013.07.032
33. Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and Risk Factors for infections in myelodysplastic syndromes. Transplant Infectious Disease. 2013; 15(6): 652-657. doi: 10.1111/tid.12130
34. Bejar R, Tiu RV, Sekeres MA, Komrokji RS. Myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2013: 256-270.
35. Gotlib J, Tiu RV, Savona MR, et al. Diagnosis and Management of Myelofibrosis: Practical Strategies for the Healthcare Team. Proceedings from a Multidisciplinary Roundtable. Personalized Medicine in Oncology. 2013; 2(7): S131-S142.
36. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013; 6(1): 81. doi: 10.1186/1756-8722-6-81
37. Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2013. doi: 10.1038/leu.2013.269
38. Visconte V, Tabarroki A, Rogers HJ, et al. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica. 2013; 98(9): e105-e107. doi: 10.3324/haematol.2013.090506
39. Wenzell CM, Gallagher EM, Earl M, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol. 2013; 88(10): 906-909. doi: 10.1002/ajh.23530
40. Tabarroki A, Visconte V, Rogers HJ, et al. Clinical Experiences with Ruxolitinib in Symptomatic MPN Patients with Chronic Kidney Disease. Leukemia and Lymphoma. 2014; 55(1): 213-216.
41. Hasrouni E, Rogers HJ, Tabarroki A, et al. A Case of Mistaken Identity: When Lupus Masquerades as Primary Myelofibrosis. SAGE Medical Case Reports. 2013. doi: 10.1177/2050313X13498709
42. Adès L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013. doi: 10.1016/j.leukres.2013.01.004
43. Otrock ZK, Tiu RV, Maciejewski JP, Sekeres MA. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol. 2013; 6(1): 59-68.
44. Mahfouz RZ, Jankowska A, Ebrahem Q, et al. Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res. 2013; 19(4): 938-948. doi: 10.1158/1078-0432.CCR-12-1722
45. Stein BL, Tiu RV. Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABLNegative Myeloproliferative Neoplasms. J Interferon Cytokine Res. 2013; 33(4): 145-153. doi: 10.1089/jir.2012.0120
46. Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012. doi: 10.1182/blood-2012-06-434639
47. Traina F, Visconte V, Jankowska AM, et al. Single nucleotidepolymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One. 2012; 7(8): e43090.
48. Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV. Comprehensive Review of JAK Inhibitors in Myeloproliferative Neoplasms. Therapeutic Advances in Hematology. 2013; 4(1): 15-35. doi: 10.1177/2040620712461047
49. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012; 120(16): 3173-3186. doi: 10.1182/blood-2012-05-430876
50. Sugimori C, Padron E, Caceres G, et al. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012; 2(3): e63. doi: 10.1038/bcj.2012.7
51. Brady A, Gibson S, Rybicki L, et al. Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 IsAssociated with an Increased Risk of Death in Acute Myeloid Leukemia. Eur J Haematol. 2012; 89(4): 288-293. doi: 10.1111/j.1600-0609.2012.01825.x
52. Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012; 119(25): 6109-6117. doi: 10.1182/blood-2011-12-397620
53. Sakaguchi H, Makishima H, Muramatsu H, et al. Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leuk Res. 2012; 36(12): e215-e217. doi: 10.1016/j.leukres.2012.06.002
54. Abu Kar S, Jankowska AM, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic. leukemia Haematologica. 2013; 98(1): 107-113. doi: 10.3324/haematol.2012.064048
55. Ali Tabarroki and Ramon V. Tiu. Immunomodulatory Agents in Myelofibrosis. Expert Opinion on Investigational Drugs. 2012; 21(8): 1141-1154. doi: 10.1517/13543784.2012.693913
56. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the Spliceosomal Machinery in myelodysplastic syndromes and other hematologic disorders. eukemia. 2012; 26(3): 542-545.
57. Sugimoto Y, Sekeres MA, Makishima H, et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012; 5(1): 4. doi: 10.1186/1756-8722-5-4.
58. Jerez A, Gondek LP, Jankowska AM, et al. Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited. J Clin Oncol. 2012; 30(12): 1343-1349. doi: 10.1200/JCO.2011.36.1824
59. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012; 119(14): 3203-3210. doi: 10.1182/blood-2011-12-399774
60. Bejanyan N, Tiu RV, Raza A, et al. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2011.
61. Mukherjee S, Tiu RV, Sekeres MA. Blood consult: treating del (5q) myelodysplastic syndromes. Blood. 2012; 119(2): 342-344. doi: 10.1182/blood-2011-09-376103
62. Afable MG 2nd, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011: 90-95. doi: 10.1182/asheducation-2011.1.90
63. Portell C, Sekeres MA, Rogers HJ, Tiu RV. De Novo polycythemia vera arising five years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. BJH. 2012; 157(2): 266-267. doi: 10.1111/j.1365-2141.2011.08972.x
64. Mali RS, Ramdas B, Ma P, et al. Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011; 20(3): 357-369. doi: 10.1016/j.ccr.2011.07.016
65. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012; 26(3): 542-545. doi: 10.1038/leu.2011.232
66. Reikvam H, Tiu R. Venous Thromboembolism in Patient with Essential Thrombocythemia and Polycythemia Vera-Risk Stratification and Management. Leukemia. 2012; 26(4): 563-571.
67. Tiu RV, Sekeres MA. Lenalidomide in del 5q MDS: Responses and side effects revisited. Leuk Res. 2011; 35(11): 1440-1441.
68. Tiu RV, Kalaycio M. Targeted Therapy for Patients with Chronic Myeloid Leukemia: Clinical Trial Experience and Challenges in Intertrial Comparisons. Leukemia and Lymphoma. 2012; 53(7): 1263-1272. doi: 10.3109/10428194.2011.647309
69. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011; 118(14): 3932-3941. doi: 10.1182/blood-2010-10-311019.
70. Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011; 96(9): 1269-1275. doi: 10.3324/haematol.2011.042622
71. Afable MG 2nd, Wlodarski M, Makishima H, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011; 117(25): 6876-6884. doi: 10.1182/blood-2010-11-314393.
72. Tiu RV, Traina F, Sekeres MA. Clofarabine for myelodysplastic syndromes. Expert Opin Investig Drugs. 2011; 20(7): 1005-1014. doi: 10.1517/13543784.2011.585967
73. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates on Cytogenetic and Molecular Markers in MDS. Current Hematologic Malignancy Reports. 2011; 6(2): 126-135. doi: 10.1007/s11899-011-0081-2
74. Tiu RV, Gondek LP, OKeefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011; 117(17): 4552-4560. doi: 10.1182/blood-2010-07-295857
75. Pulsipher MA, Young NS, Tolar J, et al. Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011; 17(3): 291-299. doi: 10.1016/j.bbmt.2010.10.028
76. Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010; 24(10): 1799-1804. doi: 10.1038/leu.2010.167
77. Byrne M, Bergmann A, Silver B, Maciejewski J, Tiu RV. Post-Splenectomy Thrombo-embolic Disease in Congenital Sideroblastic Anemia. British Medical Journal. 2010. doi: 10.1136/bcr.12.2009.2514
78. Tiu RV, Singh AD, Workman J, Cotta C, Sweetenham J. Concomitant Conjunctival MALT Lymphoma And Small Lymphocytic Lymphoma Associated With IgM Macroglobulinemia Successfully Treated With Intensity Modulated Radiation Therapy. Leuk Lymphoma. 2010; 51(5): 952-955.
79. Advani AS, Tiu R, Saunthararajah Y, et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leuk Res. 2010; 34(12): 1622-1626. doi: 10.1016/j.leukres.2010.03.021
80. Huh J, Tiu RV, Gondek LP, et al. Characterization of Chromosome 20q Abnormalities in Myeloid Malignancies Using Genome-Wide Single Nucleotide Polymorphism Array Analysis. Genes, Chromosomes and Cancer. 2010; 49(4): 390-399. doi: 10.1002/gcc.20748
81. Tiu RV, Gondek LP, OKeefe C, et al. New Lesions Detected by SNP-A Array Based Chromosomal Analysis Have Important Clinical Impact in AML. J Clin Oncol. 2009; 27(31): 5219-5226. doi: 10.1200/JCO.2009.21.9840
82. Jasek M, Gondek LP, Bejanyan N, et al. TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p. Leukemia. 2009; 24(1): 216-219. doi: 10.1038/leu.2009.189
83. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies. J Clin Oncol. 2009; 27(36): 6109-6116. doi: 10.1200/JCO.2009.23.7503
84. Tiu RV, Yacoub H, Maciejewski JP, Sila CA. Recurrent Ischemic Stroke in Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria or Missed Patent Foramen Ovale? Journal of Stroke and Cerebrovascular Diseases. 2009; 18(5): 409-410. doi: 10.1016/j.jstrokecerebrovasdis.2008.12.002
85. Maciejewski JP, Tiu RV, OKeefe C. Application of Array Based Whole Genome Scanning Technologies as a Cytogenetic Tool in Hematologic Malignancies. BJH. 2009; 146(5): 479-488. doi: 10.1111/j.1365-2141.2009.07757.x
86. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009; 113(25): 6403-6410. doi: 10.1182/blood-2009-02-20569
87. Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genetics and Cytogenetics. 2008; 187(2): 101-111. doi: 10.1016/j.cancergencyto.2008.08.002
88. Advani AS, Jin T, Ramsingh G, et al. Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2008; 49(8): 1560-1566. doi: 10.1080/10428190802146078
89. Tiu RV, Sekeres MA. The role of AMG-531 in the treatment of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura and Myelodysplastic Syndromes. Expert Opinion. 2008; 8(7): 1021-1030. doi: 10.1517/14712598.8.7.1021
90. Gondek LP, Tiu R, OKeefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood. 2008; 111(3): 1534-1542.
91. Gondek LP, Haddad AS, OKeefe CL, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol. 2007; 35(11): 1728-1738.
92. Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu RV, Maciejewski JP. Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia. 2008; 22(3): 551-558. doi: 10.1038/sj.leu.2405055
93. Tiu R, Gondek L, OKeefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia. 2007; 21(8): 1648-1657.
94. Gondek LP, Tiu R, Haddad AS, et al. Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia. 2007; 21(9): 2058-2061. doi: 10.1038/sj.leu.2404745
95. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ. Tumor Lysis Syndrome. Seminars in Thrombosis and Hemostasis. 33(4): 397-407. doi: 10.1055/s-2007-976175
96. Maciejewski JP, OKeefe C, Gondek L, Tiu R. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol. 2007; 45(1): 5-14.
97. OKeefe CL, Tiu R, Gondek LP, et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol. 2007; 35(2): 240-251.
98. Tiu R, Maciejewski J. Immune pathophysiology of Paroxysmal Nocturnal Hemoglobinuria. International Journal of Hematology. 2006; 84(2): 113-117.
99. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis(RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006; 108(7): 2173-2181.
100. Kalmadi S , Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Department of Hematology and Oncology. Taussig Cancer Center. The Cleveland Clinic Foundation. Cancer. 2006; 107(1): 136-140.
101. Mountantonakis S, Tiu R, Moutzouris D, McPherson C. Ibutilide to expedite Emergency Department Management of Atrial Fibrillation. American Journal of Emergency Medicine. 2006; 24(4): 407-412.

Keechilat Pavithran, MD, DM, FRCP(L)

Professor and Head
Department of Medical Oncology
Amrita Cancer Institute
PO. AIMS Ponekkara
Cochin 682041, Kerala

BiographyResearch InterestScientific ActivitiesPublications

Dr. Pavithran, has done MD in Internal Medicine from Calicut Medical College and DM in Medical oncology from Kidwai Memorial Institute of Oncology, Bangalore. He is the Fellow of the Royal college of Physicians of London. He had training in hematology from Royal Hallamshire Hospital, Sheffield, United Kingdom and gained experience in Bone-marrow transplantation from Fred Hutchinson cancer centre, Seattle, USA.
Currently, he is working as Professor and Head of the Department of Medical Oncology and Hematology at Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India, since 2004.
He is the Member of many national (ISHTM, ISMPO, ISO, API) and international organizations (International Medical sciences Academy, International Society of Geriatric Oncology, European Society of Medical Oncology, International Network for Cancer treatment and Research (INCTR) and International society of gynecologic oncology.
He has presented many papers and delivered many lectures at various national and international conferences. Has published 65 papers in International Journals and 82 in National journals. Edited two books on cancer and has contributed more than 37 chapters in various books. Participated in more than 25 clinical trials.
He is the Reviewer for Biomed Central (www.biomedcentral.com) journals, American journal of Clinical Oncology, Supportive oncology, Indian Journal of Cancer, Journal of Cancer Research and Experimental Oncology, Indian Journal of Medical & Pediatric Oncology, Journal of Association of Physicians of India, Indian Journal of Dermatology & Venereology, Indian Journal of Medical Sciences and Indian journal of Hematology and Transfusion Medicine. Also serves in the editorial board of many national and international journals.

His research interests include: Breast cancer, Lung cancer, Gi cancers and Hematooncology.


• International Society of Hematology-Asia Pacific division
• European Society of Medical Oncology
• International Network for Cancer treatment and Research (INCTR)
• International Society of Geriatric Oncology
• Multinational Association of Supportive Care in Cancer (MASCC)
• International Society for Oral Oncology
• International Association for Study of Lung Cancer
• International Society of Gastrointestinal Oncology
• International Society of gynecologic Oncology
• Indian Society of Hematology and Transfusion Medicine
• Indian Society of Medical and Pediatric Oncology
• Indian Society of Oncology
• Association of Physicians of India
• Indian Medical Association
• Indian Society of Human Geetics
• Geriatric Society of India


•(2008) Calicut Medical College Alumni Oration award
•(2007) UT Thithin Raj Memorial Award (2007)
•(2006) Dr. Kuruvila Memorial Oration 2006 at AROI meeting, Calicut on 12th November
•(2005) Travel Scholarship by the Multinational Association of Supportive Care in Cancer (MASCC)
•(2003) Listed in the 21st Edition of Marquis Who’s who in the world
•(2003) Fellowship of the Indian College of physicians
•(2001) Fellow of the International Medical Sciences Academy
•(1993) Fellowship by the world Federation of Haemophilia
•(1984) Second Rank in the Final MBBS Examination, University of Calicut
•(1988) First Rank in the Kerala Public Service Commission Examination for Lecturer in Haematology
•(1986) First rank in the Entrance Examination for Post-Graduate courses in Kerala
•(1984) Ashoka Gold Medal in Surgery


1. Nair RS, Reshmi T, Reshmi P, et al. Biocompatibility studies of pectin- fibrin nanocomposite bearing Bal BALB/C mice. Cellulose Chem. Technol. 2015; 49 (1): 55-60.
2. Chandran P, Kavalakatt A, Malarvizhi GL, et al. Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomedicine. 2014; 10(4): 721-732. doi: 10.1016/j.nano.2013.09.008.
3. Pavithran K, Manoj P, Vidhyadharan G, Shanmughasundaram P. Inflammatory myofibroblastic tumor of the lung: unusual imaging findings. World J Nucl Med. 2013; 12(3): 126-128. doi: 10.4103/1450-1147.136739
4. Niu X, Rajanbabu A, Delisle M, et al. Brain metastases in women with epithelial ovarian cancer: Multimodal treatment including surgery or Gamma-Knife Radiation is associated with prolonged survival. JOGC. 2013.
5. Pavithran K, Pande SB, Dinesh M. Report of a case of radiation-induced new-onset vitiligo with collective review of cases in the literature of radiation-related vitiligo. Case Rep Med. 2013; 345473. doi: 10.1155/2013/345473
6. Zaheeruddin PM, Prameela CG, Antony MA, Pavithran K, Dinesh M. Metastatic endometrial carcinoma in the lung: Unusual timing and site. South African Journal of Gynaecol. 2013; 5(2): 64-67.
7. Chandran S, Praveen G, Snima KS, et al. Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer. Curr Drug Deliv. 2013; 10(3): 326-335. doi: 10.2174/1567201811310030009
8. Chandran P, Gupta N, Retnakumari AP, et al. Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. Nanomedicine. 2013; 9(8): 1317-1327. doi: 10.1016/j.nano.2013.04.012
9. Retnakumari AP, Hanumanthu PL, Malarvizhi GL, et al. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. Mol Pharm. 2012; 9(11): 3062-3078. doi: 10.1021/mp300172e
10. Nair IR, Jojo A, Pavithran K. Pathological profile of lymphomas in a tertiary care centre in Kerala. Pathol Int. 2012; 62(5): 360-362. doi: 10.1111/j.1440-1827.2012.02799.x
11. Anupama R, Bobby ST, Wesley MJ, Pavithran K, Vijayakumar DK. Malignancies during Pregnancy - A Case Series and a Brief Review of literature. Research and reviews- Journal of Hematology oncology. 2012; 1: 2.
12. Pavithran K, Pande SB. Janus kinase inhibitors: Jackpot or Potluck? Oncology Reviews. 2012; 6: e13. doi: 10.4081/oncol.2012.e13
13. Thomas B, Muthu P, Siyad I, Pavithran K. Thalidomide reversed chronic anemia in blue Rubber Bleb Nevus syndrome. Research and review- A journal of Medicine. 2012; 2.
14. Anupama R, Ahmad SZ, Kuriakose S, Vijaykumar DK, Pavithran K, Seethalekshmy NV. Disseminated peritoneal leiomyosarcomas after laparoscopic myomectomy and morcellation. J Minim Invasive Gynecol. 2011; 18(3): 386-389. doi: 10.1016/j.jmig.2011.01.014.
15. Palaniappan M, Jose W, Bindhu MR, Sudheer OV, Pavithran K. Carcinosarcoma of the Pancreas-report of a case with a concise. Review of literature Journal of Clinical and Diagnostic Research. 2011; 5(3): 621-624.
16. Jose W, Unnikrishnan A, Palaniappan A, Kumar K, Pavithran K. Simultaneous presentation of systemic lupus erythematosus (SLE) with aplastic anemia-a clinical vignette and review of literature. Journal of Clinical and Diagnostic Research. 2011; 5(3): 637-639.
17. Mehta AA, Jose W, Pavithran K. Hyperesoinophilic syndrome with fip1l1 pdgfrα mutation: A case study. Journal of Clinical and Diagnostic Research. 2011; 5(3): 625-627.
18. Pavithran K, Sudhindran S. Hanging liver tumor. J Gastrointestin Liver Dis. 2011; 20(1): 8.
19. Palaniappan M, Jose WM, Mehta A, Kumar K, Pavithran K. Umbilical metastasis-a case series of four sister joseph nodules from four different visceral malignancies. Current Oncology. 2010; 17(6): 78-81.
20. Mehta AA, Rajesh V, Jose W, Palaniappan M, Pavithran K. Multiple myeloma presenting as eosinophilic pleural effusion. Asia-Pacific Journal of Clinical Oncology. 2010; 6(4): 256-259. doi: 10.1111/j.1743-7563.2010.01324.x
21. Jose W, Kumar K, Unnikrishnan A, Palaniappan M, Nair A, Pavithran K. Autoimmune thrombocytopenic purpura in acute hepatitis a-a report and review of literature. Asia-Pacific Journal of Oncology and Hematology. 2010; 2(1). 137-139.
22. Sharma S, Hiran KR, Pavithran K, Vijaykumar DK. A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study. World J Surg Oncol. 2009; 7(1): 35. doi: 10.1186/1477-7819-7-35
23. Panicker JN, Pavithran K, Thomas M. Management of subdural hematoma in immune thrombocytopenic purpura: Report of seven patients and a literature review. Clin Neurol Neurosurg. 2009; 111(2): 189-192. doi: 10.1016/j.clineuro.2008.08.002
24. Mohana S, Seethalekshmy NV, Pavithran K. Splenic Cystic lymphangiomatosis presenting with massive splenomegaly. The Internet Journal of Pathology. 2009; 8: 1.
25. Sharan R, Iyer S, Chatni SS, et al. Increased plate and osteosynthesis related complications associated with postoperative concurrent chemoradiotherapy in oral cancer. Head Neck. 2008; 30: 1422-1430. doi: 10.1002/hed.20886
26. Doval DC, Pande SB, Sharma JB, Pavithran K, Jena A, Vaid AK. Prometheus spirit: quality survival in advanced hepatocellular carcinoma after gemcitabine and cisplatin-based chemotherapy. Singapore Med J. 2008; 49(10): e293-e295.
27. Doval DC, Bhatia K, Vaid AK, et al. Spinal cord compression secondary to bone metastases from hepatocellular carcinoma. World J Gastroenterol. 2006; 12(32): 5247-5252.
28. Doval DC, Bhatia K, Pavithran K, Sharma JB, Vaid AK, Hazarika D. Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature. Hepatobiliary Pancreat Dis Int. 2006; 5(2): 305.
29. Pavithran K, Doval DC. Chronic myeloid leukemia in a man with papillary carcinoma of the thyroid treated with radioactive iodine. American Journal of Clinical Oncology. 2005; 28(2): 216.
30. Pavithran K, Prabhash K, Hazarika D, Doval DC. Neuroendocrine carcinoma of gallbladder: report of 2 cases. Hepatobiliary Pancreat Dis Int. 2005; 4(1): 144-146.
31. Pavithran K. Hypermethylation of FHIT predicts poor prognosis in NSCLC. Thorax. 2004; 59(6): 511. doi: 10.1136/thx.2004.la0094
32. Padmanabhan VT, Sugunan AP, Brahmaputhran CK, Nandini K, Pavithran K. Heritable anomalies among the inhabitants of regions of normal and high background radiation in Kerala: results of a cohort study, 1988-1994. Int J Health Serv. 2004; 34(3): 483-515.
33. Maniangatt S, Panicker J, Thomas M, Pavithran K. A rare case of porphyria. Ann Acad Med Singapore. 2004; 33(3): 359-361.
34. Pavithran K, Doval DC. Contemporaneous Pulmonary sarcoidosis and chronic myeloid leukemia. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2004; 21(2): 157.
35. Pavithran K, Arjun R, Aruna R, Thomas M. Scrotal ulceration during induction therapy of APML with ATRA. American Journal of Hematology. 2004; 75(4): 260-261. doi: 10.1002/ajh.20036
36. Talwar V, Pavithran K, Vaid AK, Doval DC. Spontaneous fracture with pulmonary embolization from central venous catheter. The Journal of Vascular Access. 2003; 4: 158- 159.
37. Pavithran K, Raji NL. Aplastic anemia in Down’s syndrome. American Journal of Hematology. 2003; 73(3): 213.
38. Pavithran K, Rajalakshmi A, Aruna R, Thomas M. Refractory Iron deficiency anemia. Is H pylori the culprit?. Medscape General Medicine. 2003; 5(2): 34.
39. Roy DD, Pavithran K, Henry PY, Elizabeth KE, Sindhu P, Vijayakumar T. Correlation of age and birth order of parents with chromosomal anomalies in children. Genetika. 2003; 39(6): 834-839.
40. Pavithran K, Thomas M. Essential thrombocythemia presenting as Dural sinus thromosis. Case Reports and Clinical Reviews. 2003; 4(3): 212-213.
41. Pavithran K, Ajithkumar BV, Aruna R, Thomas M. Bilateral retinal detachment in Acute Myeloid Leukemia. Asian Journal of Ophthalmology. 2003; 5(3): 13-14.
42. Pavithran K, Doval DC, Pandey KK. Gastric cancer in India. Gastric cancer. 2002; 5(4): 240-243.
43. Pavithran K. Raji NL, Thomas M. Aplastic anemia associated with SLE- Case report and review of the literature. Rheumatology International. 2002; 22(6): 253-255.
44. Pavithran K. Thomas M. Management of venous thromboembolism. International journal of Medicine.
45. Pavithran K, Ajithkumar BV, Roy D, Thomas M. Adenocarcinoma of the stomach in Fanconis Anemia. Annals of Hematology. 2002; 8(11): 666-667.
46. Pavithran K. Cancer Immunology (Book Review). Lancet Oncology. 2002; 3(2): 124.
47. Pavithran K, Panakkel C, Roy D, Thomas M. Chronic myeloid leukaemia in a man with myasthenia gravis treated by thymectomy. European Journal of Hematology. 2002; 69: 105-107.
48. Pavithran K, Doval DC. Nail changes due to docetaxel. British Journal of Dermatology. 2002; 146(4): 709-710.
49. Pavithran K, Kapoor G. Acute myeloid leukemia in a child with goldenhar syndrome. Medical and Pediatric Oncology. 2002; 38(6): 451-452. doi: 10.1002/mpo.10040
50. Pavithran K, Doval DC. Thrombopoietin-biology and clinical applications. Oncology Forum. 2001; 5: 20-24.
51. Pavithran K, Doval DC, Hukku S, Jena A. Isolated Hypoglossal paralysis due o skull base metastasis from breast cancer. Australasian Radiology. 2001; 45: 534-535. doi: 10.1046/j.1440-1673.2001.00977.x
52. Pavithran K, Thomas M. Spontaneous resolution of subdural hematoma in hemophilia. Haematologica. 2002; 87: (01)ELT03.
53. Pavithran K, Thomas M. Chronic myeloid leukemia presenting as gout. Clinical Rheumatology. 2001; 20: 288-289. doi: 10.1007/PL00011204
54. Muralikrishnan K, Pavithran K, Thomas M. Intracranial bleeding in Weils disease. J Postgrad Med. 2002; 48(2): 158.
55. Pavithran K, Thomas M. Chronic myeloid leukemia associated with Ebstein’s anomaly. Turkish Journal of Hematology. 2001; 18(3): 215.
56. Pavithran K, Doval DC, Verma RN, Vaid AK. Small cell carcinoma of the Gall bladder-case report with review of the literature. Tropical Gastroenterology. 2001; 22: 170-171.
57. Pavithran K, Doval DC. Chemotherapy of advanced colorectal cancer-recent advances. International Journal of Medicine.
58. Pavithran K, Doval DC, Dewan AK. Sister Joseph nodule in a case of Ovarian Carcinoma. Electornic Journal of Oncology. 2000; 2: 33-35.
59. Pavithran K, Doval DC, Rao CR, Bapsy PP, Anantha N. Pediatric Solitary Plasmacytoma-A Case report. Acta Oncol. 1997; 36(1): 83-84.
60. Pavithran K, Doval DC, Mukherjee G, Kumaraswamy SV, Bapsy PP. Rhabdomyosarcoma of the oral cavity-report of 8 cases. Acta Oncol. 1997; 36(8): 819-821.
61. Pavithran K. Thrombopoietin. International Journal of Medicine.
62. Pavithran K, Thomas M. Management of chronic myeloid leukemia. International Journal of Medicine.
63. Nair K, Pavithran K, Philip J, Thomas M, Geetha V. Cold agglutinin disease in SLE. Yonsei Med Journal. 1997; 38(4): 233-235.


1. Jose WM, Boyella PK, Nair IR, Eapen M, Pavithran K. Revisiting cutaneous metastasis from carcinoma gall bladder. Indian J Dermatol Venereol Leprol. 2014; 80(1): 82-85. doi: 10.4103/0378-6323.125486
2. Mehta AA, Wesley M Jose, Pavithran K, Ganesan S Triavadi The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. Indian J Palliat Care. 2013; 19(1): 48-53.
3. Khadakban D, Gorasia-Khadakban T, Vijaykumar DK, Pavithran K, Anupama R. Factors associated with better survival after surgery in metastatic breast cancer patients. Indian J Surg Oncol. 2013; 4(1): 52-58. doi: 10.1007/s13193-012-0204-9
4. Mehta AA, Jose WM, Pavithran K, Triavadi GS. The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. Indian J Palliat Care. 2013; 19(1): 48-53.
5. Vijaykumar DK, Antony MA, Indu R. Nair, Pavithran K. Recent Advances in Granulosa Cell Tumor Ovary: A Review. Indian Journal of Surgical Oncology. 2013; 4(1): 37-47. doi:
6. Khadakban D, Gorasia-Khadakban T, Vijaykumar DK, Pavithran K, Anupama R. Factors associated with better survival after surgery in metastatic breast cancer patients. Indian Journal of Surgical Oncology. 2013; 4(1): 52-58.
7. Anupama R, Kuriakose S, Vijaykumar DK, et al. Carcinosarcoma of the Uterus-A Single Institution Retrospective Analysis of the Management and Outcome and a Brief Review of Literature. Indian Journal of Surgical Oncology. 2013; 4(3): 222-228. doi: 10.1007/s13193-012-0206-7
8. Anupama R, Kuriakose S, Vijaykumar DK, et al. Carcinosarcoma of the uterus-a single institution retrospective analysis of the management and outcome and a brief review of literature. Indian J Surg Oncol. 2013; 4(3): 222-228.
9. Thomas B, Muthu P, Karichala A, Keechilat P. Pericardial effusion and the unsuspected culprit. J Cancer Res Ther. 2012; 8(3): 462-463. doi: 10.4103/0973-1482.103538
10. Pande SB, Doval DC, Pavithran K, Sharma JB, Shirali R, Jena A. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. Ind J Med Ped Oncol. 2012; 33: 42-47. doi: 10.4103/0971-5851.96968
11. Vijaykumar DK, Michelle AK, Indu RN, Pavithran K. Recent advances in granulosa cell tumor ovary: A review. Indian Journal of Surgical Oncology. 2012.
12. Dhiraj K, Tejal GK, Vijaykumar DK, Pavithran K, Anupama R. Factors associated with better survival after surgery in metastatic breast cancer patients. Indian Journal of Surgical Oncology. 2012.
13. Mehta AA, Jose W, Pavithran K. Hyperesoinophilic Syndrome with FIP1L1 PDGFRα Mutation: A Case Study. Journal of Clinical and Diagnostic Research. 2011; 5(3): 625-627.
14. Palaniappan M, Jose W, Bindhu MR, Sudheer OV, Pavithran K. Carcinosarcoma of the Pancreas- report of a case with a concise review of the literature. Journal of Clinical and Diagnostic Research. 2011; 5(3): 621-624.
15. Jose W, Athira U, Palaniappan M, Kishore Kumar, Pavithran K. A plastic Anaemia Complicating Systemic Lupus Erythematosus (SLE) at Presentation: A Clinical Vignette and Review of Literature. Journal of Clinical and Diagnostic Research. 2011; 5(3): 637-639.
16. Palaniappan M, Jose W, Pavithran K. Spontaneous hematoma of upper lip: an interesting presentation of an uncommon hematological syndrome. Bloodline-Online Journal. 2010.
17. Haji AG, Sharma S, Majeed KA, Vijaykumar DK, Pavithran K, Dinesh M. Primary pancreatic lymphoma: Report of three cases with review of literature. Indian Journal of Medical and Pediatric Oncology. 2009; 30(1): 20-23. doi: 10.4103/0971-5851.56331
18. Vijaykumar DK, Chitrathara K, Sharma S, Pavithran K, Kumar K. Epithelial ovarian carcinoma at Amrita institute, Cochin, Kerala; A 4 year experience. Indian Journal of Medical and Pediatric Oncology. 2009; 30(5): 23-24.
19. Pavithran K, Prasad N. Variants of multiple myeloma. Amrita journal of Medicine. 2008; 4: 8-12.
20. Panicker JN, Thomas M, Pavithran K, Nair MD, Sharma PS. Circardian variation in Ischemic stroke occurrence. Amrita journal of Medicine. 2008; 426-427.
21. Pavithran K. Adjuvant chemotherapy for breast cancer. Amrita journal of Medicine. 2007; 3: 5-7.
22. Sharma S. Vijayakumar DK, Chithrathara K, Haji AG, George RC, Pavithran K. Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study. Indian Journal of Medical and Pediatric Oncology. 2007; 28(1): 7-13.
23. Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Iyer S, Kuriakose MA. Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Can Res Ther. 2006; 2: 100-104.
24. Prabhash K, Pavithran K, Hazarika D, Doval DC. Carcinoma Ovary with isolated metastasis to breast. Indian Journal of Medical and Pediatric Oncology. 2006; 27(3): 50-53.
25. Ray S, Pavithran K, Nair PS. Cranial Neuropathy and Bone Involvement in Primary Systemic Amyloidosis. J Assoc Phys India. 2006; 54: 577-580.
26. Pavithran K, Doval DC, Hazarika D, Kumar R. Bellini duct carcinoma. Indian Journal of Medical and Pediatric Oncology.
2006; 27(1): 38-41.
27. Thomas M, Pavithran K. Chemotherapy, myths and realities. J Indian Med Assoc. 2005; 103(9): 489-490.
28. Pavithran K. Letrozole in male breast cancer. Indian Journal of Medical and Pediatric Oncology. 2005; 26(4): 71-73.
29. Pavithran K, Sharma JB, Kumar R, Kumar K, Doval DC. A case of Metatarsal Ewings sarcoma. Indian Journal of Medical and Pediatric Oncology. 2003; 24(3): 31-32.
30. Pavithran K, Doval DC, Talwar V, Vaid AK. Flagellate hyperpigmentation from Bleomycin. Indian J Dermatol Venereol Leprol. 2004; 70(1): 46-47.
31. Raj RS, Najeeb S, Aruna R, Pavithran K, Thomas M. Plasma cell leukemia in the Young. Indian Journal of Cancer. 2003; 40(3): 116-117.
32. Talwar V, Vaid AK, Pavithran K, Doval DC. Synchronous double malignancy-Squamous Cell Carcinoma Lung with Chronic Lymphocytic Leukemia. Indian Journal of Cancer. 2003.
33. Pavithran K, Doval DC, Kumar R, Pandey KK. Ankylosing spondylitis associated with male breast cancer. Indian Journal of Medical and Pediatric Oncology. 2002 ; 23 (1): 9-10.
34. Panicker JN, Thomas M, Pavithran K, Nair D, Sarma PS. Morbidity predictors in ischemic stroke. Neurol India. 2003; 51(1): 49-51.
35. Pavithran K, Thomas M. Benign Intracranial hypertension as the initial manifestation of Chronic myeloid leukemia. Neurology India. 2002; 50: 230.
36. Pavithran K, Raji LN, Thomas M. Ankylosing Spondylitis Associated with Non-Hodgkin’s Lymphoma. J Assoc Physicians India. 2002; 50(6): 836-837.
37. Pavithran K, Thomas M. Hematopoietic growth factors in drug induced agranulocytosis. J Assoc Physicians India. 2002; 50(5): 679-681.
38. Pavithran K, Issac MV, Krishnakumar VV, Thomas M, Raji NL. Leukemic Ascites. J Assoc Phys India. 2001; 49: 1045-1046.
39. Pavithran K, Doval DC. Systemic chemotherapy for advanced colorectal cancer-current status and Future Perspectives. Gastroenterology Today. 2001; 5: 155-160.
40. Pavithran K, Mukundan C, Thomas M. Pamidronate in bone lesions of multiple myeloma. JK Practitioner. 2001; 8(3): 164-166.
41. Pavithran K, Sankar S, Thomas M. Late presentation of congenital factor V deficiency- A case report. Indian Journal of Medical Science. 2001; 55: 271-272.
42. Doval DC, Pavithran K. Cancer Treatment-Future Perspectives. JAMA India-The Physicians Update. 2001; 4: 70-76.
43. Pavithran K, Thomas M. Chronic myeloid leukemia. Recent advances. Journal of Internal Medicine of India. 2000; 3(2): 91-97.
44. Panicker JN, Pavithran K, Thomas M. POEMS syndrome. J Assoc Phys India. 2000; 48(10): 1025-1026.
45. Thomas M, Pavithran K, Somarajan AS. Thrombocytosis-report of a case. J Assoc Phys India. 2000; 48(4): 441-442.
46. Sreedharan PS, Rakesh S, Sajeev S, Pavithran K, Thomas M. Subdural hematoma with Spontaneous resolution - Rare manifestation of Idiopathic thrombocytopenic purpura. J Assoc Phys India. 2000; 48(4): 432-434.
47. Pavithran K, Thomas M, Vimal A, Krishnamohan VE. Chronic lymphatic leukemia presenting as hemolytic anemia. Indian Journal of Medical Science. 1999; 53: 490-492.
48. Pavithran K, Doval DC, Kumaraswamy SV, Bapsy PP. Squamous cell carcinoma of the gingiva in Xeroderma pigmentosum. J Ind Academy Oral Med Oral Radiol. 1999; 10(4): 108-110.
49. Doval DC, Pavithran K, Acharya RS, Mukherjee G, Bapsy PP. Ewing’s Sarcoma with central nervous system metastasis - Report of 2 cases. Indian Journal of Cancer. 1997; 34: 26-29.
50. Pavithran K, Doval DC, Ravi S, Mittal R, Bapsy PP. Cardiac metastasis from Carcinoma breast. Indian Journal of Medical Science. 1997; 51: 15-17.
51. Sreedharan PS, Pavithran K, Thulasidharan NK, Madhusoodhanan M. Multiple myeloma presenting with cutaneous plasmacytomas (Pictorial CME). J. Assoc Phys India. 1997; 45: 777.
52. Pavithran K, Lakshminarasimhan S, Bapsy PP. Testicular germ cell tumor with cardiac metastasis. Indian Journal of Radiology and Imaging. 1997; 7: 121-122.
53. Thomas M, Pavithran K. Immunotherapy for Aplastic Anaemia-An alternative to bone marrow transplantation. J Assoc Phys India. 1997; 45: 257-260.
54. Krishnan MN, Pavithran K. Jervell and lange-neilsen syndrome-a case report. J Assoc Phys India. 1997; 45.
55. Pavithran K, Sreekumar A, Krishnamohan CE. Idiopathic thrombocytopenic purpura with Graves Disease. Indian Journal of Medical Science. 1996; 50(2): 43-46.
56. Pavithran K, Thomas M. Pregnancy associated Aplastic anemia. J Assoc Phys India. 1996; 44: 273.
57. Pavithran K, Thomas M. An Unusual presentation of chronic granulocytic Leukemia. J Assoc Phys India. 1996; 44: 496-497.
58. Pavithran K, Thomas M. Idiopathic lateral sinus thrombosis. J Assoc Phys India. 1996; 44: 149.
59. Thomas M, Pavithran K, Lissy K. Platelet adrenergic receptors in health and disease (Editorial). J Assoc Phys India. 1996; 44: 301-302.
60. Pavithran K, Vijayalekshmi N, Sreekumar A. A case of spontaneous haemothorax in congenital factor VII deficiency. Lung India. 1995; 13: 25-26.
61. Pavithran K, Seethalekshmi NV. Clodronate. Indian Journal of Clinical Practice. 1995; 5: 47-48.
62. Thomas M, Pavithran K. Thrombotic thrombocytopenic purpura (Editorial). J Assoc Phys India. 1995; 43: 667-668.
63. Sreekumar A, Pavithran K. Tacrolimus. Indian Journal of Clinical Practice. 1995; 6: 59-61.
64. Pavithran K. Mercury and Aplastic anaemia. National Medical Journal of India. 1994, 7: 252.
65. Pavithran K. Immune thrombocytopenic purpura in pregnancy. J Assoc Phys India. 1994; 42: 666.
66. Pavithran K, Thomas M. Platelet hyperactivity in bronchial Asthma. J Assoc Phys India. 1994; 426.
67. Pavithran K, Latheef MIA, Mathew S, Babu D. Purpura fulminans following Chicken poox. Indian Journal of Haematolgy and Blood Transfusion. 1994; 12: 60-61.
68. Satheesh P, Pavithran K, Thomas M. Hereditary spherocytosis and Glucose 6-phosphate dehydrogenase deficiency. J Assoc Phys India. 1994; 42: 59.
69. Pavithran K. Fenugreek in Diabetes Mellitus. J. Assoc Phys India. 1994; 42: 259.
70. Pavithran K. Granulocyte Macrophage Colony stimulating factor. Indian Journal of Clinical Practice. 1994; 5(2): 77-78.
71. Pavithran K. Management of Post splenectomy sepsis. Indian Journal of Clinical Practice. 1994; 5(5): 41-42.
72. Pavithran K, Vijayalekshmi N. Haemophilia presenting as recurrent Iliacus haematoma. The antiseptic. 1993; 90(12): 547-548.
73. Pavithran K, Seethalekshmi NV. Ondansetron. Indian Journal of Clinical Practice. 1993; 4(6): 65-66.
74. Rasalam, Pavithran K, Khanafer A. Acute Leukemia in Downs syndrome. Kerala Med Journal. 1993; 30(4): 105-106.
75. Balakrishnan Nair K, Pavithran K, Ahmed S. Dental care of patients with Classical haemophilia. Kerala Dental Journal. 1993; 15: 715-715.
76. Pavithran K, Vijayalekshmi N. Haemophilic arthropathy-a review. Kerala Med Journal. 1993; 34(2): 36-39.
77. Hakim KA, Pavithran K. Sjogren-Larson syndrome - report of 3 cases. The Antiseptic. 1993; 90(20): 65-66.
78. Mammi MVI, Dileepkumar P, Pavithran K, Abdurahiman P. Therapeutic effect of Fenugreek seed (Trifolium foenum graecum) in diabetes mellitus-A preliminary report. Kerala Med journal. 1992; 33(5): 158-159.
79. Pavithran K, Hakim KA. Systemic Lupus erythematosus presenting as Guillain-Barre syndrome. Kerala Med Journal. 1992; 33(5): 158-159.
80. Pavithran K, Hakim KA. Ataxia Telangiectasia-report of 2 cases. Kerala Med Journal. 1991; 32(4): 130-131.
81. Mammi MVI, Pavithran K, Abdurahiman P, Pishrody R, sugathan K. Acute myocardial infarction in north Kerala-a 20 year hospital based study. Indian Heart Journal. 1991; 43(2): 93-95.
82. Raju A, Jose M, Philip A, Pavithran K. Skin hypopigmentation in a patient with papillary carcinoma thyroid treated with Sorafenib. Cancer Stud Mol Med Open J. 2015; 2(2): 72-74. doi: 10.17140/CSMMOJ-2-110


1. Pavithran K, DC Doval. An adult with carcinomatous meninigitis http://www.indegene.com/Onc/ClinRound/indOncCase4.html
2. Pavithran K. Hematological changes in Malaria. http://www.indegene.com/Onc/FeatArt/indOncFeatArt3.html
3. Pavithran K. A 14 year old boy with pancytopenia http://www.indegene.com/Onc/ClinRound/indOncCase8.html
4. Pavithran K. Autologous blood transfusion. http://www.indegene.com/Onc/FeatArt/indOncFeatArt11Frame.html


1. Pavithran K, Neeraj S. Haemolytic transfusion reaction: critical issues. Medicine Update. In: Banerjee AK, ed. Association of Physicians of India, Ahmedabad. 2011.
2. Pavithran K. Cancers in the predisposed host. In: Munjal YP, ed. API textbook of Medicine. 9th ed. 2012.
3. Pavithran K. Cancers in the predisposed host. In: Munjal YP, ed. API textbook of Medicine. 9th ed. 2011.
4. Jose W, Pavithran K. Concurrent Chemotherapy and Radiation for Carcinoma cervix. In: Rajaram S, eds. Cervical Cancer: Contemporary Management. 1st edition. Jaypee Brothers Publishers, Delhi.
5. Pavithran K, Mathew Thomas. Myeloproliferative neplasms. In: Rao M, ed. Medicine Update. Association of Physicians of India, Jaipur. 2010; 577-582.
6. Thomas M, Pavithran K. A clinical approach to Polycythemia. In: Rao M, ed. Medicine Update. Association of Physicians of India, Jaipur. 2010; 583-587.
7. Thomas M, Pavithran K. Nodal marginal zone lymphoma. In: Agarwal MB, ed. Non Hodgkins Lymphoma. 2009; 33-34.
8. Pavithran K. Newer agents in ovarian cancer. In Ovarian cancer-comprehensive and contemporary management. In: Chitrathara K, Rajaram S, Maheswari A, ed. Jaypee Publishers, New Delhi, 2009.
9. Pavithran K, Boban T. Recent advances in the management of lung cancer. In: Bichili SK, ed. Medicine Update. Association of Physicians of India, Cochin. 2008.
10. Thomas M, Pavithran K. Management of Non-Hodgkin’s Lymphoma. In: Munjal YP, ed. Postgraduate Medicine. Association of Physicians of India, Cochin. 2008.
11. Pavithran K. Variant Myeloma in Hematology Update 2007. (Ed AK Tripathi). ISHTM meeting, Lucknow, 2007.
12. Pavithran K, Thomas M. Recent advances in the management of systemic fungal infections. In: Sahay BK, ed. Medicine Update. Association of Physicians of India, 2006, Patna.
13. Thomas M, Pavithran K. Disseminated intravascular coagulation. In: Sahay BK, ed. Medicine Update. Association of Physicians of India, Patna. 2006.
14. Pavithran K, Sibi NS, Thomas M. Aspirin resistance. In: Gupta SB, ed. Medicine Update. Association of Physicians of India, Mumbai. 2005.
15. Pavithran K, Thomas M. Recent Advances in Multiple myeloma. In: Venkataraman Lt CoS, ed. Medicine Update. Association of Physicians of India, Hyderabad, Patna. 2004.
16. Thomas M, Pavithran K. Antiphospholipid antibody syndrome. In: Venkataraman Lt CoS, ed. Medicine Update. Association of Physicians of India, Hyderabad. 2004.
17. Thomas M, Pavithran K. Refractory anemias. In: Das S, ed. Medicine Update Association of Physicians of India, Varanasi. 2003; 873-878.
18. Thomas M, Mathew VT, Pavithran K. Prevalence of Iron Deficiency Anemia (IDA). In: Agarwal MB, ed. Iron deficiency. 2004.
19. Krishnadas KV. Pavithran K. Biological and Clinical events in Thalassemia. In Thalassemia -A Technical Report Series, Indian College of Physicians. 2003; 14-27.
20. Thomas M, Pavithran K. Gene therapy in Thalassemia. Thalassemia- A Technical Report Series, Indian College of Physicians 2003; 134-141.
21. Thomas M, Pavithran K. Folic acid deficiency anemia. Anemia Technical Report Series, API, 2003.
22. Pavithran K, Thomas M. Hematopoietic growth factors - A glimpse into the future. In: Thakur BB, ed. Post Graduate Medicine. Association of Physicians of India, 2002, Chennai.
23. Thomas M, Pavithran K. Venus thrombosis- Physicians role. In: Chandrasekharan S, ed. Medicine Update. Association of Physicians of India, Chennai. 2002.
24. Pavithran K, Thomas M. Optimising platelet transfusion in chronically thrombocytopenic patients. In: Panja M, ed. Medicine Update. Association of Physicians of India, New Delhi, 2001; 165-170.
25. Thomas M, Pavithran K. New Approaches and management of Hemophilia. In: Das AK, ed. Post Graduate Medicine. Association of Physicians of India, New Delhi, 2001; 229-234.
26. Thomas M, Pavithran K. Hormonal manipulation in Malignancy. Medicine Update. Association of Physicians of India, Jaipur, 2000.
27. Pavithran K, Thomas M. Thrombopoeitin. In Medicine Update, Volume 10, Association of Physicians of India, Jaipur, 2000.
28. Pavithran K, Thomas M. Telomerase- Biological and Clinical importance In: Singh MM, ed. Medicine Update Assoc phys India, Calcutta, 1999.
29. Thomas M, Pavithran K. Tumor markers. In: Singh MM, ed. Medicine Update Assoc phys India, Calcutta, 1999.
30. Thomas M, Pavithran K. Hypercoagulable states. Continuing Medical Education Programme of API Calcutta, 1999.
31. Pavithran K. Multiple myeloma - Recent advances in Pathogenesis and treatment. Update in Medicine. In: Das AK, Sen AK, eds. API, Assam, 1998; 100-106.
32. Thomas M, Pavithran K. Genes and Cancer. Update in Medicine. In: Das AK, ed. API Bangalore, 1998.
33. Pavithran K, Thomas M. Tumor angiogenesis. A novel target for cancer therapy. In: Manoria PC, ed. Post Graduate Medicine. Assoc Phys India, Kathmandu, 1996; 10: 222-226.
34. Thomas M, Pavithran K. Drug resistance in cancer and its remedies. In: Manoria PC, ed. Post Graduate Medicine. Assoc Phys India, Kathmandu, 1996; 10: 208-214.
35. Pavithran K. Cell Adhesion molecules, In: Shankar PS, ed. Medicine Update. Assoc Phys India, Madras, 1995; 8-11.
36. Pavithran K. Haemophilia A - Current concepts. Proceedings of the Padmasree Dr. K.N.Pai Memorial CME. Trivandrum, 1994.
37. Pavithran K. Clinical profile of Craniovertebral anomalies (Dissertation), University of Calicut, Calicut, 1989.

Frank S. Lieberman, MD

Department of Neurology
University of Pittsburgh School of Medicine
5150 Centre Avenue, Rm 561
Pittsburgh, PA 15232, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Lieberman has been active clinical translational investigators focusing on develop of novel therapies for patients with malignant and low grade gliomas since 1985. He has extensive experience in the design, conduct, and interpretation of translational clinical trials of conventional cytotoxic drugs, molecularly targeted agents, and immunotherapeutic strategies. His clinical and translational research efforts have encompassed the application of molecular neuropathology and neuroimaging to strategies for personalized, molecularly targeted therapies for patients with primary central nervous system tumors. He currently serve as the director of the adult neurooncology program within the University of Pittsburgh Cancer Institute, where he oversee the design and conduct of clinical trials for patients with primary and metastatic brain tumors. He currently serve as our institution’s principal investigator for participation in the Adult Brain Tumor Consortium, NRG Consortium, the Collaborative Ependymoma Research Network, and ECOG-ACRIN. He serves on the CNS Tumor Committee of NRG and ECOG- ACRIN, the Biomarker and Experimental Imaging committees for ECOG-ACRIN, and the imaging committee for the ABTC. He had served as principal investigator as well as co-investigator in innovative glioma vaccine trials, for both high grade and low grade gliomas. He had a national leadership role in the translational imaging efforts to develop imaging biomarkers for treatment response in oncology clinical trials, focusing on malignant gliomas. He served as co-investigator (with James Mountz) for our institutional Quantitative Imaging Network U01 project assessing novel PET tracers and high field strength MRI spectroscopy and dynamic contrast imaging as early biomarkers of response in clinical trials for newly diagnosed and recurrent glioblastoma. He is a co-investigator for the QIN proposal expanding this work to evaluation of imaging biomarkers of response in immunotherapy trials for high grade gliomas. He served as chair of the working group for Clinical Trials Design and Development for the Quantitative Imaging Network and as a liaison between QIN and the NCI collaborative trial groups. He has been an institutional leader in the application of molecular profiling to management of patients with low grade gliomas, with our institution beginning molecular profiling of all gliomas beginning in 2002 with FISH and PCR based LOH analysis and more recently with next generation sequencing. He is an active participant in our institutional phase 1 program, specifically focusing on expanding phase 1 option for patients with malignant gliomas, through the use of molecular profiling.

His research interests include: Translational clinical trials for treatment of primary CNS tumors, including low grade and malignant gliomas, ependymomas, meningiomas, and medulloblastoma. He actively involved in the evaluation of molecularly targeted drugs and immunotherapeutics and in the development of quantitative MRI and PET imaging techniques to better define tumor response and progression in clinical trials for patients with low grade and malignant gliomas. Their center has been one of the leaders in applying genetic profiling using first FISH and microdissection based LOH analysis and more recently Next Generation Sequencing to refine the diagnosis of gliomas and to identify molecular subgroups for molecularly targeted therapies. He also had been a coinvestigator in one of the largest occupational exposure studies conducted to identify potential environmental agents associated with increased risk of developing malignant gliomas.

Memberships in Professional and Scientific Societies

• (1994-Present) American Association of Cancer Research
• (1995-Present) American Academy of Neurology – Neuro-Oncology Section
• (1996-Present) Society for Neuro-Oncology
• (1996-Present) American Society of Clinical Oncology
• (2004-Present) NRG Radiation Therapy Oncology Group-CNS Tumors Committee
• (2006-Present) ECOG-ACRIN: Biomarker Committee, CNS Tumor Committee
• (2006-Present) Collaborative Ependymoma Research Network


•(1975) Phi Beta Kappa
•(1978) Merck Award for Excellence in Clinical Medicine
•(1979) Alpha Omega Alpha
•(1985) Sigma Xi

Referred Articles

1. Lieberman F, Marton LS, Stefansson K, Patter. Pattern of reactivity of IgM from the sear of 8 patients with IgM monoclonal gammopathy and neuropathy with components of neural tissue: evidence for interaction with more than one epitope. Acta Neuropathol (Berl). 1985; 68: 296-299.
2. Sitrin MD, Lieberman FS, Jensen WE, Noronha A, Milburn C, Addington W. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. Ann Intern Med. 1987; 107: 51-54. doi: 10.7326/0003-4819-107-1-51
3. Monestier M, Fasy TM, Bohm L, Lieberman FS. Anti-histone antibodies in subacute sensory neuropathy. J Neuro. 1991; 11: 71-75. doi: 10.1007/BF00167000
4. Hormigo A, Lieberman F. Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuro Immunol. 1994; 55: 205-212. doi: http://dx.doi.org/10.1016/0165-5728(94)90011-6
5. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg. 1995; 83: 672-681. doi: 10.3171/jns.1995.83.4.0672
6. Verschuuren J, Chuang L, Rosenblum MK, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996; 91: 519-525. doi: 10.1007/s004010050460
7. Lieberman F, Bulati S. Headaches after inadvertent lumbar puncture during bone marrow harvest. Neurology. 1996; 46: 268-269. doi: 10.1212/WNL.46.1.268
8. Lieberman F, Portlock C. Recurrent episodes of transient memory disturbance after unilateral thalamic infarction in a Hodgkin’s disease patient with herpes zoster. J Neurovasc Dis. 1996; 1: 9-12.
9. Hormigo A, Ball C, Lieberman F. Internalization of anti-Hu antibody is not Fcy receptor mediated. Neurology. 1996; 47: 607-609. doi: 10.1212/WNL.47.2.607
10. Lieberman FS, Odel J, Hirsch J, Heinemann M, Michaeli J, Posner JB. Bilateral optic neuropathy with IgGkappa multiple myeloma improved after myeloablative chemotherapy. Neurology. 1999; 52: 414-416.
11. Lieberman F, Korf BR. Emerging approaches toward the treatment of neurofibromatoses. Genet Med. 1999; 1: 158-164.
12. Lim DJ, Rubenstein AE, Evans DG, et al. Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet. 2000; 14(2): 63-106. doi: 10.3109/01677060009083477
13. Okada H, Pollack IF, Lotze MT, et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther. 2000; 11(4): 637-653. doi: 10.1089/10430340050015824
14. Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001; 12(5): 575-595. doi: 10.1089/104303401300042528.
15. Pollack IF, Hamilton RL, Finklestein SD, Lieberman F. Molecular abnormalities and correlations with tumor response and outcome in glioma patients. Neuroimaging Clin N Am. 2002; 12(4): 627-639.
16. Lieberman FS, Schold SC. Distant effects of cancer on the nervous system. Oncology(Huntingt). 2002; 16(11): 1539-1548; discussion 1550-1551, 1554-1556.
17. Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfect fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol. 2003; 64(1-2): 13-20. doi: 10.1023/A:1024969422010
18. Finkelstein SD, Mohan D, Hamilton R, Sasatomi E, Swalsky PA, Lieberman FS. Microdissection genotyping assists discrimination of reactive gliosis versus glioma. Am J Clin Pathol. 2004; 121/5: 671-678. doi: 10.1309/WF2HL03T7YP713NK
19. Mohan D, Finklestein SD, Swalsky PA, et al. Microdissection genotyping of gliomas: therapeutic and prognostic considerations. Mod Pathol. 2004; 17(11): 1346-1358. doi: 10.1038/modpathol.3800194
20. Pudavelli VK, Yung WK, Hess KR, et al. Phase II study of fenretinide(NCS 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004; 22(21): 4282-4289. doi: 10.1200/JCO.2004.09.096
21. Cloughesy TF, Kuhn J, Robins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J Clin Oncol. 2005; 23(27): 6647-6656. doi: 10.1200/JCO.2005.10.068
22. Lassman, AB, Rossi MR, Raizer JR, et al. Molecular study of malignant gliomas treated with EGFR inhibitors: tissue analysis from North American Brain Tumor Consortium(NABTC) trials 01-03 and 00-01. Clin Cancer Res. 2005; 11(21): 7841-7850. doi: 10.1158/1078-0432.CCR-05-0421
23. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1): 15-49. doi: http://dx.doi.org/10.1053/j.seminoncol.2005.12.010
24. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J Clin Oncol. 2006; 24 (22): 3651-3656. doi: 10.1200/JCO.2006.06.2323
25. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006; 12(16): 4899-4907. doi: 10.1158/1078-0432.CCR-06-0773
26. Bernardi RJ, Bomgaars L, Fox E, et al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2007. doi: 10.1007/s00280-007-0601-x
27. Loghin ME, Prados MD, Wen P, et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. Clin Cancer Res. 2007; 13(23): 7133-7138. doi: 10.1158/1078-0432.CCR-07-0874
28. Okada H, Lieberman F, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007; 5(1): 67. doi: 10.1186/1479-5876-5-67
29. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. North American Brain Tumor Consortium. Neuro Oncol. 2008; 10(2): 162-170. doi: 10.1215/15228517-2007-062
30. Kano H, Niranjan A, Khan A, et al. Does radiosurgery have a role in the management of ogliodendrogliomas? J Neurosurg. 2008. doi: 10.3171/2008.5.17582
31. Chang SM, Lamborn KR, Kuhn JG, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008. doi: 10.1215/15228517-2008-021
32. Marsh GM, Buchanich JM, Youk AO, et al. Long-term health experience of jet engine manufacturing workers: I. Mortality from central nervous system neoplasms. J Occup Environ Med. 2008; 50(10): 1099-1116. doi: 10.1097/JOM.0b013e31818bc30e
33. Marsh GM, Buchanich JM, Youk AO, et al. Long-term health experience of jet engine manufacturing workers: II. Total and cause-specific mortality excluding central nervous system Neoplasms. J Occup Environ Med. 2008; 50 (10): 1117-1129. doi: 10.1097/JOM.0b013e31818bc327
34. Butowski N, Lamborn KR, Lee BL, et al. A North American Brain Tumor Consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009; 91(2): 183-189. doi: 10.1007/s11060-008-9705-3
35. Buchanich JM, Youk AO, Marsh GM, et al. Methodological issues in a retrospective cancer incidence study. Am J Epidemiol. 2009; 170 (1): 112-119. doi: 10.1093/aje/kwp091
36. Park DM, Yeaney GA, Hamilton RL, et al. Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme. Neuro Oncol. 2009; 11 (4): 452-455. doi: 10.1215/15228517-2008-101
37. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010; 96(2): 211-217. doi: 10.1007/s11060-009-9948-7
38. Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial or erolotinib on patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meniniomas. Neuro Oncol. 2010; 12 (1) : 87-97. doi: 10.1093/neuonc/nop017
39. Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010; 12 (1): 95-103. doi: 10.1093/neuonc/nop015
40. Yiin JJ, Hu B, Schornack PA, et al. ZD6474, a Multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the Brain. Mol Cancer Ther. 2010; 9 (1): 929-941. doi: 10.1158/1535-7163.MCT-09-0953
41. Marsh GM, Buchanich JM, Youk AO, et al. Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. Ann Epidemiol. 2010; 20 (10) 759-765. doi: 10.1016/j.annepidem.2010.06.008
42. Buchanich JM, Youk AO, Marsh GM, et al. Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. Ann Epidemiol. 2010; 20(10): 759-765. doi: 10.1016/j.annepidem.2010.06.008
43. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clini Onco. 2011; 29(19): 2689-2695. doi: 10.1200/JCO.2010.34.1636
44. Clarke JL, Ennis MM, Young WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011; 13(10): 1118-1124. doi: 10.1093/neuonc/nor110
45. Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma; North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011; 13(5): 509-516. doi: 10.1093/neuonc/nor017
46. Kofler J, Bartynski WS, Reynolds TQ, Lieberman FS, Murdoch GH, Hamilton RL. Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy. J Comput Assist Tomogr. 2011; 35(1): 39-42. doi: 10.1097/RCT.0b013e3181f31917.
47. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011; 29(3): 330-336. doi: 10.1200/JCO.2010.30.7744
48. Nghiemphu PL, Wen PY, Lamborn KR, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011; 81(5): 1422-1427. doi: 10.1016/j.ijrobp.2010.07.1997
49. Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery. 2012; 2(5): 458-471. doi: 10.1158/2159-8290.CD-11-0284
50. Lieberman F, Yazbeck V, Raptis A, Felgar R, Boyiadzis M. Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neuro-Oncol. 2012; 107(2): 225-232. doi: 10.1007/s11060-011-0739-6
51. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neuro-Oncol. 2012; 106(1): 147-153. doi: 10.1007/s11060-011-0650-1
52. Lee EQ, Kuhn J, Lamborn KR, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma; North American Brain Tumor consortium study 05-02. Neuro Oncol. 2012; 14(12): 1511-1518. doi: 10.1093/neuonc/nos264
53. Lee EQ, Puduvalli VK, Reid JM, et al. Phase I study of vorinostat in combination with emozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012; 18(21): 6032-6039. doi: 10.1158/1078-0432.CCR-12-1841
54. Kurland BF, Gerstner ER, Mountz JM, et al. Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging. 2012; 30(9): 1301-1312. doi: 10.1016/j.mri.2012.06.009
55. Laymon CM, Oborski MJ, Lee VK, et al. Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. Magn Reson Imaging. 2012; 30(9): 1268-1278. doi: 10.1016/j.mri.2012.05.011
56. Baldwin KJ, Zivović SA, Lieberman FS. Neurologic emergencies in patients who have cancer: diagnosis and management. Neurol Clin. 2012; 30(1): 101-128. doi: 10.1016/j.ncl.2011.09.004
57. Park KJ, Kano H, Iyer A, et al. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol. 2012; 107(2): 323-333. doi: 10.1007/s11060-011-0744-9
58. Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM. Comparison of proton magnetic resonance spectroscopy with fluorine-18 w-fluoro-deoxyglucose positron semission tomography for assessment of brain tumor progression. J Neuroimaging. 2012; 22(2): 184-190. doi: 10.1111/j.1552-6569.2010.00561.x
59. Oborski MJ, Laymon CM, Lieberman FS, Mountz JM. Distinguishing Pseudoprogression from progression in high-grade gliomas: A brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. Clin Nucl Med. 2013. doi: 10.1097/RLU.0b013e318286c148.
60. Oborski MJ, Laymon CM, Lieberman FS, Mountz JM. Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. Clin Nucl Med. 2013; 38(5): 381-384. doi: 10. 1097/RLU. 0b013e318286c148
61. Marsh GM, Buchanich JM, Youk AO, et al. Long-term health experience of jet engine manufacturing workers: results from a 12-year exploratory investigation. J Occup Environ Med. 2013; 55(6): 652-653. doi: 10. 1097/JOM. 0b013e3182851605. doi: 10.1097/JOM.0b013e3182851605
62. Kondziolka D, Parry PV, Lunsford LD, et al. The accuracy of predicting survival in individual patients with cancer. J Neurosurg. 2013. doi: 10.3171/2013.9.JNS13788
63. Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM. Molecular and metabolic pattern classification for detection of brain glioma progression. Eur J Radiol. 2013; S0720-048X(13): 00590-00591. doi: 10. 1016/j. ejrad. 2013. 06. 033
64. Oborski MJ, Demirci E, Laymon CM, Lieberman FS, Mountz JM. Assessment of Early Therapy Response with 18F-FLT PET in Glioblastoma Multiforme. Clin Nucl Med. 2013. doi: 10.1097/RLU.0000000000000321
65. Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM. Molecular and metabolic pattern classification for detection of brain glioma progression. Eur J Radiol. 2014; 83(2): e100-e105. doi: 10.1016/j.ejrad.2013.06.033
66. Oborski MJ, Laymon CM, Qian Y, Lieberman FS, Nelson AD, Mountz JM. Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10. Transl Oncol. 2014; 7(1): 111-119. doi: 10.1593/tlo.13868
67. Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM. First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav. 2014; 4(2): 312-315. doi: 10.1002/brb3.217
68. Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res. 2014; 6: 149-170. doi: 10.2147/CMAR.S54726
69. Wen PY, Chang SM, Lamborn KR, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014; 16(4): 567-578.
70. Qian Y, Panigrahy A, Laymon CM, et al. Short-T2 imaging for quantifying concentration of sodium (23 Na) of bi-exponential T2 relaxation. Magn Reson Med. 2014. doi: 10.1002/mrm.25393
71. Vera-Bolanos E, Aldape K, Yuan Y, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2014. nou162.
72. Oborski MJ, Demirci E, Laymon CM, Lieberman FS, Mountz JM. Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med. 2014; 39(10): e431-e432. doi: 10.1097/RLU.0000000000000321
73. Okada H, Butterfield LH, Hamilton RL, et al. Induction of robust type-1 CD8+ T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2014; clincanres. 1790. 2014. doi: 10.1158/1078-0432.CCR-14-1790

Khalid Al-Nedawi, PhD

Assistant Professor
Department of Medicine
McMaster University and St. Joseph’s Healthcare
50 Charlton Street East
Hamilton, Ontario, Canada

BiographyResearch InterestScientific ActivitiesPublications

Dr. Al-Nedawi received his PhD in Medical Biology and Biotechnology. He received a post-doctoral fellowship and scientific adjunctposition at the center for medical research at the Polish Academy of Science. He joined McGill University as a post-doctoral fellow and later as medical scientist and faculty lecturer. Dr. Al-Nedawi has received several awards and recognition for his scientific accomplishments. He is the winner of the 2010 Michael G. DeGroote academic fellowship award at McMaster University. Currently, Dr Al-Nedawi is an Assistant Professor at McMaster University/Department of Medicine.


Dr. Al-Nedawi has contributed to research on thrombosis haemostasis, cancer progression, angiogenesis, metastasis and biomarkers. Dr. Al-Nedawi’s primary interest is the mechanisms of intercellular interactions through short exosomes / microvesicles. Dr. Al-Nedawi reported the mechanism by which cancer cells can shed oncogenic proteins via microvesicles to the neighboring non-cancer cells providing them with an ectopic transformed phenotype. Furthermore, he reported the transfer of oncogenic proteins from cancer cells to tumour endothelial cells triggering the angiogenic switch. In addition, he contributed to the detection of oncogenic proteins in the cargo of microvesicles circulating in the cancer patient’s peripheral blood. Dr. Al-Nedawi has published in high ranked medical journals like “Blood, ATVB, NCB, PNAS”, and contributed to many international scientific conferences. Dr Al-Nedawi is funded by prostate cancer Canada (Movember foundation), and St Joseph’s Hospital. Dr Al-Nedawi lab located at St Joseph’s healthcare, Hamilton Center for Kidney Research. A postdoctoral fellow and four graduate students, currently working in Dr Al-Nedawi’s lab pursuing different research projects.

His research interests include: Microvesicles/exosomes as source of biomarkers, Intercellular communication through microvesicles and short peptides, Signal Transduction, Biology of Cancer and cellular transformation, Angiogenesis, Transgenic mouse and stem Cell biology, Thrombosis - Haemostasis


• (2010) Michael DeGroote Academic Fellow, McMaster University

1. Al-Nedawi K. The yin-yang of microvesicles (exosomes) in cancer biology. Frontiers in Oncology. 2014; 4: 172. doi: doi: 10.3389/fonc.2014.00172
2. Kathleen Gabriel, Alistair Ingram, Austin R, et al. Regulation of the tumor suppressor PTEN through exosomes: A diagnostic potential for prostate cancer. PLOS One. 2013; 8, 7: e70047. doi: 10.1371/journal.pone.0070047
3. Al-Nedawi K, Meehan B, Micaleff J, Lahotak W, Guha Ab, Rak J. Intercellular Transfer of the Oncogenic EGFRvIII via Tumor Cell Derived Microvesicles. Nature Cell Biology. 2008; 10(5): 619-624. doi: 10.1038/ncb1725.
4. Al-Nedawi K, Meehan B, Kerbel R, Anthony C. Allison, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-Derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (PNAS). 2009; 106(10): 3794-3799. doi: 10.1073/pnas.0804543106
5. Al-Nedawi K, Meehan B, Rak J. Microvesicles- messengers and mediators of tumor progression. Cell Cycle. 2009; 8(13):2014-2018. doi: 10.4161/cc.8.13.8988
6. Lee TH, D’Asti A, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer the emerging science of cellular ‘debris’. Semin Immunopathol. 2011; 33(5):455-467. doi: 10.1007/s00281-011-0250-3
7. Milsom C, Magnus N, Meehan B, Al-Nedawi K, Garnier D, Rak J. Tissue Factor and Cancer Stem Cells- Is there a Linkage? Arteriosclerosis Thrombosis and Vascular Biology. 2009; 29(12): 2005-2014. doi: 10.1161/ATVBAHA.108.177444
8. Al-Nedawi K, Szemraj J, Cierniewski CS. Mast cell-derived exosomesactivate endothelial cells to secrete plasminogen activator inhibitor type 1. Arteriosclerosis Thrombosis and Vascular Biology. 2005; 25(8): 1744-1749. doi: 10.1161/01.ATV.0000172007.86541.76
9. Al-Nedawi K, Czyz M, Bednarek M, et al. Thymosin β4 Induces the SynthesisOf Plasminogen Activator Inhibitor-1 in Cultured Endothelial Cells and Increases ItsExtracellular Expression. Blood. 2004; 103(4):1319-1324. doi: 10.1182/blood-2003-04-1015.
10. Milsom C, Yu J, May L, et al. The Role of Tumor and Host-Related Tissue Factor Pools in Oncogene-Driven Tumor Progression. Thrombosis Research. 2007; 120(2): 82-91. doi: http://dx.doi.org/10.1016/S0049-3848(07)70135-4
11. Ullerås E, Trzaska D, Arkusz J, et al. Development of the “Cell Chip”: A New In-Vitro AlternativeTechnique for Immunotoxicity Testing. Toxicology. 2005; 206(2):245-256. doi: 10.1016/j.tox.2004.08.016
12. Szemraj J, Al-Nedawi K, Pawlowska Z, Chabielska E, Buciko W. Tissue Distribution of Phosphorothioate Oligodeoxyribonucleotides Antisense to PAI-1 mRNA in Rats. Acta Biochimica Polonica. 2005; 52 (4):849-855 .
13. Swiatkowska M, Szemraj J, Al-Nedawi K, Pawlowska Z. Reactive Oxygen Species upregulate expression of PAI-1 in endothelial cells. Cellular and Molecular BiologyLetters. 2002; 7(4): 1065-1071.
14. Al-Nedawi K, Pawlowska Z, Cierniewski CS. Interferon-gamma bound to endothelial cells is phosphorylated by ecto-protein kinases. Acta Biochimica Polonica. 1999; 46(3): 693-702.

Ramachandran Murali, PhD

Associate Professor
Research Division of Immunology and Infectious Disease
Department of Biomedical Sciences
Cedars-Sinai Medical Center
8700 Beverly Boulevard
Davis Building 5091
Los Angeles, CA 90048, USA

BiographyResearch InterestScientific ActivitiesPublications

•(1978) BSc, University of Madras, India (Physics)
•(1980) MSc, University of Madras, India (Physics)
•(1986) PhD, University of Madras, India (Biophysics)
•(1986-1988) Postdoctoral Fellow, Columbia University, New York, NY
•(1988-1994) Postdoctoral Fellow, The Wistar Institute, Philadelphia
•(1994-1996) Postdoctoral Fellow, University of Pennsylvania


•(1997-1999) Research Associate in Pathology and Laboratory Medicine, University of Pennsylvania
•(1999-2006) Research Assistant Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
•(2007-2010) Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
•(2010-Present) Adjunct Associate Professor, Department of Pathology and Laboratory of Medicine, University of Pennsylvania, Philadelphia
•(2010-Present) Associate Professor, Dept. of Biomedical Sciences, Cedars-Sinai Medical Center, LA
•(2011-Present) Director, Molecular Therapeutics Core Facility, Cedars-Sinai Medical Center, LA

His research interests include: Molecular basis of cancer metastasis and identification of new therapeutic strategies to limit resistance, recurrence of cancer. Studies are focused on role of the tumor necrosis factor receptors and the epidermal growth factor receptors in breast, lung and pancreatic cancers. Employ structural biology for drug discovery and develop molecular probes for tumor imaging and drug delivery.


•(1987-1994) Member, American Physics Association
•(1996) NRSA Fellowship, NIH
•(1996-1999) Member, American Crystallographic Association
•(2014-Present ) Member, American Pancreatic Association
• (1999-Present) Member, International Union for Crystallography
•(2000-Present) Member, Cancer Center, U of Penn, Philadelphia
•(2008-Present) Member, Institute for Translational of Medicine and Therapeutics, U of Penn, PA
•(2010-Present) Member, Samuel-Oschin Cancer Institute, CSMC
•(2010) Associate Professor, The Biomedical Imaging Research Institute, CSMC


1. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF.alpha. binding to its receptor. Nat Biotechnol. 1997; 15(12): 1266-1270. doi: 10.1038/nbt1197-1266
2. Park BW, Zhang HT, Wu C, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol. 2000; 18: 194-198. doi: 10.1038/72651
3. Horie T, Shen Y, Kajino K, et al. Study of Disabling T-Cell Activation and Inhibiting T-Cell-Mediated Immunopathology Reveals a Possible Inverse Agonist Activity of CD4 Peptidomimetics. Exp Mol Pathol. 2002; 73(2): 93. doi: 10.1006/exmp.2002.2444
4. Kim N, Ussin L, Cheng X, Murali R, Sullivan KE. TNFalpha inhibition in MRL/lpr mice ameliorates pulmonary but not renal disease. J Autoimmun. 2002; 19(4): 215-222. doi: 10.1006/jaut.2002.0617
5. Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem. 2004; 279(9): 8269-8277. doi: 10.1074/jbc.M309690200
6. Hasegawa A, Cheng X, Kajino K, et al. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A. 2004; 101(17): 6599-6604. doi: 10.1073/pnas.0401597101
7. Murali R, Cheng X, Berezov A, et al. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci U S A. 2005; 102(31): 10970-10975. doi: 10.1073/pnas.0504301102
8. Aoki K, Saito H, Itzstein C, et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest. 2006; 116(6): 1525-1534. doi: 10.1172/JCI22513.
9. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007; 67(1): 202-208. doi: 10.1158/0008-5472.CAN-06-1287
10. Zhou Z, Song X, Berezov A, et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A. 2008; 105(14): 5465-5470. doi: 0711350105 doi: 10.1073/pnas.0711350105.
11. Zhou Z, Tone Y, Song X, et al. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A. 2008; 105(2): 641-645. doi: 10.1073/pnas.0711206105.
12. Levine DH, Ghoroghchian PP, Freudenberg J, et al. Polymersomes: A new multi-functional tool for cancer diagnosis and therapy.Methods. 2008; 46: 25-32. doi: 10.1016/j.ymeth.2008.05.006.
13. Razmara M, Hilliard B, Ziarani AK, et al. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol. 2009; 174(2): 460-474. doi: 10.2353/ajpath.2009.080462
14. Nakachi H, Aoki K, Tomomatsu N, et al. A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model. Eur J Pharmacol. 2012; 679(1-3): 132-138. doi: 10.1016/j.ejphar.2011.12.046.
15. Ponde DE, Su Z, Berezov A, et al. Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg Med Chem Lett. 2011; 21(8): 2550-2553. doi: 10.1016/j.bmcl.2011.02.013
16. Murali R, Greene MI. Structure based antibody-like peptidomimetics. Pharmaceuticals. 2012; 5(12): 209-235. doi: 10.3390/ph5020209.
17. Kanzaki H, Ohtaki A, Merchant FK, Greene MI, Murali R. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. Exp Mol Pathol. 2013. doi: 10.1016/j.yexmp.2012.11.003.
18. Ohtaki A, Kieber-Emmons T, Murali R. Structure-based peptide mimicry of tumor-associated antigens. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2013; 32(1): 1-5. doi: 10.1089/mab.2012.0076.
19. Kieber-Emmons T, Saha S, Pashov A, Monzavi-Karbassi B, Murali R. Carbohydrate-mimetic peptides for pan anti-tumor responses. Frontiers in immunology. 2014; 5: 308. doi: 10.3389/fimmu.2014.00308.
20. Saha S, Pashov A, Siegel ER, Murali R, Kieber-Emmons T. Defining the recognition elements of lewis y-reactive antibodies PloS one. 2014; 9: e104208. doi: 10.1371/journal.pone.0104208.

Maureen E. Lane, PhD

Assistant Research Professor of Molecular Biology in Medicine
Director, Hem/Onc Translational Core Laboratory
The Leukemia Biorepository and Personalized Medicine Center
Weill Cornell Medical College
1300 York Avenue, Box 113
NewYork 10065, NYC, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Lane is an Assistant Research Professor of Molecular Biology in Medicine and the Director of The Clinical Translational Core Lab and the Leukemia Bio repository and Personalized Medicine Center within hem/onc at Weill Cornell Medical College in NYC. Dr. Lane has fostered collaborative efforts between academia, industry and biotechnology companies, and has served as the principal investigator on several research grants focused on cancer screening assessment, targeted therapeutic efficacy and biomarker studies. Her work is published in both basic science and clinical journals. Maureen has a BS in Cytotechnology from SUNY Health Science Center in Syracuse, a Masters from SUNY Binghamton, and she completed her PhD at North-eastern University in Boston. She is involved with several professional organizations including the American Association for Cancer Research, American Society of Clinical Pathologists and Women in Cancer Research.

Her research interest include: Molecular biology of both solid and liquid tumors and the use of targeted combination therapeutics in treating cancer and achieving improved outcomes in our patients.


• International Society for Biological and Environmental Biorepositories (ISBER)
• Cancer and Leukemia Group B (CALGB)
• AACR Tumor Microenvironment Group
• American Association for Cancer Research
• American Society of Clinical Pathologists (ASCP)
• International Early Lung Cancer Action Project (Steering Committee)
• New York Academy of Sciences
• Weill Cornell Cancer Center
• Women in Cancer Research


• American Association for Cancer Research Scholar-in-Training Award
• Member/Reviewer, Early Career Reviewer (ECR) Program at the Center for Scientific Review (CSR)
• Firefly Frontiers Award for microRNA Discovery and Validation, Firefly Bioworks Inc


1. Yu B, Lane M, Pestell R, Albanese C, Wadler S. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol Cell Biol Res Commun. 2000; 3: 352-359. doi: 10.1006/mcbr.2000.0238
2. Lane ME, Yu B, Rice A, et al. A novel cdk2 inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001; 61: 6170-6177.
3. Wadler S, Makower D, Yu B, et al. Clinical applications of p53-directed gene therapy. Suppl Tumori. 2002; 1(6): S21.
4. Yu, B, Lane ME, Wadler S. SU9516, a cyclin dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002; 64: 1091-1100. doi: 10.1016/S0006-2952(02)01264-9
5. Wadler S, Yu B, Tan JY, et al. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res. 2003; 9: 33-43.
6. Makower D, Rozenblit A, Kaufman H, et al. Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus, ONYX-015, in Patients with Hepatobiliary Tumors with Correlative p53 Studies. Clin Cancer Res. 2003; 9: 693-702.
7. Cham MD, Lane ME, Henschke CI, Yankelevitz DF. Lung biopsy: special techniques. Semin Respir Crit Care Med. 2008; 29: 335-349. doi: 10.1055/s-2008-1081278
8. Altorki N, Lane ME, Bauer T, et al. A Phase II Proof-of-Concept Study of Pazopanib (GW786034) Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small Cell Lung Cancer. J Clin Oncol. 2010; 28 (19): 3131-3137.
9. Ocean A, Christos P, Sparano J, et al. Phase II Trial of Ribonucleotide Reductase Inhibitor 3-aminopyridine-2-carboxaldehydethiosmeicarbazone plus Gemcitabine in patients with Advanced Biliary Tract Cancer. Cancer Chemother Pharmacol. 2011; 68(2): 379-388. doi: 10.1007/s00280-010-1481-z
10. Jain S, Ward MM, O Loughlin J, et al. Incremental increase in VEGFR1+ hematopoietic progenitor cellsand VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Res Treat. 2012; 132(1): 235-242. doi: 10.1007/s10549-011-1906-3
11. Jain S, Cohen J, Ward M, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol. 2013; 24(6). doi: 10.1093/annonc/mds654
12. Niesvizky R, Mark TM, Ward M, et al. Overcoming the response plateau in multiple myeloma: A novelbortezomib-based strategy for secondary induction and high-yieldCD34+ stem cell mobilization. Clin Cancer Res. 2013; 19(6): 1534-1546. doi: 10.1158/1078-0432.CCR-12-1429.
13. Ocean AJ, Christos P, Sparano JA, et al. Phase II trial of bortezomib alone and in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs. 2014; 32(3): 542-548. doi: 10.1007/s10637-014-0070-0
14. Ebenezer GJ, Carlson K, Donovan D, et al. Ixabepilone‐induced mitochondria and sensory axon loss in breast cancer patients. Annals of Clinical and Translational Neurology. 2014. doi: 10.1002/acn3.90

Walter A. Hall, MD, MBA

Department of Neurosurgery
SUNY Upstate Medical University
750 East Adams Street
Syracuse, NY 13210, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Hall is a Professor of Neurosurgery at the State University of New York Upstate Medical University in Syracuse, New York. Prior to his arrival in Syracuse in 2007, he was a Professor of Neurosurgery, Radiation Oncology, and Radiology at the University of Minnesota School of Medicine and the Shelly N. and Jolene J. Chou Chair in Neurosurgery. Dr. Hall received his BA degree from Columbia College of Columbia University in 1979 and his MD degree from the College of Physicians and Surgeons of Columbia University in 1983. He completed his General Surgery Internship at the University of Pittsburgh in 1984 and his neurosurgical residency was completed at the University of Pittsburgh in 1990. During his training, he spent two years at the National Institutes of Health in the Surgical Neurology Branch as a Medical Staff Fellow from 1987 to 1989. He was the 1990 recipient of the Van Wagenen Fellowship of the American Association of Neurological Surgeons which he spent working in the Department of Tumor Biology of the Norwegian Radium Hospital in Oslo, Norway. Dr. Hall joined the faculty of the University Of Minnesota School of Medicine in February 1991. In 1996 he was awarded the Mahaley Clinical Research Award in brain tumors by the Joint Section of Tumors of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons. In 1998, Dr. Hall received his MBA degree from the Carlson School of Management of the University of Minnesota. He was the Director of the Brain Tumor Center of Minnesota and has extensive clinical and laboratory experience in developing new therapeutic modalities for treating brain tumors. Treatment modalities for brain tumors that have been developed under Dr. Halls guidance include stereotactic radiosurgery, fractionated stereotactic radiotherapy, blood-brain barrier disruption chemotherapy, interventional magnetic resonance imaging-guided neurosurgery, and targeted toxin therapy. He performed more that 1,000 neurosurgical procedures using intraoperative magnetic resonance imaging guidance over from 1997 to 2007. In addition, Dr. Hall has authored more than 180 publications on brain tumors, targeted toxins, intraoperative magnetic resonance imaging-guided neurosurgery, and central nervous system infections.

His research interests include: Central Nervous System Infections, Neuro-Oncology, Intraoperative MRI, Targeted Toxins, Brain Tumors, Neurosurgery.


• (1975) Senior Scholar-Athlete Award of St. Stephens School, Alexandria, Virginia
• (1978) Phi Gamma Delta Educational Foundation Award, New York, New York
• (1989) Southern Medical Association Section on Neurosurgery Physician-in-Training Award
• (1990) Van Wagenen Fellowship Norwegian Radium Hospital, Oslo, Norway Frenchay Hospital, Bristol, United Kingdom
• (1991) American College of Surgeons Fellowship second alternate
• (1994) Preuss Award for Resident Brain Tumor Research (Eric P. Flores, M. D.)
• (1994) State of Minnesota Outstanding Physician under 40 years of age
• (1996) Preuss Award for Resident Brain Tumor Research (Margaret A. Wallenfriedman, M. D.)
• (1996) Mahaley Clinical Award from the Joint Section on Tumors of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons
• (1997) Preuss Award for Resident Brain Tumor Research (Walter C. Jean, M. D.)
• (2000) Minneapolis/St. Paul Magazine “Top Doctor” for Neurosurgery
• (2002) Minneapolis/St. Paul Magazine “Top Doctor” for Neurosurgery
• (2004) Consumers CHECKBOOK Guide to Top Doctors (Minneapolis)
• (2005) Consumers CHECKBOOK Guide to Top Doctors (Minneapolis)
• (2006-2007) Shelly N. and Jolene J. Chou Chair in Neurosurgery, University of Minnesota
• (2007-2011) Robert B. and Molly G. King Chair in Neurosurgery, SUNY Upstate Medical University
• (2007) ISMRM and ESMRMB Joint Annual Meeting Outstanding Teacher Award in Cross- discipline clinical categorical courses
• (2009) “The Best Doctors in America” induction
• (2009) Central New York Magazine “Top Doctor” for Neurosurgery
• (2012) Patients Choice Award


• (1985) Visiting Fellow in Neurology, The Neurological Institute, New York, New York
• (1986) Clinical Instructor in Neuropathology, University of Pittsburgh School of Medicine, • Pittsburgh, Pennsylvania
• (1986) Neurosurgeon, University of Pittsburgh Football Team, Pittsburgh, Pennsylvania
• (1987) Clinical Instructor in the Trauma Nurse Course, Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania
• (1987-1989) Medical Staff Fellow, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
• (1990-1995) Assistant Professor of Neurosurgery, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1994-1995) Assistant Professor of Radiation Oncology, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1995-1999) Associate Professor of Neurosurgery, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1995-1999) Associate Professor of Radiation Oncology, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1998-1999) Associate Professor of Radiology, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1999-2007) Professor of Neurosurgery, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1999-2007) Professor of Radiation Oncology, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (1999-2007) Professor of Radiology, University of Minnesota School of Medicine, Minneapolis, Minnesota
• (2003-2007) Member of the Graduate Faculty in the Field of Biophysical Sciences and Medical Physics
• (04/07-08/09) Chairman, Department of Neurosurgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York
• (04/07-08/11) Program Director, Department of Neurosurgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York
• (2007-Present) Professor of Neurosurgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York

University of Minnesota Activities

• (1991) Medical Record and Patient Care Information Committee
• (1991) Biomedical Ethics Education Subcommittee
• (1992) Clinical Outcomes Task Force Subcommittee
• (1992) Surgical Specialties Course Director
• (1996) Years 3 & 4 Externship Director
• (1998) Member, Curriculum Council
• (1993) Untenured Faculty Advisory Committee
• (1993) Program Development Committee
• (1995) Chairman, Neuroscience Subcommittee
• (1993) Associate Member of the Graduate Faculty
• (1993) Director of Graduate Studies
• (1993) Emerging Technology Task Force
• (1993) Health Sciences Policy and Review Council Program Review Subcommittee
• (1993) Departmental Education Liaison for Curriculum
• (1994) Advisory Search Committee for Cancer Center Director
• (1994) Director of Quality Assurance in Neurosurgery
• (1994) Cancer Center Tumor Bank Committee
• (1996) Executive Committee Cancer Center Tumor Bank
• (1995) Professional Services Committee
• (1996) Director of Graduate Medical Education for Neurosurgery
• (1997) Graduate Medical Education Committee
• (1997) University of Minnesota Physicians Compensation, Benefits and Human Resources Committee
• (1997) University of Minnesota Physicians Clinical Services and Quality Assurance Committee
• (1997) Medical Director for Clinical Integration of Neurosciences
• (1997) Member, Institutional Review Board: Human Subjects Committee
• (1997) University of Minnesota Physicians Finance Council
• (1997) Chairman, Neuroscience Quality Improvement Committee
• (1998) Chairman, University of Minnesota Physicians Program Development Committee
• (1998) University of Minnesota Physicians Oncology Service Task Force
• (1998-2004) Member, Curriculum Committee
• (1998) Council of Clinical Sciences GME Subcommittee
• (1998) Chairman, Fairview-AHC Access Pathways Review Committee
• (1998) Member, Search Committee for Neuropathology
• (1998) Member, Search Committee for Chairman of Therapeutic Radiology
• (1998) Member, Consultation Process Advisory Committee
• (1999-2003) Alternate Member, Promotions and Tenure Committee of the Medical School
• (1999) Member, Search Committee for Chairman of Neurology
• (1999-2004) Years 3 and 4 Neurosurgery Course Director
• (1999) Chairman, Grade Inflation Subcommittee
• (2000) Clinical Sciences Committee for AHC Planning
• (2000) Co-Director, Fairview-University Brain Tumor Center
• (2000) Member, University of Minnesota Physicians Human Resources Committee
• (2000) Member, University of Minnesota Physicians Clinical Services & Program Development Committee
• (2000) Medical/Surgical Collaborative Practice Committee
• (2000-2006) Member, University of Minnesota Physicians Board of Directors
• (2000) Member, Search Committee for Endowed Chair in Pediatric Brain Tumors
• (2001) Member, Search Committee for Neuropathology
• (2001) Member, University of Minnesota Physicians Compliance and Clinical Practice Committee
• (2001) Member, University of Minnesota Physicians Risk Management Subcommittee
• (2001) Member, Medical School Years 3 and 4 Transition Course Committee
• (2001) Member, University of Minnesota Physicians Nominating Committee
• (2001) UM Physicians Compliance Leader, Department of Neurosurgery
• (2002-2004) Co-chair, Neuroscience Clinical Program, University of Minnesota Physicians
• (2002-2004) Member, Council of Clinical Program Leaders, University of Minnesota Physicians
• (2002) Member, Technology Assessment Committee
• (2003) Chair, University of Minnesota Physicians Human Resources Committee
• (2003) Member, University of Minnesota Physicians Compensation Committee
• (2003) Member, Peer Review Subcommittee of the University of Minnesota Physicians Compliance Committee
• (2003) Member, University of Minnesota Physicians Interdisciplinary Program Development Committee
• (2003) Member, University of Minnesota Physicians Investment Committee
• (2003) Member, University of Minnesota Physicians Committee on Committees
• (2004) Member, Faculty Advisory Council
• (2005-2006) Chief of Clinical Service (Neurosurgery)
• (2005-2006) Executive Committee of the Medical Staff of Fairview-University Medical Center
• (2005) Co-Director, Gamma Knife Center
• (2005) Chair, Institutional Review Board 02 Committee
• (2005) Member, Institutional Review Board Executive Committee
• (2006) Member, University of Minnesota Cancer Center Oncology Council
• (2006) Member, Search Committee for Neuroscience Administrative Center Director
• (2006) Department of Neurosurgery Associate Department Head for Academic Affairs
• (2006) Chair, University of Minnesota Physicians Investment Committee
• (2006) Alternate Reviewer, UMMC Medical Staff Credentialing Committee


• (2007-2009) College of Medicine Executive Committee
• (2007-2009) University Hospital Governance Committee
• (2007-2009) Operative Services Planning Committee
• (2007-2009) Strategic Planning Committee
• (2007-2009) University Medical Associates at Syracuse, Inc. Governing Board
• (2007-2009) Vertical Expansion Steering Committee
• (2007-2009) Neuroscience Quality Team Committee
• (2007-2009) Institute for Human Performance Magnetic Resonance Imaging Core Advisory Committee
• (2007-2009) Stroke Center Committee
• (2007-2009) Intensive Care Unit Governance Committee


•(1979) Senior Society of Nacoms of Columbia College
•(1980) Alumni Secondary Schools Committee of Columbia College
•(1990) Stuart Rowe Society of the University of Pittsburgh Department of Neurosurgery
•(1991) Peyton Society of the University of Minnesota Department of Neurosurgery
•(1991) American Medical Association
•(1991) Minnesota Medical Association
•(1991) Hennepin County Medical Society
•(1991) Minnesota Neurosurgical Society
•(2003) Treasurer
•(2004) President
•(1991) Neurosurgical Research Society
•(1991) Brain Tumor Cooperative Group
• Principal Investigator, University of Minnesota Hospital and Clinic •(1992) Congress of Neurological Surgeons (1992)
•(1992) Alternate Delegate to the Joint Council of State Neurosurgical Societies
•(1992) Member Open Scientific Session Committee
•(1992) Member Young Physicians Committee
•(1993-1994) Member Sergeant-At-Arms Committee
•(1993) Member General Scientific Session I Committee
•(1993) Member General Scientific Session IV Committee
•(1994) Chairman Poster Session Committee
•(1995) Chairman Host Committee
•(1992) Joint Section on Tumors
•(1995) Member Membership Committee (1995)
•(1996) Chairman General Scientific Session I Committee
•(1996) Co-chairman Sergeant-at-Arms Committee
•(1996) Member Scientific Program Committee Tumor Satellite Conference
•(2000) Joint Section on Stereotactic and Functional Neurosurgery
•(1992) American Association for Cancer Research
•(1992) International Stereotactic Radiosurgery Society
•(1993) Radiation Therapy Oncology Group
•(1993) Neurosurgery Subcommittee of the Surgical Committee
•(1994) American Association of Neurological Surgeons
•(1995) Fellow of the American College of Surgeons
•(1995) North American Society for Neuro-Oncology
•(1997-2001) American College of Physician Executives
•(1998) Society for Neuroscience
•(2000) American Society for Stereotactic and Functional Neurosurgery (2000)
•(2000) World Society for Stereotactic and Functional Neurosurgery
•(1998) Society for Neuro-Oncology
•(2000) Scientific Program Committee
•(2000) Future Sites Committee
•(2004) Chairman, Future Sites Committee
•(2004) Scientific Program Committee (2004)
•(2004) Board of Directors
•(2001) Neurosurgical Society of America
•(2005) Member, Nominating Committee
•(2005-2007) Van Wagenen Selection Committee of the American Association of Neurological Surgeons
•(2007) Van Wagenen Fellowship Committee of the American Association of Neurological Surgeons
•(2006-2007) Chairman, Van Wagenen Selection Committee of the American Association of Neurological Surgeons
•(2007) Society of Neurological Surgeons
•(2007) Onondaga County Medical Society
•(2007) Medical Society of the State of New York
•(2007-2009) New York State Neurosurgical Society
•(2008) Intraoperative Imaging Society
•(2008-2010) Board of Directors
•American Board of Neurological Surgery •(2008) Guest Oral Board Examiner
•(2009) American Radium Society


1. Wise TN, Hall WA, Wong O. The relationship of cognitive styles and affective status to postoperative analgesic utilization. J Psychosom Res. 1978; 22: 513-519.
2. Wise TN, Hall WA, Wong O. A simple screening technique to estimate narcotic utilization. South Med J. 1979; 72: 415-417.
3. Wise TN, Hall WA, Wong O. Pain response compared: After back surgery, cholecystectomy. Va Med. 1981; 108: 183-185.
4. Hall WA, Yunis EJ, Albright AL. Anaplastic ganglioglioma in an infant: Case report and review of the literature. Neurosurgery. 1986; 19: 1016-1020.
5. Hall WA, Lunsford LD. Changing concepts in the treatment of colloid cysts: An eleven year experience in the computed tomography era. J Neurosurg. 1987; 66: 186-191.
6. Hall WA, Martinez AJ, Dummer JS, Lunsford LD. Nocardial brain abscess: Diagnostic and therapeutic use of stereotactic aspiration. Surg Neurol. 1987; 28: 114-118.
7. Martinez AJ, Pollack I, Hall WA, Lunsford LD. Touch preparations in the intraoperative diagnosis of central nervous system lesions: A comparison with frozen sections and paraffin-embedded sections. Modern Pathology. 1988; 1: 378-384.
8. Hall WA, Albright AL, Brunberg JA. Diagnosis of tethered cords by magnetic resonance imaging. Surg Neurol. 1988; 30: 60-64.
9. Hall WA, Martinez AJ, Dummer JS. Progressive multifocal leukoencephalopathy after cardiac transplantation. Neurology. 1988; 38: 995-996.
10. Hall WA, Martinez AJ, Dummer JS, et al. Central nervous system infections in heart and heart-lung transplant recipients. Arch Neurol. 1989; 46: 173-177.
11. Hall WA, Oldfield EH, Doppman JL. Recanalization of spinal arteriovenous malformations following embolization. J Neurosurg. 1989; 70: 714-720.
12. Hall WA, Merrill MJ, Youle RJ. Growth factor receptors on brain tumors. Surgical Forum. 1989; 40: 498-500.
13. Hall WA, Martinez AJ. Neuropathology of pediatric liver transplantation. Ped Neurosci. 1989; 15: 269-275.
14. Pollack IF, Pang D, Hall WA. Subarachnoid-pleuromediastinal fistula. Neurosurgery. 1990; 26: 519-525.
15. Hall WA, Merrill MJ, Walbridge S, Youle RJ. Epidermal growth factor receptors on ependymomas and other brain tumors. J Neurosurg. 1990; 72: 641-646.
16. Horowitz MJ, Hall WA. Central nervous system germinomas: A review. Arch Neurol. 1991; 48: 652-657. doi: 10.1001/archneur.1991.00530180110026
17. Hall WA, Fodstad Ø. Immunotoxins and central nervous system neoplasia. J Neurosurg. 1992; 76: 1-12.
18. Wen DY, Bottini AJ, Hall WA, Haines SJ. The intraventricular use of antibiotics. Neurosurg Clin N Am. 1992; 3: 343-354.
19. Hall WA. Neurosurgical infections in the compromised host. Neurosurg Clin N Am. 1992; 3: 435-442.
20. Hall WA, Godal A, Juell S, Fodstad Ø. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg. 1992; 76: 838-844. doi: 10.3171/jns.1992.76.5.0838
21. Wen DY, Hall WA, Godal A, Fodstad Ø. Rapid transferrin receptor determination on human brain tumors. Surgical Forum. 1992; 43: 526-528.
22. Nida TY, Hall WA, Glantz MJ, Clark HB. Metastatic carcinoid tumor to orbit and brain. Neurosurgery. 1992; 31: 949-952.
23. Hall WA. Neurosurgical infections in the compromised host. Neurosurgical Consultations. 1992; 3: 25.
24. Wen DY, Hall WA, Miller DA, Seljeskog EL, Maxwell RE. Targeted brain biopsy: A comparison of freehand computed tomography-guided and stereotactic techniques. Neurosurgery. 1993; 32: 407-413.
25. Sung C, Dedrick RL, Hall WA, Johnson PA, Youle RJ. The spatial distribution of immunotoxins in solid tumors: Assessment by quantitative autoradiography. Cancer Res. 1993; 53: 2092-2099.
26. Hall WA. Infectious lesions of the brain stem. Neurosurg Clin N Am. 1993; 4: 543-551.
27. Hall WA. Central nervous system germinomas. Neurosurgical Consultations. 1993; 4: 15.
28. Wen DY, Hall WA, Fodstad Ø. Rapid detection of transferrin receptor expression on glioma cell lines using magnetic microspheres. Neurosurgery. 1993; 33: 878-881.
29. Madison MT, Hall WA, Latchaw RE, Loes DJ. Radiologic diagnosis, staging, and follow-up of adult central nervous system primary malignant glioma. Radiologic Clin N Am. 1994; 32: 183-196.
30. Nussbaum ES, Hall WA. Rhinocerebral mucormycosis: Changing patterns of disease. Surg Neurol. 1994; 41: 152-156.
31. Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad Ø. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery. 1994; 34: 649-656. doi: 10.1097/00006123-199404000-00012
32. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann Intern Med. 1994; 120: 817-820.
33. Hall WA. Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease) presenting with polymicrobial brain abscess. J Neurosurg. 1994; 81: 294-296.
34. Weprin BP, Hall WA, Bergman TA. Central neurocytoma: Diagnosis and treatment. Minnesota Medicine. 1994; 77: 43-46.
35. Myklebust AT, Helseth A, Hall WA, Breistøl K, Fodstad Ø. Nude rat models for human tumor metastasis to CNS. Procedures for intracarotid delivery of cancer cells and drugs. J Neuroonc. 1994; 21: 215-224.
36. Wen DY, Hall WA, Conrad J, Godal A, Flørenes VA, Fodstad Ø. In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line. Neurosurgery. 1995; 36: 1158-1164.
37. Chiang L, Flores EP, Wen DY, Hall WA, Low WC. Gene therapy for neurodegenerative disorders and malignant brain tumors. Behavioral and Brain Sciences. 1995; 18: 52-53.
38. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer and cerebrospinal fluid flow abnormalities. Cancer. 1995; 75: 2919-2931.
39. Hall WA, Djalilian HR, Sperduto PW, et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol. 1995; 13: 1642-1648.
40. Gerbi BJ, Roback DM, Humphrey SD, Hall WA. Maintaining accuracy in stereotactic radiosurgery. Int J Rad Oncol Biol Phys. 1995; 32: 1199-1203.
41. Hall WA, Clark HB. Sacrococcygeal cordoma metastatic to the brain with review of the literature. J Neurooncol. 1995:25: 155-159.
42. Latchaw RE, Hu X, Ugurbil K, Hall WA, Madison MT, Heros RC. Functional magnetic resonance imaging as a management tool for cerebral arteriovenous malformations. Neurosurgery. 1995; 37: 619-626.
43. Peterson K, Clark HB, Hall WA, Truwit CL. Multifocal enhancing magnetic resonance imaging lesions following cranial irradiation. Ann Neurol. 1995; 38: 237-244.
44. Hall WA, Flores EP, Low WC. Antisense oligonucleotides for central nervous system tumors. Neurosurgery. 1996; 38: 376-383.
45. Hall WA. Immunotoxin therapy. Neurosurg Clin N Am. 1996; 7: 537-546.
46. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases: Histology, multiplicity, surgery and survival. Cancer. 1996; 78: 1781-1788.
47. Sperduto PW, Hall WA. Radiosurgery, cost-effectiveness, gold standards, the scientific method, cavalier cowboys and the cost of hope. Int J Rad Oncol Biol Phys. 1996; 36: 511- 513.
48. Weprin BP, Hall WA, Cho KH, Sperduto PW, Gerbi BJ, Moertel C. Stereotactic radiosurgery in pediatric patients. Pediatr Neurol. 1996; 15: 193-199.
49. Eriksen SK, Hall WA. Chemotherapy delivered with blood-brain barrier disruption offers new option for treating malignant brain tumors. Cope. 1996; 38-39.
50. Nussbaum ES, Hall WA. Rapid diagnosis of intracranial fungal infections: Technical note. Chula Med J. 1996; 40: 255-258.
51. Hall WA. Stereotactic radiosurgery for brain metastases. Crit Rev Neurosurg. 1996; 6: 257-262.
52. Galicich W, Hall WA, Cho KH. The use of stereotactic radiosurgery to treat neurological tumors. Minnesota Medicine. 1997; 80: 18-22.
53. Djalilian HR, Hall WA. Malignant gliomas of the cerebellum: An analytic review. J Neuroonc. 1998; 36: 247-257.
54. Weprin BP, Hall WA, Goodman J, Adams GS. Long term survival in rhinocerebral mucormycosis: A case report. J Neurosurg. 1998; 88: 570-575.
55. Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC. Interleukin-12 based immunotherapy against peripheral and central nervous system 9L glioma. Neurosurgery. 1998; 42: 850-857.
56. Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer. 1998; 82: 1749-1755.
57. Jean WC, Hall WA. Management of cranial and spinal infections. Contemporary Neurosurgery. 1998; 20(9): 1-10.
58. Cho KH, Hall WA, Lee AK, et al. Stereotactic radiosurgery for patients with single brain metastasis. J Radiosurgery . 1998; 1: 79-85.
59. Martin AJ, van Vaals JJ, Hall WA, Liu H, Truwit CL. Intra-operative MR monitored neurosurgery. Medica Mundi. 1998; 42: 12-21.
60. Cho KH, Hall WA, Gerbi BJ, Higgins PD, Bohen M, Clark HB. Selection criteria for the treatment of brain metastases with stereotactic radiosurgery. J Neuroonc. 1998; 40: 73-86.
61. Maurer CR Jr, Hill DLG, Martin AJ, et al. Measurement of intraoperative brain deformation using a 1.5 tesla interventional MR system: Preliminary results. IEEE Transactions on Medical Imaging. 1998; 17: 817-825.
62. Wen DYK, Hall WA. Complications of subcutaneous low-dose dose heparin therapy in neurosurgical patients. Surgical Neurol. 1998; 50: 521-525.
63. Hall WA, Martin AJ, Liu H, et al. High-field strength interventional MR imaging for pediatric neurosurgery. Pediatric Neurosurgery. 1998; 29: 253-259. doi: 10.1159/000028732
64. Hall WA, Martin AJ, Liu H, Nussbaum ES, Maxwell RE, Truwit CL. Brain biopsy using high-field strength interventional MR imaging. Neurosurgery. 1999; 44: 807-814.
65. Wallenfriedman MA, Conrad JA, Hall WA, et al. Effects of localized infusion of granulocyte-macrophage colony stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg. 1999; 90: 1064-1071.
66. Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol. 1999; 51: 554-558.
67. Gerbi BJ, Lewandowski LA, Higgins PD, et al. Stereotactic radiosurgery for treatment of subfoveal choroidal neovascularization in age- related macular degeneration. J Radiosurgery. 1999; 2: 113-118.
68. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Rad Oncol Biol Phys. 1999; 45: 1133-1141.
69. Hall WA, Liu H, Martin AJ, Truwit CL. Comparison of stereotactic brain biopsy to interventional MRI-guided brain biopsy. Stereotact Funct Neurosurg. 1999; 73:148-153.
70. Doolittle ND, Miner M, Hall WA, et al. Safety and efficacy of a multi- center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of malignant brain tumors. Cancer. 2000; 88: 637-47.
71. Hall WA, Liu H, Truwit CL. Navigus trajectory guide. Neurosurgery. 2000; 46: 502-504.
72. Hall WA. Targeted toxin therapy for malignant astrocytoma. Neurosurgery. 2000; 46: 544- 552.
73. Hall WA, Liu H, Martin AJ, Pozza CH, Maxwell RE, Truwit CL. Safety, efficacy, and functionality of high-field strength interventional magnetic resonance imaging for neurosurgery. Neurosurgery. 2000; 46: 632-642.
74. Martin AJ, Hall WA, Liu H, Pozza CH, Maxwell RE, Truwit CL. Intraoperative monitoring of brain tumor resection with high-field interventional MR: Initial results. Radiology. 2000; 215: 221-228.
75. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. Medical Oncology. 2000; 17: 1-8.
76. Cho KH, Hall WA, Gerbi BJ, Higgins PD. The role of radiosurgery for multiple brain metastases. Neurosurg Focus. 2000; 2(2).
77. Hall WA. Targeted Toxin Therapy for Brain Tumors. Minnesota Physician. 2000; 14: 32-34.
78. Liu H, Hall WA, Martin AJ, Maxwell RE, Truwit CL. MR-guided and MR-monitored neurosurgical procedures at 1.5 T. J Comput Assist Tomogr. 2000; 24: 909-918.
79. Kim K-U, Ni HT, Cho KH, Low WC, Vallera DA, Hall WA. In vitro efficacy of recombinant diphtheria toxin-murine interleukin-4 conjugate (DT390-mIL4) on mouse glioblastoma and neuroblastoma cell lines and its additive effect with irradiation. Neurosurg Focus. 2000; 6(5).
80. Hall WA. High-field MRI in intracranial interventions. Medica Mundi. 2000; 44: 10-15.
81. Hill DLG, Hartkens T, Martin AJ, Hall WA, Liu H, Truwit CL. Measuring tissue deformation with interventional MR. Medica Mundi. 2000; 44: 16-19.
82. Kim KU, Ni HT, Low WC, Hall WA. Growth factor receptor expression on brain tumor cell lines: Preliminary study for in vitro and in vivo experiments of immunotoxin therapy. J Korean Neurosurg Soc. 2000; 29: 731-739.
83. Hall WA, Liu H, Martin AJ, Maxwell RE, Truwit CL. Brain biopsy using prospective stereotaxis and a trajectory guide. J Neurosurg. 2001; 91: 67-71.
84. Doolittle ND, Anderson CP, Hall WA, et al. Importance of dose-intensity in neuro-oncology clinical trials. Neuro-onc. 2001; 3: 46-54.
85. Hall WA, Martin AJ, Liu H, Truwit CL. Improving diagnostic yield in brain biopsy: Coupling spectroscopic targeting with real time needle placement. J Magn Reson Imaging. 2001; 13: 12-15. doi: 10.1002/1522-2586(200101)13:13.0.CO;2-Q
86. Liu H, Hall WA, Martin AJ, Truwit CL. Biopsy needle tip artifact in MR-guided neurosurgery. J Magn Reson Imaging. 2001; 13: 16-22.
87. Martin AJ, Liu H, Hall WA, Truwit CL. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR. 2001; 22: 959-968.
88. Ni H-T, Spellman SR, Jean WC, Wallenfriedman MA, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neuroonc. 2001; 51: 1-9.
89. Liu H, Hall WA, Martin AJ, Truwit CL. An efficient chemical shift imaging scheme for magnetic resonance-guided neurosurgery. J Magn Reson Imaging. 2001; 14: 1-7.
90. Lam CH, Hall WA, Truwit CL, Liu H. Intraoperative MRI-guided approaches to the pediatric posterior fossa tumors. Pediatric Neurosurgery. 2001; 34: 295-300.
91. Tummala RP, Chu RM, Hall WA. Focal intracranial infections due to Propionibacterium acnes: Report of three cases. Neurosurgery. 2001; 49: 717-720.
92. Hall WA, Liu H, Martin AJ, Truwit CL. Minimally invasive procedures: Interventional MR image-guided neurobiopsy. Neuroimaging Clin N Am. 2001; 11: 705-713.
93. Tummala RP, Chu RM, Liu H, Truwit CL, Hall WA. Optimizing brain tumor resection: High-field interventional MR imaging. Neuroimaging Clin N Am. 2001; 11: 673-683.
94. Truwit CL, Hall WA. Intraoperative MR systems: High field approaches. Neuroimaging Clin N Am. 2001; 11: 647-652.
95. Liu H, Hall WA, Truwit CL. Neuronavigation in interventional MR imaging: Prospective stereotaxy. Neuroimaging Clin N Am. 2001; 11: 697-706.
96. Kucharczyk J, Hall WA, Broaddus WC, Gillies GT, Truwit CL. Cost-efficacy of MR- guided neurointerventions. Neuroimaging Clin N Am. 2001; 11: 769-774.
97. Lo S, Cho KH, Hall WA, Hernandez WL, Lee CK, Clark HB. Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low grade gliomas?. Int J Cancer. 2001; 96: 71-78.
98. Djalilian HR, Tekin M, Hall WA, Adams GL. Metastatic head and neck squamous cell carcinoma to the brain. Auris Nasus Larynx. 2002; 29: 47-54.
99. Hall WA, Martin AJ, Kowalik K, Liu H, Truwit CL, Kucharczyk J. Economic justification for MR-guided neurosurgery. Medica Mundi. 2002; 46: 72-78.
100. Doolittle ND, Abrey LE, Hall WA, et al. Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium. Clin Cancer Res. 2002; 8: 1702-1709.
101. Vallera DA, Li C, Jin N, Hall WA. Targeting overexpressed urokinase-type plasminogen activator receptor (uPAR) on human glioblastoma with the diphtheria toxin fusion DTAT in nude mice. J Natl Cancer Inst. 2002; 94: 597-606.
102. Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Engineering. 2002; 15: 419-427.
103. Lo SS, Cho KH, Hall WA, et al. Single dose versus fractionated stereotactic radiotherapy for meningiomas. Can J Neurol Sci. 2002; 29: 240-248.
104. Hall WA, Liu H, Maxwell RE, Truwit CL. Influence of 1.5-tesla intraoperative MR imaging on surgical decision making. Acta Neurochir. 2002; 85: 29-37.
105. Liu H, Hall WA, Truwit CL. The roles of functional MRI in MR-guided neurosurgery in a combined 1.5 tesla MR-operating room. Acta Neurochir. 2002; 85: 127-135.
106. Hall WA, Kowalik K, Liu H, Truwit CL, Kucharczyk J. Costs and benefits of intraoperative MR-guided brain tumor resection. Acta Neurochir. 2002; 85: 137-142.
107. Hall WA, Liu H, Truwit CL. MR spectroscopy-guided biopsy of intracranial neoplasms. Techniques in Neurosurgery. 2002; 7: 291-298.
108. Tummala RP, Chu RM, Liu H, Truwit CL, Hall WA. High-field functional capabilities for magnetic resonance imaging-guided brain tumor resection. Techniques in Neurosurgery. 2002; 7: 319-325.
109. Liu H, Hall WA, Truwit CL. Remotely-controlled approach to stereotactic neurobiopsy. Computer Aided Surgery. 2002; 7: 237-247.
110. Hall WA, Rustamzadeh E, Asher AL. Convection-enhanced delivery in clinical trials. Neurosurgical Focus. 2003; 14(2).
111. Hall WA, Liu H, Truwit CL. Intraoperative MR-guided instillation of phosphorus-32 for cystic craniopharyngiomas. Case report. Tech in Can Res & Treat. 2003; 2: 19-23.
112. Hartkens T, Hill DLG, Hall WA, et al. Measuring brain deformation during neurosurgery. IEEE Transactions on Medical Imaging. 2003; 22: 82-92.
113. Tummala RP, Chu RM, Liu H, Truwit CL, Hall WA. Application of diffusion tensor imaging to magnetic resonance-guided brain tumor resection. Pediatric Neurosurgery. 2003; 39: 39-43.
114. Kim KU, Ni HT, Cho KH, Spellman SR, Low WC, Hall WA. Changes in expression of transferrin, insulin-like growth factor-1, and interleukin-4 receptors after irradiation of primary malignant brain tumor cell lines. Radiation Research. 2003; 160: 224-231.
115. Maron BJ, Poliac LC, Hall WA, Ashare AB. Sudden death due to neck blows among amateur hockey players. JAMA. 2003; 290: 599-601.
116. Rustamzadeh E, Low WC, Vallera DA, Hall WA. Immunotoxin therapy for CNS tumors. J Neurooncology. 2003; 64: 101-116.
117. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA. Targeting the overexpressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncology. 2003; 65: 63-75.
118. Weber F, Asher A, Hall WA, et al. Safety, tolerability, and tumor response of IL4-toxin (NBI-3001) in patients with recurrent malignant gliomas. J Neurooncology. 2003; 64: 125-137.
119. Lo SS, Hall WA, Cho KH, Orner J, Lee CK, Dusenbery KE. Radiation dose response for supratentorial low-grade glioma-institutional experience and literature review. J Neurol Sci. 2003; 15: 43-48.
120. Chu RM, Tummala RP, Hall WA. Intraoperative magnetic resonance imaging-guided neurosurgery. Neurosurgery Quarterly. 2003; 13: 234-250.
121. Weber FW, Floeth F, Hall W, et al. Local convection enhanced delivery of IL-4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. 2003; 88: 93-103.
122. Hall WA. Extending survival in gliomas: surgical resection or immunotherapy? Surg Neurol. 2004; 61: 145-148.
123. Cho KH, Hall WA, Lo SS, Dusenbery KE. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme. Tech in Can Res & Treat. 2004; 3: 41-49.
124. Wu A-H, Hall WA, Low WC. Identification of HLA a0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SP and DNA sequencing. J Neurooncol. 2004; 66: 1-8.
125. Jean WC, Spellman SR, Hall WA, et al. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 12-based immunotherapy against intracranial glioma in rat. J Neurooncol. 2004; 66: 39-49. doi: 10.1023/B:NEON.0000013477.94568.0f
126. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Engineering. 2004; 17: 157-164.
127. Anderson C, Graupman P, Sweeny M, Hall WA, Lam CL. Pediatric intracranial complications of central venous catheter placement-case reports. Pediatric Neurosurgery. 2004; 40: 28-31.
128. Djalilian HR, Lessan K, Hall WA, et al. A new immune competent animal model of mucosally derived squamous cell carcinoma. Otolaryngology, Head and Neck Surgery. 2004; 131: 781-783.
129. Gerbi BJ, Higgins PD, Cho KW, Hall WA, Maxwell RE, Orner J. Linac-based stereotactic radiosurgery for treatment of trigeminal neuralgia. Journal of Applied Clinical Medical Physics. 2004; 5: 80-90.
130. Tummala RP, Chu RM, Hall WA. Subdural empyema in children. Neurosurgery Quarterly. 2004; 14: 257-265.
131. Kubicek GJ, Hall WA, Orner JB, Gerbi BJ, Dusenbery KE. Long-term follow-up of trigeminal neuralgia treatment using a linear accelerator. J Functional Stereotactic Neurosurg. 2004; 82: 244-249.
132. Hall WA, Truwit CL. 1.5 Tesla: Spectroscopy supported brain biopsy. Neurosurg Clin N Am. 2005; 16: 165-172.
133. Doolittle ND, Abrey LE, Hall WA, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the tenth annual blood-brain barrier disruption consortium meeting. Clin Cancer Res. 2005; 11: 421-428.
134. Hall WA, Liu H, Truwit CL. Functional MRI-guided resection of low grade gliomas. Surg Neurol. 2005; 64: 20-27.
135. Hall WA, Truwit CL. Intraoperative MR imaging. Magn Reson Imaging Clin N Am. 2005; 13: 533-543.
136. Wu A-H, Xiao J, Hall WA, et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol. 2006; 76: 23-30.
137. Truwit CL, Hall WA. Intraoperative magnetic resonance imaging-guided neurosurgery at 3-T. Neurosurgery. 2006; 58(2): 338-346.
138. Hall WA, Sherr G. Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv. 2006; 3: 371-377.
139. Rustamzadeh E, Hall WA, Todhunter D, et al. Intracranial therapy of glioblastoma with the fusion protein DT390IL13 in immunodeficient mice. Int J Cancer. 2006; 118: 2594-2601.
140. Hall WA, Sherr G. Convection-enhanced delivery: Targeted toxin treatment of malignant glioma. Neurosurg Focus. 2006; 20(4): E10.
141. Hall WA, Vallera DA. Anti-angiogenic targeted toxins against glioblastoma. Neurosurg Focus. 2006; 20 (4): E23.
142. Hall WA, Doolittle N, Daman M, et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol. 2006; 77:279-284.
143. Turner SG, Hall WA. Programmable shunt-related suicide attempt. Case report. Acta Neurochir (Wien). 2006; 148: 1307-1310.
144. Rustamzadeh E, Hall W, Todhunter D, et al. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer. 2007; 120: 411-419.
145. Rustamzadeh E, Hall WA, Todhunter D, Low WC, Elson M, Vallera DA. Immunotoxin pharmokinetics: A comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol. 2006; 77: 257-266.
146. Hall WA, Galicich W, Bergman T, Truwit CL. 3-Tesla Intraoperative MR Imaging for Neurosurgery. J Neurooncol. 2006; 77: 297-303.
147. Hall WA, Truwit CL. 3-tesla functional magnetic resonance imaging-guided tumor resection. Int J CARS. 2007; 1: 223-230.
148. Doolittle ND, Peereboom DM, Hall WA, et al. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection in primary and metastatic brain tumors: report of the eleventh annual blood-brain barrier consortium meeting. J Neurooncol. 2007; 81: 81-91.
149. McClelland S III, Higgins PD, Gerbi BJ, Orner JB, Hall WA. Fractionated stereotactic radiotherapy for pituitary adenomas following microsurgical resection: safety and efficacy. Technol Cancer Res Treat. 2007; 6: 177-180.
150. Muldoon LL, Soussain C, Hall W, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007; 25: 2595-2305.
151. McClelland S III, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2,111 neurosurgery cases. Clin Inf Dis. 2007; 45: 55-59.
152. Djalilian HR, Caicedo E, Hall WA, et al. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol Immunother. 2007; 56: 1207-1214.
153. McClelland S III, Higgins PD, Dusenbery K, Hall WA. Fractionated stereotactic radiotherapy for facial nerve neuroma. J Functional Stereotactic Neurosurg. 2007; 85: 299-302.
154. Oh S, Odland R, Hall WA, et al. Hollow fiber catheter improves the distribution of small molecules and viral vectors in the mammalian brain. J Neurosurg. 2007; 107: 568-577.
155. McClelland S III, Gerbi BJ, Cho KH, Hall WA. The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy. J Robotic Surg. 2007; 1: 227-230.
156. McClelland S III, Higgins PD, Gerbi BJ, Orner JB, Hall WA. Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas. J Neurooncol. 2008; 86: 191-194.
157. SantaCruz K, Brace J, Hall WA. A case of cranial fasciitis originating within the diploic space of an adult. Neurosurgery. 2007; 61: 1338.
158. Wu A, Xiao J, Chen W, Hall WA, Low WC, Ohlfest JR. Expression of MHC I and NK ligands on human CD133+ brain tumor stem cells: possible targets of immunotherapy. J Neurooncol. 2007; 83: 121-131.
159. Hall WA, Truwit CL. Intraoperative MR-guided neurosurgery. J Magn Reson Imaging. 2008; 27: 368-375.
160. Wu A, Ericson K, Oh S, Hall WA, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells and Development. 2008; 17: 173-184. doi: 10.1089/scd.2007.0133
161. Hall WA, Truwit CL. The surgical management of infections involving the cerebrum. Neurosurgery. 2008; 62: SHC519-531. doi: 10.1227/01.neu.0000316255.36726.5b
162. Martin AJ, Hall WA, Roark C, Starr PA, Larson PS, Truwit CL. Minimally invasive precision brain access using prospective stereotaxy and a trajectory guide. J Magn Reson Imaging. 2008; 27: 737-743. doi: 10.1002/jmri.21318
163. Hall WA, Kim P, Truwit CL. Functional magnetic resonance imaging-guided brain tumor resection. Top Magn Reson Imaging. 2009; 19: 205-212. doi: 10.1097/RMR.0b013e3181934a09
164. Hall WA. Magnetic resonance imaging in neurointervention. Top Magn Reson Imaging. 2009; 19: 177. doi: 10.1097/RMR.0b013e31819699b1
165. Hall WA. Convection-enhanced delivery: neurosurgical issues. Curr Drug Target. 2009; 10: 126-130.
166. Kim PD, Truwit CL, Hall WA. Three-tesla high field applications. Neurosurg Clin N Amer. 2009; 20: 173-178. doi: 10.1016/j.nec.2009.04.009
167. Oh S, Ohlfest JR, Hall WA, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol. 2009; 95: 331-342. doi: 10.1007/s11060-009-9932-2
168. Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins. 2010; 2: 2645-2662. doi: 10.3390/toxins2112645
169. Hall WA, Truwit CL. Intraoperative magnetic resonance imaging. Curr Med Image Rev . 2010; 6: 266-272.
170. Hall WA, Truwit CL. Intraoperative magnetic resonance imaging. Acta Neurochir. 2011; 109: 119-129. doi: 10.1007/978-3-211-99651-5_19
171. Abdulhamid MM, Li YM, Hall WA. Spontaneous acute subdural hematomas as the initial manifestation of chronic myeloid leukemia. case report. J Neurooncol. 2011; 101: 513-516. doi: 10.1007/s11060-010-0278-6
172. Hall WA. Brain abscess: still a surgical entity. World Neurosurg. 2011; 75: 616-617.
173. Li YM, Hall WA. Cell surface receptors on malignant glioma. Neurosurgery. 2011; 69: 980-994. doi: 10.1227/NEU.0b013e318220a672
174. Hall WA. To clip or not to clip, that is the question?. World Neurosurgery. 2012; 77: 291-292.
175. Huang J, Li YM, Massague J, Sicheneder A, Vallera DA, Hall WA. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. J Neurooncol. 2012; 109: 229-238. doi: 10.1007/s11060-012-0904-6
176. Hall WA. Free-living amoebas: is it safe to go in the water? . World Neurosurgery. 2012; 78: 610-611.
177. Kim PD, Hall WA. Use of positron emission tomography scanning to evaluate pseudoresponse Trans Pediatrics. 2013; 2: 57-58. doi: 10.3978/j.issn.2224-4336.2013.04.07
178. Li YM, Vallera DA, Hall WA. Diphtheria toxin-based targeted toxin therapy for brain tumors. J Neurooncol. 2013; 114: 155-164. doi: 10.1007/s11060-013-1157-8
179. Li YM, Blaskiewicz DJ, Hall WA. Shunt related intracranial abscess caused by Staphylococcus lugdunensis in a hydranencephalic patient. World Neurosurgery. 2013; 80: e387-389.
180. Hall WA. Spinal parasites. World Neurosurgery. 2013; S1878.
181. Hall WA. Improving outcomes in cerebral aspergillosis. World Neurosurgery. 2014; 82: e139-140.
182. Hall WA. Cranioplasty infections - adding insult to injury. World Neurosurgery. 2014; 82: e435-437. doi: 10.1016/j.wneu.2013.03.005
183. Hall WA, Li YM, Vallera DA. Diphtheria-based immunotoxins that target glioblastoma multiforme. Toxin Rev. 2014; 33: 119-124.

Myriam N. Bouchlaka, PhD

Post Doctoral Fellow
Immunotherapy and Hematopoietic Stem Cell Transplant Research Group (Capitini)
University of Wisconsin-Madison
1111 Highland Ave, WIMR 4136
Madison, WI 53705, USA

BiographyResearch InterestScientific ActivitiesPublications

•(2011) PhD, Cellular and Molecular Biology, University of Nevada, Reno, School of Medicine
Advisor: William J. Murphy, PhD
Thesis: Cancer Immunotherapy: Limitations and Potential Strategies
•(2007) BS, Biology, University of Nevada, Reno, NV
Minor: Chemistry

Her research interests include: Cancer immunotherapy, inflammation mediated from immunotherapy, translational studies for bone marrow transplantation, GVHD biology, and trafficking of adoptive cellular therapies..


•(2014-2015) American Association of Immunologists (AAI) Career in Immunology Fellowship
•(2014) Caymans Women in Research Travel Grant for presenting an abstract at the American Association of Immunologists (AAI), Pittsburgh, PA
•(2010) University of Nevada Travel Award for presenting an abstract at the American Association of Immunologists (AAI), Baltimore, MD
•(2007-2011) Graduate Assistantship, University of Nevada, Reno, NV
•(2003-2007) Undergraduate Student Athlete Academic Scholarship, University of Nevada, Reno, NV
•( 2003-2006) Scholar Award for All Western Athletic Conference (WAC) Student Athlete


•( 2014-Present) Trainee member, American Association of Immunologists (AAI)
•( 2014-Present) Trainee member, American Society of Hematology (ASH)
•(2014-Present) Inflammation Research Association (IRA)

1. Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy Following Hematopoietic Stem Cell Transplantation: Potential for Synergistic Effects. Immunotherapy. 2010; 2(3): 399-418. doi: 10.2217/imt.10.20.
2. Tietze JK, Wilkins DE, Bouchlaka MN, et al. Delineation of Antigen-Nonspecific CD8+ Memory T cells After Cancer Immunotherapy in Mice and Human. Blood. 2012; 119(13): 3073-3083. doi: 10.1182/blood-2011-07-369736.
3. Sun K, Hsiao HH, Bouchlaka M, et al. IFN-γ Receptor Deficient Donor T cells Mediate Protection from Graft-versus-Host Disease and Preserve Graft-versus-Tumor Responses After Allogeneic Bone Marrow Transplantation. J Immunol. 2012; 189(4):2033-42. doi: 10.4049/jimmunol.1102853.
4. Bouchlaka MN, Sckisel GD, Wilkins D, et al. Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-tumor Immune Responses. PLoS One. 2012; 7(10): e48049. doi: 10.1371/journal.pone.0048049.
5. Bouchlaka MN, Sckisel GD, Chen M, et al. Aging Predisposes to Acute Inflammatory Induced Pathology After Tumor Immunotherapy. J Exp Med. 2013; 210(11): 2223-2237. doi: 10.1084/jem.20131219.
6. Bouchlaka MN, Murphy WJ. Impact of Aging in Cancer Immunotherapy: The Importance of Using Accurate Preclinical Models. OncoImmunology. 2013; 2(12):e27186.
7. Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, Chen M, Murphy WM. Increased Anti-tumor Effects using IL2 with anti-TGFβ Reveals Competition Between Mouse NK and CD8 T cells. J Immunol. 2014. doi: 10.4049/jimmunol.1400034.
8. Mirsoian A, Bouchlaka MN, Sckisel D, et al. Adiposity Induces Lethal Cytokine Storm After Systemic Administration of Stimulatory Immunotherapy Regimens in Aged Mice. J Exp Med. 2014.

Chatchawin Assanasen, MD

Director, UT Southeast Asian Pediatric Hematology Oncology Program
CCRI Distinguished Chair in Pediatric Oncology
Associate Professor
Department of Pediatric Hematology/Oncology
University of Texas Health Science Center at San Antonio
7703 Floyd Curl MC 7810
San Antonio, TX 78229, USA

BiographyResearch InterestScientific ActivitiesPublications

Year Degree Discipline Institution/Location

•(1996) MD Medicine St. Georges University, School of Medicine, Bay Shore, NY, USA
•(1990) BA Natural Science University of Pennsylvania, Philadelphia, PA, USA



•(2000-2003) Pediatric Hematology/Oncology in University of Texas Southwestern Medical Center, Dallas, TX, USA


•(1996-1999) Pediatrics in University of Florida College of Medicine, Health Science Center, Jacksonville, FL, USA


•(2012 - Present) Distinguished Chair in Pediatric Oncology, Childrens Cancer, Research Institute, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
•(2011 -Present) Associate Professor/Clinical Non-Tenured and Medical Director, South Texas Pediatric Blood and Cancer Center, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
Details: Pediatric Hematology & Oncology
•(2011-2011) Assistant Professor/ Clinical Non-Tenured and Medical Director, Howard A. Britton MD Childhood Cancer and Blood Disorders Center, University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX
Details: Pediatric Hematology & Oncology
•(2010-2011) Adjunct Clinical Assistant Professor, Lake Erie College of Osteopathic Medicine, Department of Pediatrics, Bradenton, FL
•(2006-2011) Clinical Assistant Professor Florida State University College of Medicine, Department of Pediatrics, Tallahassee, FL

His research interests include: Complement Dysfunction, Global Health, OnControl Bone Marrow Biopsy Needle, Oncofertility, Pediatric Oncology.


•(2014) Best Doctors in America
•(2013) NCI - Platinum Certificate of Excellence: For Exceptional Achievement in patient enrollments in National Cancer Institute Treatment and Cancer Control Clinical Trials
•(2013) Best Doctors in America
•(2010) Montclair Whos Who in North America
•(2010) Best Doctors in America
•(2009) Americas Top Oncologist, Consumers Research Council of America
•(2009) Best Doctors in America
•(2008) Guardian Angel Award, Sacred Heart Foundation: Pensacola, FL
•(2005) Golden Apple Teaching Award: University of Florida Pediatric Residency Program; Pensacola, FL
•(2005) Physician of the Year, Nemours Childrens Clinics
•(1997) Student Teaching Apple Award: University of Florida Health Science Center, Jacksonville, FL


•(2014-Present) American Association for Cancer Research
•(2012-Present) Cancer Therapy and Research Center
•(2010-Present) Society of Clinical Research Associates
•(2008-2011) Nemours Center for Childhood Cancer Research
•(2004-2010) Florida Association of Pediatric Tumor Programs
•(2000-Present) Childrens Oncology Group
•(2000-Present) American Society of Pediatric Hematology/Oncology
•(2000-Present) American Society of Clinical Oncology
•(2000-Present) American Society of Hematology
•(2000-Present) American Academy of Pediatrics

1. Ranch D, Crowther BR, Arar MY, Assanasen C. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatric Transplantation. 2014; 18(6): E185-E189. doi: 10.1111/petr.12290.
2. Durham SH, Lee A, Assanasen C. Burkholderia cepacia Septicemia in a Pediatric Oncology Patient: A Pharmacotherapy Challenge. Ann Pharmacother. 2012; 46(6): e16. doi: 10.1345/aph.1R015.
3. Lee A, Henry DW, Ng JS, et al. Ifosfamide Neurotoxicity in Pediatric Patients: A Multi-Institutional Case Series Report. Journal of Hematology Oncology Pharmacy. 2011; 1(3): 12-17.
4. Amin R, Bohnert A, Holmes L, Rajasekaran A, Assanasen C. Response to "Childhood clustering in Florida: weighing the evidence". Pediatr Blood Cancer. 2010; 54(7): 1053-1053. doi: 10.1002/pbc.22488.
5. Amin R, Bohnert A, Holmes L, Rajasekaran A, Assanasen C. Epidemiologic mapping of Florida childhood cancer clusters. Pediatr Blood Cancer. 2010; 54(4): 511-518. doi: 10.1002/pbc.22403.
6. Kreiger PA, Judkins AR, Russo PA, et al. Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas. Mod Pathol. 2009; 22(1): 142-150. doi: 10.1038/modpathol.2008.185.
7. Fine RL, Shah SS, Moulton TA, et al. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol. 2007; 59(4): 429-437.
8. Assanasen C, Mineo C, Seetharam D, et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest. 2005; 115(4): 969-977.
9. Assanasen C, Quinton RA, Buchanan GR. Acute myocardial infarction in sickle cell anemia. J Pediatr Hematol Oncol. 2003; 25(12): 978-981.

Saeed Sadeghi, MD

Associate Clinical Professor
Division of Hematology-Oncology
David Geffen School of Medicine
University of California
Los Angeles, CA 90095, USA

BiographyResearch InterestScientific ActivitiesPublications

•(1991-1995) BS, University of California, Los Angeles
•(1995-1999) MD, St. Louis University School of Medicine


•(1999-2000) LAC/USC Medical Center, Keck School of Medicine at USC


•(2000-2002) LAC/USC Medical Center, Keck School of Medicine at USC


•(2002-2005) David Geffen School of Medicine at UCLA


Current Academic Appointment

(2012-Present) Associate Clinical Professor, David Geffen School of Medicine at UCLA, Division of Hematology-Oncology

Previous Academic Appointments

(2005-2012) Assistant Clinical Professor, David Geffen School of Medicineat UCLA, Division of Hematology-Oncology

Current Administrative Appointment(s)

(2005-Present) Medical Director, UCLA Santa Monica Hematology & Oncology Practice

His research interests include: Antiphospholipid, Biliary, Breast, Cancers of the Digestive Tract, Chronic Myelogenous Leukemia, Colorectal (colon, rectum and anus), Esophageal, Gastric Cancer, Gastrointestinal Malignancies, General Hematology, General Oncology, Genitourinary, Geriatric Breast Cancer, Geriatric Prostate Cancer, Gynecologic Oncology, Head and Neck Oncology, Hematologic Malignancies, Hepatobiliary, Larynx, Leukemia, Liver, Lung, Lung Cancer & Chest Malignancies, Lymphoma, Mesothelioma, Multiple Myeloma, Ovarian Cancer, Pancreas, Prostate Cancer, Sickle Cell Anemia, Testicular Cancer, Thoracic Cancer, Unknown Primary, Waldenstroms Disease.


Committee Service:

•(2010-Present) Member of Internal Scientific Peer Review Committee (ISPRC)

Community Service:

•(2009-Present) Medical Board Member of Persian American Cancer Institute (PACI)

Scholarly Societies:

•(1995-Present) Member of American Medical Student Association
•(1995-Present) Member of American Medical Association
•(1996-Present) Member of American College of Physicians
•(2005-Present) Member of American Society of Hematology
•(2005-Present) Member of American Society of Clinical Oncology


•(1991-1995) Dean’s Honor List, University of California, Los Angeles
•(1992-Present) Golden Key National Honor Society
•(1994-Present) Phi Sigma Biology Honor Society
•(1995) Chancellor’s Service Award, University of California, Los Angeles
•(1995) Phi Beta Kappa, Graduated Cum Laude and With Departmental Honors (Biology), University of California, Los Angeles
•(1997) Winner, 3rd Place, AOA Research Competition, St. Louis University School of Medicine
•(1998) Winner, Medical Student Research, Abstract Competition, American College of Physicians, 79th Annual Session, San Diego, California
•(1999) Distinction in Research Award, St. Louis University School of Medicine
•(2009-2010) UCLA Division of Hematology-Oncology Teacher of the Year


1. OBrien WA, Sumner-Smith M, Mao S-H, Sadeghi S, Zhao J-Q, Chen ISY. Anti-HIV-1 activity of an oligocationic compound is mediated via gp120 V3 interactions. J Virol. 1996; 70: 2825-2831.
2. Grovit-Ferbas K, Ferbas J, Gudeman V, et al. Potential contributions of viral and host genetic factors in a HIV-1 long term survivor. J Virol. 1998; 72(11): 8650-8658.
3. Hill DA, Sadeghi S, Schultz M, Burr J, Dehner LP. Pleuropulmonary Blastoma in the adult - An Initial Report. Cancer. 1999; 85(11): 2368-2374.
4. Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkins lymphoma in patients with type 1 Human Immunodeficiency Virus infection. Cancer. 2002; 94(5): 1500-1506.
5. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (Rituximab). Ann Rheum Dis. 2002; 61(10): 922-924.
6. Sadeghi S, Marder VJ, Stewart D, et al. Safety of Plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. J Thromb Haemost. 2003; 1(12): 2621-2625.
7. Johnston S, Pippen J Hr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27(33): 5492-5494. doi: 10.1200/JCO.2009.23.3734.
8. Tsang RY, Sadeghi S, Finn RS. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of Egfr and Her2, in Her2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights: Therapeutics. 2011; 3: 1-13.
9. Eiermann W, Pienkowski T, Crown J, et al. Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel as Adjuvant Treatment in Patients With HER2-Normal, Node-Positive Breast Cancer: Breast Cancer International Research Group (BCIRG)-005 Trial. J Clin Oncol. 2011; 29(29): 3877-3884.
10. Sadeghi S, Finn RS. Systemic therapy for cholangiocarcinoma. Clinical Liver Disease. 2014; 3(4): 86-89.
11. Macias MN, Shin DS, Ledezma B, Sadeghi S. Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Rep. 2014. doi: 10.1136/bcr-2013-203400.
12. Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumabemtansine. Pharmgenomics Pers Med. 2014; 7: 329-338. doi: 10.2147/PGPM.S47524.

Sun-Young Kong, MD, PhD

Associate Professor
Department of System Cancer Science, GCSP
Chief, Translational Epidemiology Branch, Research Institute
National Cancer Center/Department of laboratory Medicine
National Cancer Center
Goyang, Gyeonggi, Republic of Korea, South Korea

BiographyResearch InterestScientific ActivitiesPublications

•(2005) PhD(Laboratory Medicine), College of Medicine, Sungkyunkwan University, Seoul, Republic of Korea
•(2001) MS (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea
•(1997) MD (Laboratory Medicine), College of Medicine, Ewha Womens University, Seoul, Republic of Korea


•(2005-Present) Faculty: Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2009-2011) Research Fellowship: Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
•(2003-2005) Fellowship: Laboratory Medicine, Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
•(2002-2003) Fellowship: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1998-2002) Residency: Laboratory Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea
•(1997-1998) Internship: Medicine, Samsung Medical Center, Sungkyunkwan Univesity, Seoul, Republic of Korea

Her research interests include: To develop translational biomarker for cancer diagnosis and therapeutics. We have been published papers for tumor marker in blood including cytokines, circulating tumor cells, and pharmacogenetic markers.


• Koichi Matsuda, Human Genome Center, the University of Tokyo, Tokyo, Japan
• Kenneth C. Anderson, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA

1. Tai YT, Horton HM, Kong SY, et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012; 119(9): 2074-2082. doi: 10.1182/blood-2011-06-364521.
2. Kong SY, Han MH, Yoo HJ, et al. Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer. Ann Surg Oncol. 2011. doi: 10.1245/s10434-011-1943-5.
3. Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011; 104(7): 1126-1134. doi: 10.1038/bjc.2011.24.
4. Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011; 104(7): 1126-1134. doi: 10.1038/bjc.2011.24.
5. Han MH, Eom HS, Park WS, et al. Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood. Leuk Res. 2010; 34(9): 1127-1131. doi: 10.1016/j.leukres.2009.11.028.
6. Kong SY, Lim HS, Nam BH, et al. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 2009; 10(7): 1147-1155. doi: 10.2217/pgs.09.48.
7. Kong SY, Park JW, Kim JO, et al. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009; 135(8): 1091-1098. doi: 10.1007/s00432-009-0549-9.
8. Lee HL, Eom HS, Yun T, et al. Serum and urine levels of interleukin-8 in patients with non-Hodgkins lymphoma. Cytokine. 2008; 43(1): 71-75. doi: 10.1016/j.cyto.2008.04.004.
9. Kong SY, Lee HL, Eom HS, et al. Reference intervals for circulating angiogenic cytokines. Clin Chem Lab Med. 2008; 46(4): 545-550. doi: 10.1515/CCLM.2008.092.
10. Kong SY, Ki CS, Yoo BC, Kim JW. UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers. Cancer Sci. 2008; 99(2): 340-344. doi: 10.1111/j.1349-7006.2007.00693.x.
11. Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007; 46(2): 446-455. doi: 10.1002/hep.21720
12. Kong SY, Ki CS, Kim HJ, et al. Evaluation of imprecision for short tandem repeats analysis using mixed blood cells in variable concentrations. Clin Chem. 2004; 50(11): 2193-2195. doi: 10.1373/clinchem.2004.036103

Shengle Zhang, MD

Associate Professor and Attending Pathologist
Director of Molecular Diagnostic Lab (AP)
Department of Pathology
SUNY Upstate Medical University
750 East Adams Street, Syracuse, NY 13210, USA

BiographyResearch InterestScientific ActivitiesPublications

• 02/1978 - 08/1982, MD, Wannan Medical College, Wuhu, China
• 09/1982 - 08/1985, MSc, Biochemistry, Shangdong Academy of Medical Sciences, China


• 07/1997 - 06/2001, Resident, Pathology (AP/CP), Saint Barnabas Health Care System, New Jersey.
• 07/2001 - 06/2002, Clinical Fellow, Oncologic Surgical Pathology, Roswell Park Cancer, Institute, New York
• 07/2002 - 06/2004, Clinical Fellow, Molecular Genetic Pathology/Molecular Diagnostics, Johns Hopkins Medical Institute, Maryland


• 03/2010 - present, Associate Professor and Attending Pathologist, Director of Anatomic, Molecular Diagnostic Lab, Upstate Medical University, New York
• 07/2004 - 2/2010, Assistant Professor and Attending Pathologist, Director of Anatomic, Molecular Diagnostic Lab, Upstate Medical University, New York
• 11/1992 - 06/1997, Research Associate, Immunology and Molecular Oncology, Memorial, Sloan-Kettering Cancer Center, New York
• 09/1990 - 10/1992, Research Fellow, Immunology, College of Physicians and Surgeons, Columbia University, New York
• 06/1990 - 08/1990, Visiting Scientist, Tumor Biomarkers, Catholic Medical Center of Brooklyn and Queens, Inc., New York.
• 09/1988 - 05/1990, Instructor, Pathology, Comprehensive Cancer Center, Sun Yat-Sen, University of Medical Sciences, China
• 09/1985 - 08/1988, Resident, Pathology, Comprehensive Cancer Center, Sun Yat-Sen, University of Medical Sciences, China

His research interests include: Molecular Oncology and its clinical application. His clinical interests are Surgical pathology, molecular pathology.


• Director of Molecular Diagnostic Lab (AP) (2004 - present), Certificate of Qualification in molecular and cellular oncology markers (NY)
• Establishment and development of molecular diagnostic laboratories in anatomic pathology (2004 -present)
• Leading validation of 14 NY State (DOH) approved molecular assays (2004 - present):
a. KRAS gene mutation by DNA sequencing
b. EGFR gene mutation by PCR
c. BRAF gene mutation by real-time PCR
d. EWS gene translocation by RT-PCR
e. EGFR gene amplification by FISH
f. ALK gene rearrangement by FISH
g. ROS-1 gene rearrangement by FISH
h. 1p/19q deletion by FISH
i. DDIT3 (CHOP) gene break-apart by FISH
j. EWSR gene-break apart by FISH
k. FOXO1(FKHR) gene break-apart by FISH
l. HER2 gene amplification by FISH
m. N-myc gene amplification by CISH
n. SS18 (SYT) gene break-apart by FISH
o. IgH/CCND1 gene fusion by FISH


• United States and Canadian Academy of Pathology
• Association for Molecular Pathology
• American Society of Clinical Pathologists
• American Association for Cancer Research

1. Alfredo L Valente AL, Tull J, Zhang S. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial Sarcoma. Appl Immunohistochem Mol Morphol. 2013; 21: 408–413. doi: 10.1097/PAI.0b013e318279f9ee.
2. Yu M, He Y, Wang K, Zhang P, Zhang S, Hu H. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Human Gene Therapy. 2013; 24: 317–330.
3. Rong R, Tull J, Zhang S. Molecular Biomarker Profile of EGFR Copy Number, KRAS and BRAF Mutations in Colorectal Carcinoma. J Solid Tumors. 2012; 2(4): 27-31.
4. Valente AL, Tull, J, Zhang S. Utility of fluorescence in situ hybridization in sub-classifying unclassified high-grade sarcomas: a study of 40 cases using break-apart probes of EWSR1, FOXO1A, SS18 and DDIT3 Genes. J Solid Tumors. 2012; 2(2): 4-9.
5. Swati I, Zhang S, Tull J, Khurana KK. Accuracy of cytology specimen and needle core biopsies for detection of KRAS mutation in non-small cell carcinoma: comparison with resection specimen. World J Oncol. 2011; 2(6): 275-280.
6. Narendra S, Valente A, Tull J, Zhang S. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma - assay validation and clinical experience. Diagn Mol Pathol. 2011; 20: 218-224. doi: 10.1097/PDM.0b013e3182107eb9.
7. Deng FM, Galvan K, De La Roza G, Zhang S, Souid AK, Stein CK. Molecular characterization of an EWSR1-POU5F1 fusion associated with a t(6; 22) in an undifferentiated soft tissue sarcoma. Cancer Genet. 2011; 204: 423-429. doi: 10.1016/j.cancergen.2011.05.006.
8. Zhang S, Pavlovitz B, Tull J, Wang Y, Deng F, Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010; 19: 151-156. doi: 10.1097/PDM.0b013e3181bb216a.
9. Griffith C, Zhang S, Mukhopadhyay S. Synchronous metastatic medullary and papillary thyroid carcinoma in a patient with germline RET mutation: case report, molecular analysis, implication for pathologist. Endocr Pathol. 2010; 21: 115-119. doi: 10.1007/s12022-010-9117-8.
10. Rong R, Doxtader EE, Tull J, Zhang S. Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary - molecular genetic analysis. Int J Clin Exp Pathol. 2010; 3(2): 217-221.
11. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein ALA. Absence of BRAF mutation in HBME1 And CK19 positive atypical cell clusters in hashimotos thyroiditis: evidence against preneoplastic change. Am J Clin Pathol. 2009; 132: 906-912.
12. El-Zammar O, Zhang S, Katzenstein ALA. Comparison of FISH, PCR, Immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. Diagn Mol Pathol. 2009; 18: 133-137.
13. Shah SS, Wang Y, Tull J, Zhang S. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol. 2009; 18: 30-33. doi: 10.1097/PDM.0b013e31817c1af8.
14. Zhang S. Molecular diagnostics on neoplasm . Acta Academiae Medicinae Wannan. 2008; (5): 313-315.
15. Mehra S, Roza G, Tull J, Shrimpton A, Valente A, Zhang S. Detection of FOXO1(FKHR) gene break-apart by fluorescence in situ hybridization (FISH) in formalin fixed paraffin embedded alveolar rhabdomyosarcomas and its clinicopathological correlation. Diagn Mol Pathol. 2008; 17: 14-20.
16. Hartley CE, Varma M, Fischer JP, et al. Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma. J Neurosurg. 2008; 109: 708-714. doi: 10.3171/JNS/2008/109/10/0708.
17. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein A-L. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006; 19: 1631-1637.
18. Murphy K, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn. 2006; 8: 305-11.
19. Montgomery E, Mamelak AJ, Gibson M, et al. Overexpression of Claudin Proteins in Esophageal Adenocarcinoma and its Precursor Lesion. Appl Immunohisto Mol Morph. 2006; 14: 24-30.
20. Zhang S, Ashraf M, Schinella R. Ischemic colitis with atypical reactive changes mimicking dysplasia (pseudodysplasia). Archives of Pathology and Laboratory Medicine, Arch Path Lab Med. 2001; 125: 224-227.
21. Javed MZ, Srivastava M, Zhang S, Kandathil M. Concurrent Babesiosis and Ehrlichiosis in an elderly host. Mayo Clin Proc. 2001; 76(5): 563-565.
22. Zhang S, Schinella R. Expression of ER, PR, Her2/neu and Ki-67 and their correlation in 55 cases of infiltrating ductal carcinoma of the breast. Journal of Tumor Marker Oncology. 2000; 15: 123-127.
23. Gilewski T, Adluri S, Zhang S, et al. Vaccination of high risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000; 6: 1693-701.
24. Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, Livingston P. Specificity analysis of sera from breast cancer patients vaccination with MUC1-KLH plus GS-21. British J Cancer. 1999; 79: 1806-12.
25. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry : protein antigens. Clin Cancer Res. 1998; 4: 2669-76.
26. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998; 4: 295-302.
27. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998; 58: 2844-9.
28. Livingston PO, Zhang S, Lloyd KO. Carbohydrate vaccines that induce antibodies against cancer. 1. rationale. Cancer Immunol Immunother. 1997; 45: 1-9.
29. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. II. blood group-related antigens. Int J Cancer. 1997; 73: 42-9.
30. Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry I. focus on gangliosides. Int J Cancer. 1997; 73: 50-56.
31. Zhang S, Walberg LA, Helling F, et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res. 1996; 56: 3315-19.
32. Zhang S, Walberg LA, Ogata S, et al. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res. 1995; 55: 3364-68.
33. Zhang S, Helling F, Lloyd KO, Livingston PO. Increased tumor cell reactivity and complement dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother. 1995; 40: 88-94.
34. Ragupathi G, Park TK, Zhang S, et al. Immunization of mice with a fully synthetic globo H antigen results in antibodies against human cancer cells: a combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew Chem Int Ed Engl. 1995; 36: 125-8.
35. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995; 55: 2783-88.
36. Kim IJ, Park TK, Hu S, et al. Defining the molecular recognition of Globo H (human breast cancer) antigen by the MBr1 Antibody through probe structures prepared by total synthesis. Journal of Organic Chemistry. 1995; 60: 7716-17.
37. Livingston PO, Zhang S, Adluri S, et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies. Cancer Immunol Immunother. 1995; 43: 324-30.
38. Adluri S, Helling F, Ogata S, et al. Immunogenicity of TF- and sTn-KLH conjugates in colorectal patients. Cancer Immunol Immunother. 1995; 41: 185-92.
39. Bilodeau MT, Park TK, Hu S, et al. Total synthesis of a human breast tumor associated antigen. J Am Chem Soc. 1995; 117: 7840-1.
40. Helling F, Shang A, Calves M, et al. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyana conjugate vaccines. Cancer Res. 1994; 54: 197-203.
41. Jiang H, Zhang S, Pernis B. Role of CD8 T cells in murine experimental allergic encephalomyelitis. Science. 1992; 256: 1213-15.
42. Zhang S, Liang Y, Li G, Dai Y, Huang D. Preliminary studies of serum glycoconjugates in patients with cancer using the enzyme linked lectin assay. Cancer Biochem and Biophy. 1990; 11(3): 211-6.
43. Huang D, Zhang S, Liu G. Detection of serum ribonuclease activity in patients with esophageal carcinoma. Acad J Sun Yat-Sen Univer of Med Sci. 1989; 10(4): 46.
44. Xiao X, Zhang S, Zhang C. Proparation of monoclonal antibodies to cancer-related antigens on CNE-2 cells. Chin J Cancer. 1986; 5: 310.
45. Zhang S. A methdological approach of purifying and labeling antibodies with peroxidase. J Zhongshan Med Col. 1987; 4: 29.
46. Zhang S. On the contractiveness of muscle. J Chin Poten Sci. 1986; 7(1): 33. 47. Zhang S, Xiu Y. Garlic and anti-platelet aggregation. Foreign Med (Chin drugs and herbs). 1986; (5): 17.
48. Zhang S, Xiu Y, Lu T, Gao S. Studies on anti-platelet aggregation of allitridi in hypercholesterolemic rabbits. Chin J Integr Tradi and West Med. 1986; 6(11): 677.
49. Wen S, Zhang S, Zhu Y, Wang Y. Studies on snake venoms and disseminated intravascular coagulation. J of Wannan Med Col. 1985; 4(10): 1.

Young Kwang Chae, MD, MPH, MBA

Assistant Professor
Northwestern Medicine Developmental Therapeutics Institute
Division of Hematology and Oncology
Department of Medicine
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
645 N. Michigan Ave. Suite 1006
Chicago, IL 60611, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Chae is a translational and clinical investigator focusing on novel drug and biomarker development in early phase clinical trials in oncology. His plan is to bridge the gap between the cutting edge science and clinical medicine. His interest is in personalized precision medicine, novel combination therapy including immunotherapies and targeted therapies, rational clinical trial design and implementation in first in human clinical trials, and bio-correlatives that can help select patients predicted to have higher responses and lower toxicities to targeted therapies.

His research interests include: personalized precision medicine, novel combination therapy including immunotherapies and targeted therapies, rational clinical trial design and implementation in first in human clinical trials, and bio-correlatives that can help select patients predicted to have higher responses and lower toxicities to targeted therapies.

Honors and Awards

•(2004) Samsung Scholarship: tuition and living expense support for the Johns Hopkins University MPH program
•(2006) Johns Hopkins Bloomberg School of Public Health Student Conference Award
•(2009) First place, Clinical Research Award, Albert Einstein Medical Center, for outstanding poster presented on the Research Recognition Day
•(2009) Harry Goldberg MD Award, Albert Einstein Medical Center, for excellence in creativity for intern research project
•(2009) Poster Finalist, the ACP National Abstract Competition, American Collage of Physician Annual meeting, Philadelphia, PA
•(2009) Second place, the ACP Associate Poster Competition, American College of Physicians Pennsylvania Chapter, Southeast Regional Meeting
•(2009) The SABCS Clinical Scholarship Award, AACR-ATCC San Antonio Breast Cancer Symposium, San Antonio, TX
•(2009) First place, Resident Research Competition, Albert Einstein Medical Center, for outstanding oral presentation on resident research project
•(2011) The ACP Associate Award, the ACP National Abstract Competition, Oral podium presentation, American Collage of Physician Annual meeting, San Diego, California
•(2011) Second place, Resident Research Competition, Albert Einstein Medical Center, for outstanding oral presentation on resident research project
•(2011) Sonia Stupniker MD Library Award, Albert Einstein Medical Center, for the best scholarly activity among the graduating medicine residents
•(2011) Louis B. Schatz Memorial Award, Albert Einstein Medical Center, Albert Einstein Medical Center, for the best graduating resident in the institution in clinical competency and academic excellence.
•(2012) The ASH Outstanding Abstract Achievement Award. The American Society of Hematology Annual Meeting, Atlanta, GA
•(2013) The ASCO Conquer Cancer Foundation Merit Award. The Gastrointestinal Cancer Symposium (ASCO), San Francisco, CA
•(2013) The Allison and Brian Grove Endowed Fellowship Award for Breast Medical Oncology. The MD Anderson Cancer Center, Houston, TX
•(2013) The AACR-GlaxoSmithKline Outstanding Clinical Scholar Award. The AACR Annual Meeting, Washington DC
•(2013) The Silver Medalist, The Certificate of Achievement, Lindon B. Johnson Oncology Clinic, MD Anderson Hematology & Oncology Fellowship Program, Houston, TX
•(2013) The Young Investigator Award, “ASCO/AACR Translational Cancer Research Award” Conquer Cancer Foundation. The ASCO Annual Meeting, Chicago, IL
•(2013) The ASH Outstanding Abstract Achievement Award, December, 2013, The American Society of Hematology Annual Meeting, New Orleans, LA
•(2014) MD Anderson Cancer Center Hematology Oncology LBJ Board Review Championship Award, Division of Cancer Medicine Hematology Oncology Fellowship Program, MD Anderson Cancer Center, Houston, TX
•(2014) Molecular Biology in Clinical Oncology AACR Workshop travel award, Snowmass, CO

Articles in Peer-Reviewed Journals

1. Kim MS, Yamashita K, Chae YK, et al. Promoter Methylation Pattern in the NMDA Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research. 2007; 13(22): 6658-6665. doi: 10.1158/1078-0432.CCR-07-1178
2. Chae YK, Park JC, Kim MS, Lee J, Sidransky D, Moon C. Epigenetic Silencing of T (Brachyury Homologue) Gene in Human Lung Adenocarcinoma. Biochem Biophys Res Commun. 2008; 365(2): 221-6. doi: 10.1016/j.bbrc.2007.10.144
3. Chae YK, Woo J, Jang SJ, et al. Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium. Biochem Biophys Res Commun. 2008; 366(2): 321-327. doi: 10.1016/j.bbrc.2007.11.078
4. Kim MS, Lebron C, Nagpal JK, et al. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophys Res Commun. 2008; 370(1): 38-43. doi: 10.1016/j.bbrc.2008.03.026.
5. Chae YK, Woo J, Kim M, et al. Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One. 2008; 3(5): e2162. doi: 10.1371/journal.pone.0002162.
6. Nagpal JK, Dasgupta S, Jadallah S, et al. Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Mod Pathol. 2008; 21(8): 979-991. doi: 10.1038/modpathol.2008.76.
7. Woo J, Lee J, Chae YK, et al. Over expression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett. 2008; 264(1): 54-62. doi: 10.1016/j.canlet.2008.01.029.
8. Chae YK, Kang SK, Kim MS, et al. Human AQP5 plays a role in the development of chronic myelogenous leukemia (CML). PLoS One. 2008; 3(7): e2594.
9. Moon C, Park JC, Chae YK, Yun JH, Kim S. Current Status of Experimental Therapeutics for Prostate Cancer. Cancer Lett. 2008; 266(2): 116-134. doi: 10.1016/j.canlet.2008.02.065.
10. Chae YK, Kang SK, Woo J, et al. Role of hAQP5 in colorectal carcinogenesis. Am J Pathol. 2008; 173(2): 518-525. doi: 10.2353/ajpath.2008.071198.
11. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic Polymorphisms of Estrogen Receptors α and β and the Risk of Developing Prostate Cancer. PLoS One. 2009; 4(8): e6523. doi: 10.1371/journal.pone.0006523.
12. Kim M, Louwagie J, Carvalho B, et al. Promoter DNA methylation of Oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer. PLoS One. 2009; 4(8): e6555. doi: 10.1371/journal.pone.0006555.
13. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 2010; 121(2): 273-279. doi: 10.1007/s10549-010-0870-7.
14. Moon C, Chae YK, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med. 2010; 235(8): 907-920. doi: 10.1258/ebm.2009.009181
15. Kim J, Purushottam B, Chae YK, Chebrolu L, Amanullah A. Relation between common allergic symptoms and coronary heart disease among NHANES III participants. Am J Cardiol. 2010; 106(7): 984-987. doi: 10.1016/j.amjcard.2010.05.029.
16. Jang S, Chae YK, Majhail NS. Financial Conflicts of Interest in Economic Analyses in Oncology. Am J Clin Oncol. 2010. doi: 10.1097/COC.0b013e3181f4799b.
17. Park IS, Chang X, Loyo M, et al. Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res. 2011; 4(2): 207-217. doi: 10.1158/1940-6207.CAPR-10-0147
18. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of Statins in venous thrombosis risk reduction. Am J Med. 2011; 124(9): 852-859. doi: 10.1016/j.amjmed.2011.04.019.
19. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE Inhibitors, ARBs and/or Statins. Cancer Investigation. Cancer Invest. 2011; 29(9): 585-593. doi:
20. Chae YK, Neagu S, Kim J, Smyrlis A, Gooptu M, Tester W. Association between Common Allergic Symptoms and Cancer in the NHANES III Female Cohort. PLoS One. 2012; 7(9): e42896. doi: 10.1371/journal.pone.0042896.
21. Mekaroonkamol P, Chaput KJ, Chae YK, et al. Repeat colonoscopys value in gastrointestinal bleeding. World J Gastrointest Endosc. 2013; 5(2): 56-61. doi: 10.4253/wjge.v5.i2.56.
22. Kim J, Chae YK, Chernoff A. The Risk for Coronary Heart Disease According to Insulin Resistance with and without Type 2 Diabetes. Endocr Res. 2013. doi: 10.3109/07435800.2013.766800
23. Chae YK, Hu MI, Katz RL, et al. Two birds with one stone: Octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013; 31(23): e398-e400. doi: 10.1200/JCO.2012.46.6383.
24. Chae YK, Brown EN, Lei X, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 2013; 4(7): 549-556. doi: 10.7150/jca.6888.
25. Chae YK, Khemasuwan D, Dimou A, et al. Inhibition of renin angiotensin axis may reduce the risk of developing venous thromboembolism in patients with atherosclerotic disease. PLoS One. 2014. 9(1): e87813. doi: 10.1371/journal.pone.0087813.
26. Chae YK, Trinh L, Preetesh J, et al. Statins and aspirin is associated with improved the outcome of fludarabine, cyclosphosphamide, and rituximab (FCR) salvage therapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood. 2014; 123(9): 1424-1426.
27. Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma. 2014. doi: 10.3109/10428194.2014.901513
28. Chae YK, Gonzalez-Angulo AM. Implications of proteomic profiling in breast cancer. The Oncologist. 2014; 19(4): 328-335. doi: 10.1634/theoncologist.2013-0437
29. Kaseb AO, Xiao L, Hassan MM, et al. Development and validation of an insulin-like growth factor score to assess hepatic reserve. J Natl Cancer Inst. 2014; 106(5). doi: 10.1093/jnci/dju088.
30. Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with Non-Small Cell Lung Cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 2014; 9(9): e107677. doi: 10.1371/journal.pone.0107677.

Shreya Kanodia, PhD

Associate Director, Administration
Department of Biomedical Sciences
Samuel Oschin Comprehensive Cancer Institute

BiographyResearch InterestScientific ActivitiesPublications

Dr. Shreya Kanodia is a cancer immunologist who has worked on developing therapeutic cancer vaccines since 1999. Trained as a tumor immunologist, she has over 15 years of life science research experience, including working on Phase I/II clinical trials for cancer therapy. Dr. Kanodia currently serves as Assistant Professor and Director of Grants Management in the Department of Biomedical Sciences and Associate Director for Administration in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, CA as well as Adjunct Assistant Professor at the University of Hawaii Cancer Center, Honolulu, HI. Her research interests lie in understanding the pathogenesis of mesothelioma and using this understanding to develop novel diagnostics and therapeutics. In addition to performing research, she has successfully established and operated a number of for-profit and not-for-profit organizations. She established the United States operations of Advanced Microdevices Pvt Ltd, a privately owned multinational corporation, and served as the Co-Owner/Director for Business Development. She also co-founded Advanced Bioscience Technologies LLC and functioned as the Co-Owner/Chief Financial Officer. She holds a Bachelors degree in Biochemical Engineering from the Indian Institute of Technology, Kharagpur in West Bengal, India and a Ph.D. in Immunology/Cancer Biology from the University of Texas M. D. Anderson Cancer Center in Houston, Texas.

Her research interests lie in understanding the pathogenesis of mesothelioma and using this understanding to develop novel diagnostics and therapeutics.


•(2009) NIH Travel Award – International Papillomavirus Society
•(2008) USC Norris Cancer Center Distinguished Merit Award
•(2006) Achievement Rewards for College Scientists Foundation Fellowship
•(2006) NIH Travel Award – International Papillomavirus Society
•(2004) Vivian L. Smith Outstanding Young Immunologist Award (2nd place)
•(2003) American Legion Auxiliary Fellowship (competitive renewal)
•(2003) Sowell-Huggins/Sylvan Rodriguez Fellowship
•(2002) American Society of Hematology Travel Award
•(2002) MD Anderson Cancer Center Trainee Excellence Award
•(2001) GSBS Student Travel Award (winner for 2 consecutive years)
•(2001) Womens Travel Scholarship Award

Professional Memberships:

•(2010-Present) Member, Association of American Cancer Institutes (AACI)
•(2010-Present) Member, Cancer Center Administrators Forum (CCAF)
•(2012-Present) Member, American Association Of Cancer Research (AACR)
•(2012-Present) Member, National Council Of University Research Administrators (NCURA)
•(2013-Present) Member, Association Of Cancer Executives (ACE)

Peer-Reviewed Publications

1. Rivera Z, Ferrone S, Wang X, et al. CSPG4 As a Target of Antibody-Based Immunotherapy For Malignant Mesothelioma. Clinical Cancer Research. 2012; 18(19): 5352-5363. doi: 10.1158/1078-0432.CCR-12-0628.
2. Kanodia S, Kast WM. Perspectives on prophylactic and therapeutic vaccination for HPV-induced lesions. In: Human Papillomavirus Vaccines. Future Medicine Ltd, London, UK. 2011.
3. Carbone M, Baris IY, Bertino P, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma.Proc Natl Aca Sci USA. 2011; 108: 13618-13623. doi: 10.1073/pnas.1105887108.
4. Kanodia S, Wieder ED, Lu S, et al. High-avidity PR1- CTL contribute to the maintenance of remission in IFN-sensitive CML patients off all therapy. PloS One. 2010; 5(7): e11770.
5. Kanodia S, Da Silva DM, Karamanukyan, T, Bogaert, L, Fu Y-X and Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus type 16 E6 and E7 induces significant tumor regression. Cancer Research. 2010; 70(10): 3955-3964. doi: 10.1158/0008-5472.CAN-09-3773.
6. Kanodia S, Kast WM. The immunoevasive nature of persistent oncogenic HPV infection and the development of cervical cancer. Touch Briefings. 2010.
7. Gray A, Kanodia S, Hubby B, et al. Prostate cancer immunotherapy administered at an early stage of carcinogenesis prior to the establishment of tumorassociated immunosuppression yields superior long-term survival in TRAMP mice. Vaccine. 2009; 27(6): G52-G59. doi: 10.1016/j.vaccine.2009.09.106.
8. Kanodia S, Kast WM. Peptide vaccines for cancer - Realizing their potential. Expert Review of Vaccines. 2008; 7(10): 1533-1545. doi: 10.1586/14760584.7.10.1533.
9. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. International Journal of Cancer. 2008; 122(2): 247-259. doi: 10.1002/ijc.23252
10. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Current Cancer Drug Targets. 2007; 7(1): 79-89. doi: 10.2174/156800907780006869
11. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high avidity leukemia-specific T-cells. Journal of Clinical Investigation. 2003; 111(5): 639-647. doi: 10.1172/JCI16398.
12. Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T cell-mediated immunity to chronic myelogenous leukemia. Oncogene. 2002; 21(56): 8668-8673. doi: 10.1038/sj.onc.1206093
13. Sarkar S, Sreekanth B, Kant S, Banerjee R, Bhattacharya BC. Production and optimization of microbial lipase. Bioprocess Engineering. 1998; 19(1): 29-32.

Weihua Gong, MD, PhD

Associate Professor
Department of Surgery
Zhejiang University
Jiefang Road 88, Hangzhou City
Zhejiang Province 310009, China

BiographyResearch InterestScientific ActivitiesPublications

• (1994-1999) Nankai University, Tianjin, China M.D. (Summa Cum Laude)
• (1999-2001) Nankai University, Tianjin, Master of Clinical Science (Summa Cum Laude)
• (2005-2008) Charite-University Berlin, joint school of Berlin Free University and Humboldt University, PhD (Magna Cum Laude)

Post Doctoral Training and Professional Experience

• (2001-2003) Resident in Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine
• (2004) Visiting scholar, Surgical Hospital, University of Heidelberg, Heidelberg, Germany (Chairman: Prof. Markus W. Buechler)
• (2004-2008) Guest scientist, Department of Surgery, Rudolf Virchow Klinikum, Berlin, Germany (Chairman: Prof. Peter Neuhaus)
• (2008-2009) Postdoc., Department of Surgery, University of California, Los Angeles, CA (Chairman: Prof. Ronald Busuttil)
• (2009-2012) Research fellow, Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (Co-directors: Prof. Terry B. Strom, Prof. Laurence A. Turka)
• (2013) Project manager, Natural Scientific Foundation of China, NSFC
• (2013-present) Attending in Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine
• (2014-present) PhD mentor, Zhejiang University

His research interest include biomarkers for oncology and oncogenesis.


• (1996) Scholarship, Nankai University
• (2000) Scholarship, Nankai University
• (2003) Award of Excellent Member of the CYL, Zhejiang University
• (2004) Scholarship, University of Heidelberg
• (2005-2008) Scholarship, Charité-University Berlin, Germany
• (2009-2010) Post-doctoral Scholarship, UCLA, Los Angeles
• (2010-2012) Fellowship, Beth Israel Deaconess Medical Center
• (2012) Recruited Oversea Talent via Green Channel, Zhejiang University
• (2012-present) Member, Zhejiang Provincial Qianjiang Talent Project
• (2012-present) Winner, Outstanding Youth Foundation of Zhejiang Province
• (2013) Award for College Outstanding Achievement (Science and Technology) by Ministry of Education (First-Grade Award, 3/15)


• (2001-present) Member, Chinese Surgeon Association
• (2013-present) Member, Chinese Society of Immunology
• (2013-present) Committee Member, Zhejiang Society of Clinical Immunology)

1. Gong WH, Jurisch A, Vogt K, Haase S, Höflich C, Polenz D, et al. High weight differences between donor and recipient affect early kidney graft function - a role for enhanced IL-6 signaling. Am J Transplant. 2009; 9(8): 1742-1751. doi: 10.1111/j.1600-6143.2009.02725.x.
2. Xiao X, Gong WH, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J. Immunol. 2012; 188(2): 892-901. doi: 10.4049/jimmunol.1101373.
3. Gong WH, Huang T, Ge FM, et al. Presensitized immune condition of host exaggerates prolonged cold ischemia-mediated injury of cardiac graft involving in regulatory T cells. Transplantation. 2013; 96(7): 609-615 doi: 10.1097/TP.0b013e31829df26d.
4. Ge FM, Gong WH, Yuan SZ, et al. Alteration of innate immunity by donor IL-6 deficiency in a presensitized heart transplant model. PLoS One. 2013; 8(10): e77559. doi: 10.1371/journal.pone.0077559
5. Li X, Huang T, Jiang G, Gong WH, Qian H, Zou C. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells. Biochem Biophys Res Commun. 2013; 439(2): 179-186. doi: 10.1016/j.bbrc.2013.08.066.
6. Gong WH, Ge FM, Liu DH, et al. Role of myeloid-derived suppressor cells in mouse pre-sensitized cardiac transplant model. Clinical Immunology. 2014; 153(1): 8-16. doi: 10.1016/j.clim.2014.03.013.
7. Ge FM, Huang T, Yuan SZ, Ye ZQ, Gong WH. Gender issues in solid organ donation and transplantation. Annals of Transplantation. 2013; 18: 508-514. doi: 10.12659/AOT.889323.
8. Fan ZG, Enjyoji K, Tigges J, et al. Bone marrow derived hematopoietic stem and progenitor cells infiltrate allogeneic and syngeneic transplants. American Journal of Transplantation. 2014. doi: 10.1111/ajt.12931.
9. Wu P, Wu D, Gong WH , et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014; 40(5): 785-800. doi: 10.1016/j.immuni.2014.03.013.
10. Thornley TB, Balasubramanian S, Gong WH, et al. Fragile TIM-4-expressing tissue resident macrophages are migratory and immunoregulatory. J Clin Invest. 2014; 124(8): 3443-3454. doi: 10.1172/JCI73527.
11. Chen J, Gong WH, Ge FM, Huang T, Wu D, Liang TB. A review of various techniques of mouse liver transplantation. Transplantation Proceedings. 2013; 45(6): 2517-2521. doi: 10.1016/j.transproceed.2013.03.035.
12. Ge FM, Gong WH. Body weight difference between donor and recipient is an important effector on early graft function after renal transplantation. Transplantation Proceedings. 2013; 45(6): 2171-2175. doi: 10.1016/j.transproceed.2012.12.003.
13. Gong WH, Whitcher GH, Townamchai N, Xiao X, Ge FM. Biomarkers for monitoring therapeutic side effects or various supratherapeutic confounders after kidney transplantation. Transplantation Proceedings. 2012; 44(5): 1265-1269. doi: 10.1016/j.transproceed.2011.11.069.
14. Ge FM, Gong WH. Strategies for successful establishment of kidney transplantation in mouse model. Exp Clin Transplant. 2011; 9(5): 287-294.
15. Gong WH, Thornley T, Whitcher GH, et al. Introduction of modified cervical cardiac transplant model in mice. Exp Clin Transplant. 2012; 10(2): 158-162. doi: 10.6002/ect.2011.0123
16. Gong WH, Ge FM, Chen L. A giant ganglion cyst of hip joint causing lower limb edema. Saudi Med J. 2010; 31(5): 569-571.
17. Huang T, Gong WH, Li XC, et al. Enhancement of osteosarcoma cell sensitivity to cisplatin using paclitaxel in the presence of hyperthermia. Int J Hyperthermia. 2013; 29(3): 248-255. doi: 10.3109/02656736.2013.775511
18. Li X, Huang T, Jiang G, Gong W, Qian H, Zou C. Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett. 2013; 221(3): 197-204. doi: 10.1016/j.toxlet.2013.06.233.
19. Siepert A, Gong WH, Vogt K, et al. Tolerance induction in clinically relevant transplant models - immune monitoring and therapeutic optimisation. Xenotransplantation. 2007; 14(4): 372.
20. Gong WH, Pascher A, Jurisch A, et al. Weight differences between donor and recipient affect early graft function-rescue of delayed graft function by targeting IL-6. Am J Transplant. 2007; 281.
21. Huang T, Gong WH, Li XC, et al. Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1. Asian Pac J Cancer Prev. 2012; 13(7): 3477-3481.
22. Huang T, Gong WH, Li XC, et al. Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide. Mol Med Report. 2012; 6(5): 1013-1017. doi: 10.3892/mmr.2012.1058.
23. Huang T, Gong WH, Li XC, et al. Efficient killing effect of osteosarcoma cells by cinobufacini and Cisplatin in combination. Asian Pac J Cancer Prev. 2012; 13(6): 2847-2851.
24. Huang T, Gong WH, Li XC, et al. Induction of apoptosis by a combination of paclitaxel and carboplatin in the presence of hyperthermia. Asian Pac J Cancer Prev. 2012; 13(1): 81-85.
25. Huang T, Gong WH, Zou CP, et al. Marsdenia tenacissima extract sensitizes MG63 cells to doxorubicin-induced apoptosis. Genet Mol Res. 2014; 13(1): 354-362. doi: 10.4238/2014.January.21.3.
26. Gong WH, Que RS, Chen L, Shi XY. Biliary infection and selection of antibiotics. Zhejiang Journal of Traumatic Surgery. 2002; 7(6): 404-405.
27. Ge YB, Gong WH. Diagnosis and treatment of insulinoma: analysis of 17 cases. Chinese Journal of Pancreatology. 2004; 4(1): 58-60.
28. Que RS, Gong WH, Liu YB, Wang Y, Cao LP, Peng CH. A report of 73 cases with primary duodenal tumors. Journal of Hangzhou Medical College. 2002; 23(3): 71-73.
29. Xu SM, Gong WH, Tian H, Wang P, Zheng YX, Liu YB. Diagnosis and treatment of pancreatic islet cell tumor: a report of 35 cases. Chinese Journal of Practical Surgery. 2006; 26(3): 197-199.
30. Ge YB, Gong WH, Chen L, Chuan X. Study on clinical diagnosis and treatment for portal vein thrombosis after splenectomy. Zhejiang Journal of Traumatic Surgery. 2004; 9(3): 178-179.
31. Xu SM, Zheng YX, Gong WH, Wang P. Analysis on treatment for colorectal injury: a report of 86 cases. Chinese Journal of General Surgery. 2004, 19(6): 337-339.
32. Chen L, Chen H, Tian H, Gong WH, Tao SF. Diagnosis and treatment for pseudoaneurysm. Chinese General Practice. 2004; 3(1): 68.
33. Chen L, Yu H, Dai N, Tao SF, Gong WH. Dual cell seeding to improve cell retention on polytetrafluoroethylene grafts. Zhonghua Wai Ke Za Zhi. 2003; 41(2): 143-145.
34. Chen L, Tao SF, Gong WH. The effect of recombinant human tissue plasminogen activator on coagulation function and immune response in pigs. Zhejiang Medical Journal. 2003; 25(1): 19-21.

Gokul Das, PhD

Associate Professor
Department of Pharmacology and Therapeutics
Center for Genetics and Pharmacology Building
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Das is Associate Professor and Co‐Director of Breast Disease Site Research Group at Roswell Park Cancer Institute, Buffalo, New York. Dr. Das obtained PhD from Baylor College of Medicine, Houston, Texas, followed by Postdoctoral research at the Cold Spring Harbor Laboratory, Long Island, New York. For the past twelve years, he has been a faculty member at the Roswell Park Cancer Institute, an NCI- designated Comprehensive Cancer Center. Dr. Das has extensive experience in cancer (especially breast cancer) in both basic and translational research arenas. He has gained experience in conducting both retrospective and prospective clinical studies. His laboratory uses cell culture and animal models along with patient tissues to investigate cellular and molecular mechanisms underlying the onset and progression of cancer and translating them to the clinic when possible. He is a principal investigator on the prospective clinical trial (originally funded by NCI) on the effect of estrogen receptor-p53 interaction on tamoxifen therapy in breast cancer patients.

His research interests include: Estrogen receptor and tumor suppressor protein P53 signaling in breast and lung cancers.


•(2004) Whos Who in Medicine and Healthcare
•(1988) Mead Johnson Research Excellence Award: 19th Annual National Student Research Forum (USA)
•(1979) First position, Graduate Proficiency Test, Jawaharlal Nehru University, New Delhi, India
•(1976) Outstanding Teacher of Science (during B.Ed. program)


•(2013-Present) Member, Special Emphasis Panel, NCI omnibus R21/R03 FOA
•(2004, 2011-Present) Member, Grant review Panel, Roswell Park Alliance Foundation
•(2013) Member, Special Emphasis Panel on “Fellowship: Oncological Sciences”, NIH
•(2011-2012) Member, NIH Cancer Etiology (CE) Study Section
•(2011) Chair, Institutional Alliance Foundation Breast Cancer Grant Review Panel
•(2009) Member, NIH Challenge Grant Review Panel
•(2005-2010) Member, General Biomedical Science study section, Tobacco-Related Disease Research Program (TRDRP), University of California
•(2004-2010) Member, Grant Review Panel, DOD Breast Cancer Research Program

1. Wickramesekera NT, Das GM. Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication. Mitochondrion. 2013; 16: 26-37. doi: 10.1016/j.mito.2013.10.002.
2. Tang L, Ling X, Liu W, Das GM, Li F. Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by surviving is at least partially 53-dependent: Evidence for surviving acting as a transcription factor or co-factor. Biochem Biophys Res Commun. 2012; 421: 249-254.
3. Nayvelt I, John S, Hsu HC, et al. A potential estrogen mimetic effect of a bis(ethyl)polyamine analogue on estrogen receptor positive MCF-7 breast cancer cells. Amino Acids. 2012; 42: 899-911. doi: 10.1007/s00726-011-1005-0.
4. Liu W, Swetzig WM, Medisetty R, Das GM. Estrogen-mediated upreulation of noxa is associated with cell cycle progression in estrogen-receptor-positive breast cancer cells. PLoS One. 2011; 6(12): e29466. doi: 10.1371/journal.pone.0029466
5. Konduri S, Medisetty R, Liu W, et al. Mechanisms of Estrogen receptor antagonism towards p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA. 2010; 107: 15081-15086. doi: 10.1073/pnas.1009575107.
6. Liu W, Ip MM, Podgorsak MB, Das GM. Disruption of estrogen receptor α-p53 interaction in breast tumors: A novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Research and Treatment. 2009; 115: 43-50. doi: 10.1007/s10549-008-0044-z.
7. John S, Nayvelt I, Hsu H-C, et al. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Research. 2008; 68: 7855-7863. doi: 10.1158/0008-5472.CAN-07-5875.
8. Karipparettu BA, Zubairy S, Konduri SD, et al. Estrogen-mediated down-regulation of CD24 in breast cancer cells. International Journal of Cancer. 2008; 123: 66-72. doi: 10.1002/ijc.23480.
9. Sayeed A, Konduri S, Liu W, Bansal S, Li F, Das GM. Estrogen receptor α inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Research. 2007; 67: 7746-7755. doi: 10.1158/0008-5472.CAN-06-3724
10. Liu W, Konduri S, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem. 2006; 281: 9837-9840. doi: 10.1074/jbc.C600001200
11. Desouki MM, Kulawiec M, Bansal S, Das G, Sing KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biology & Therapy. 2005; 4: 1367-1373. doi: 10.4161/cbt.4.12.2233
12. Narayan S, Jaiswal AS, Kang D, Srivastava P, Das G, Gairola CG. Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro. Oncogene. 2004; 23: 5880-5889. doi: 10.1038/sj.onc.1207792
13. Nayak B, Das G. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene. 2002; 21: 7226-7229. doi: 10.1038/sj.onc.1205889
14. Giabernardi TA, Sakaguchi AY, Gluhak J, et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biology. 2001; 20: 577-587. doi: 10.1016/S0945-053X(01)00166-4
15. Thavathiru E, Das G. Activation of pRL-TK by 12S E1A oncoprotein: drawbacks of using an internal reference reporter in transcription assays. BioTechniques. 2001; 31: 528-532.
16. Karuppayil S, Moran E, Das G. Differential regulation of p53-dependent and -independent PCNA transcription by adenoviral 12S E1A oncoprotein. J Biol Chem. 1998; 273: 17303-17306. doi: 10.1074/jbc.273.28.17303
17. Das G, Hinkley CS, Herr W. Basal promoter elements as a selective determinant of transcriptional activator function. Nature. 1995; 374: 657-660. doi: 10.1038/374657a0
18. Rajasekharan AK, Zhou Z, Prakash K, Das G, Kreibich G. Functional characterization of the cis-regulatory elements of the rat ribophorin gene. Nucl Acid Res. 1995; 23: 313-319. doi: 10.1093/nar/23.3.313
19. Das G, Herr W. Enhanced activation of the human histone H2B promoter by the Oct-1 variant generated by alternative splicing. J Biol Chem. 1993; 268: 25026-25032.
20. Sturm RA, Cassady JL, Das G, Romo A, Evans GA. Chromosomal structure and expression of the human OTF1 locus encoding the Oct-1 protein. Genomics. 1993; 16: 333-341. doi: 10.1006/geno.1993.1194
21. Sturm R, Das G, Herr W. The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes & Dev. 1988; 2: 1582-1599. doi: 10.1101/gad.2.12a.1582
22. Das G, Henning D, Wright D, Reddy R. Upstream regulatory elements are necessary and sufficient for transcription of a U6 gene by RNA polymerase III. EMBO J. 1988; 7: 503-512.
23. Das G, Henning D, Reddy R. Structure, organization and transcription of Drosophila U6 small nuclear RNA genes. J Biol Chem. 1987; 262: 1187-1193.
24. Reddy R, Henning D, Das G, Harless M, Wright D. The capped U6 small nuclear RNA is transcribed by RNA polymerase III. J Biol Chem. 1987; 262: 75-81.
25. Das G, Henning D, Reddy R. One aspartic acid transfer RNA gene is present upstream of the U6 RNA gene cluster in Drosophila melanogaster. Nucl Acid Res. 1986; 14: 7816.
26. Rao AR, Das G, Das P. Inhibitory action of aminoglutethemide on DMBA induced mammary carcinogenesis. Oncology. 1985; 42: 119-121.

Boris R.A. Blechacz, MD, PhD

Assistant Professor (Tenure track)
Department of Gastroenterology, Hepatology and Nutrition
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Blechacz is a physician scientist who received his medical degree from the University of Heidelberg, Germany. In addition, he holds two doctoral degrees (Dr. med, Ph.D.) awarded through the University of Heidelberg/German Cancer Research Center (DKFZ), Germany, and the Mayo Clinic, Rochester, USA. Dr. Blechacz is specialized in Gastroenterology and Hepatology, and is currently an Assistant Professor in the Department of Gastroenterology, Hepatology and Nutrition at the University of Texas MD Anderson Cancer Center. His scientific and clinical focuses are hepatobiliary malignancies.

His research interest includes the assessment of viral and non-viral gene delivery systems, the evaluation of novel molecular pathway interactions and the development of innovative strategies to therapeutically target these interactions in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).


• (1999-Present) Member, Bundesaerztekammer (German Physicians’ Association), Germany
• (1999-2007) Member, Marburger Bund (German Association of Clinic Physicians), Germany
• (2003-Present) Member, American Association for Cancer Research
• (2010) PerkinElmer AlphaScreen and AlphaLisa Technology Symposium, Gaithersburg, MD: “Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.”
• (2003-2007) Member, American Society of Gene Therapy
• (2005-Present) Member, American College of Physicians
• (2005-Present) Member, American Medical Association
• (2008-Present) Member, American Association for the Study of Liver Diseases
• (2008-Present) Member, American College of Gastroenterology
• (2008-Present) Member, American Gastroenterological Association


1. Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001; 8(3): 158-167.
2. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology. 2006; 44(6): 1465-1477. doi: 10.1002/hep.21437
3. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther. 2007; 15(1): 114-122. doi: 10.1038/sj.mt.6300020
4. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009; 50(6): 1861-1870. doi: 10.1002/hep.23214.
5. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009; 338: b92. doi: 10.1136/bmj.b92.
6. Smoot RL, Blechacz BR, Werneburg NW, et al. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010; 70(5): 1960-1969. doi: 10.1158/0008-5472.CAN-09-3535.
7. Fingas CD, Blechacz BR, Smoot RL, et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010; 52(2): 550-561. doi: 10.1002/hep.23729.
8. Thabut D, Routray C, Lomberk G, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology . 2011; 54(2): 573-585. doi: 10.1002/hep.24427
9. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142(4): 1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005.
10. Bois JP, Blechacz B, Arora AS, Hanson CA. A typical case presentation of Zieves syndrome. Practical Gastroenterology. 2013; 47-49.
11. Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Hepatol. 2013.
12. Tanasanvimo S, Rashid A, Wongkham S, et al. Comparison of miRNA expression patterns between Opisthorchis Viverrini-associated cholangiocarcinoma and non-Opisthorchis Viverrini associated cholangiocarcinoma. J Hepatol. 2013.


1. Blechacz B, Russell SJ. Parvovirus vectors: use and optimisation in cancer gene therapy. Expert Rev Mol Med. 2004; 6(16): 1-24. doi: http://dx.doi.org/10.1017/S1462399404008026
2. Blechacz B, Russell SJ. Measles virus as an oncolytic vector platform. Curr Gene Ther. 2008; 8(3): 162-175. doi: 10.2174/156652308784746459
3. Blechacz B, Gajic O. Images in clinical medicine. Severe kyphosis. N Engl J Med. 2008; 358(24): e28. doi: 10.1056/NEJMicm074057.
4. Blechacz B, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008; 12(1): 131-150. doi: 10.1016/j.cld.2007.11.003.
5. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; 48(1): 308-321. doi: 10.1002/hep.22310.
6. Blechacz B, Gores GJ. Positron Emission Tomography scan for a hepatic mass. Hepatology. 2010; 52(6): 2186-2191. doi: 10.1002/hep.24002.
7. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(9): 512-522. doi: 10.1038/nrgastro.2011.131.
8. Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res. 2013; 190: 1-20. doi: 10.1007/978-3-642-16037-0_1.


1. Blechacz B, Gores GJ. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. J Hepatol. 2008; 49(2): 160-162. doi: 10.1016/j.jhep.2008.05.001.
2. Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol. 2009; 25(3): 238-239. doi: 10.1097/MOG.0b013e3283292383.

Avijit Majumdar, PhD

Senior Research Scientist
Departments of Gastroenterology, Hepatology and Nutrition
University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd., Unit: Y3.5615
Houston, TX 77030, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Majumdar, PhD, received his doctoral degree specializing in Cell and Molecular Biology from the School of Biomedical Sciences at Kent State University, Ohio on 2008. In his doctoral research, he made two key discoveries which include determining the mechanism of action of the anti-angiogenic drug fumagillin at cellular level and identifying novel tumor suppressor function of MetAP2/P67 which was a known regulator of protein synthesis machinery. He was the recipient of the ‘Excellence in Research’ and ‘Research Grant Award’ at Kent State University. Following his doctoral degree, he joined as a postdoctoral fellow in the Department of Pharmacology at Case Western Reserve University, Ohio, where he worked on the post-translational modification of retinoic acid transporter protein, cellular retinoic acid binding protein – II (CRABP-II). On 2011, he joined as a postdoctoral fellow in the Department of Gastroenterology, Hepatology and Nutrition at the University of Texas MD Anderson Cancer Center. Currently, as a Senior Research Scientist he is working on the mechanistic role of carcinoembryonic antigen (CEA), a widely used marker for determining the recurrence of colorectal cancer (CRC), in promoting CRC metastasis. He received the “Poster of Distinction” award in the ‘Digestive Disease Week’ annual conference on 2013.

His research interest is to elucidate novel therapeutic strategies and identify putative biomarkers to facilitate the early diagnosis and effective treatment of cancer.


• Majumdar A, Li Y, Lin SH, Mishra L. Targeting CEA in the treatment of advanced Colorectal Cancer. 23rd International Symposium on CEA, Toledo, Ohio, USA (2013).
• Majumdar A, Petrescu AD, Noy N. Modulation of the activity of Cellular Retinoic Acid Binding Protein – II by Sumoylation. FASEB Summer Research Conference on Retinoids. Carefree, Arizona, USA (2010).
• Majumdar A, Petrescu AD, Noy N. Modulation of the activity of Cellular Retinoic Acid Binding Protein – II by Sumoylation. Dept. of Pharmacology Retreat, Case Western Reserve University, Ohio, USA (2009).
• Majumdar A, Ghosh A, Datta R, Datta B. Analysis of the interacting domains of eukaryotic initiation factor 2 associated glycoprotein p67 and extra-cellular signal regulated kinase 2. Graduate Student Senate Research Conference, KSU, Ohio, USA (2006).
• Majumdar A, Ghosh A, Datta R, Datta B. Analysis of the interacting domains of eukaryotic initiation factor 2 associated glycoprotein p67 and extra-cellular signal regulated kinase 2. Biomedical Sciences Research Conference, NEOUCOM, Ohio, USA (2006).


• Human Subject Proficiency Training, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Aug. 6-7, 2013
• Human Subject Proficiency Training, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Aug. 6-7, 2013
• Workshop: Research and Funding Opportunities at NCI and the Peer Review Process. University of Texas MD Anderson Cancer Center, Houston, Texas, USA Feb. 11, 2013
• Hands on workshop on Bioinformatics Tools for Biologists and Clinical Researchers. University of Texas MD Anderson Cancer Center, Houston, Texas, USA Sept.28, 2012
• Workshop: “How to write winning Grant”, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Oct. 10-11, 2012


• Associate Member, American Association of Cancer Research.
• Full Member, Sigma Xi, The Scientific Research Society.


1. Katz L, Li Y, Chen JS, et al. Targeting TGF-β signaling in cancer. Expert Opinion on Therapeutic Targets. 2013; 17 (7): 743-760. doi: 10.1517/14728222.2013.782287.
2. Majumdar A, Curley SA, Wu X, et al. Hepatic stem cells and transforming growth factor – β in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology2012; 9(9): 530-538. doi: 10.1038/nrgastro.2012.114.
3. Majumdar A, Petrescu AD, Xiong Y, Noy N. Nuclear translocation of cellular retinoic acid binding protein II is regulated by retinoic acid controlled Sumoylation. J Biol Chem. 2011; 286 (49): 42749-42757. doi: 10.1074/jbc.M111.293464.
4. Berry D, Jin H, Majumdar A, Noy N. Signalling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. PNAS. 2011; 108(11): 4340-4345. doi: 10.1073/pnas.1011115108.
5. Majumdar A, Ghosh A, Datta S, Prudner BC, Datta B. p67/MetAP2 suppresses K-RasV12 mediated transformation of NIH3T3 mouse fibroblasts in culture and in athymic mice. Biochemistry. 2010; 49(47): 10146-10157. doi: 10.1021/bi101225d.
6. Datta B, Ghosh A, Majumdar A, Datta R. Auto – Proteolysis of rat p67 generates several peptide fragments: The N – Terminal Fragment, p26, is required for the protection of eIF2α from Phosphorylation. Biochemistry. 2007; 46: 3465-3475. doi: 10.1021/bi061838n
7. Ghosh A, Datta R, Majumdar A, Bhattacharya M, Datta B. The N – terminal lysine residue rich domain II and the 340-430 amino acid segment of eukaryotic initiation factor 2 associated glycoprotein p67 are the binding sites for the γ - subunit of eIF2. Exp Cell Res. 2006; 312: 3184-3203. doi: 10.1016/j.yexcr.2006.03.034
8. Datta B, Datta R, Ghosh A, Majumdar A. The binding between p67 and eukaryotic initiation factor 2 plays important roles in the protection of eIF2α from phosphorylation by kinases. Archives Biochemistry and Biophysics. 2006; 452: 138-148. doi: 10.1016/j.abb.2006.06.009
9. Datta B, Datta R, Majumdar A, Ghosh A. The stability of eukaryotic initiation factor 2- associated glycoprotein, p67, increases during skeletal muscle differentiation and that inhibits the phosphorylation of extracellular signal- regulated kinases 1 and 2. Exp Cell Res. 2005; 303: 174-182. doi: 10.1016/j.yexcr.2004.09.018
10. Datta B, Majumdar A, Datta R, Balusu R. Treatment of cells with the angiogenic inhibitor Fumagillin results in increased stability of eukaryotic initiation factor 2- associated glycoprotein, p67, and reduced phosphorylation of extracellular signal- regulated kinases. Biochemistry. 2004; 43: 14821-14831. doi: 10.1021/bi049172p
11. Datta B, Datta R, Ghosh A, Majumdar A. Eukaryotic association factor 2- associated glycoprotein, p67, shows differential effects on the activity of certain kinases during serum-starved conditions. Archives of Biochemistry and Biophysics. 2004; 427: 68-78.

Pradeep Garg, PhD

Executive Director
Center for Molecular Imaging and Therapy
Biomedical Research Foundation of Northwest Louisiana
1505 Kings Highway
Shreveport, LA 71103, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr.Garg, PhD is the Executive Director of “Center for Molecular Imaging and Therapy” (CMIT), a subsidiary of Biomedical Research Foundation of Northwest Louisiana, Shreveport, LA (BRF). Prior to his joining BRF, Dr. Garg was Professor of Radiological Sciences and Director of PET research Center at Wake Forest University School of Medicine, Winston Salem, NC, USA. Prior to Wake Forest University Health Sciences, Dr. Garg worked at Duke University Medical Center (1987-1995) and then moved as a faculty in the Department of Radiology at Yale University Medical Center, New Haven, CT (1995-2003) where he later became the Director of the Yale University PET Center.
Dr. Garg is a Molecular Imaging Scientist with research focus in the development and evaluation of novel radiopharmaceuticals as diagnostic and/or therapeutic agents. One of the major strength of his research is his ability to carry out research from bench to bedside. His research focus could be categorized into three major focus areas viz. Oncology, Cardiac and Neurobiology studies. His laboratory has developed novel methods to incorporate bioactive functional groups and radionuclides into a variety of small molecules of biological interest, monoclonal antibodies, single chain proteins, peptides, and amino acids. He participated in multiple clinical trials that ranged from studying imaging probes as tool to monitor therapeutic efficacy in patient, assessing prognostic value of molecular imaging probes in patients with cancers such as prostate and esophageal cancer, to early diagnosis of Alzheimer disease. His group has been very active in developing imaging probes for a variety of neurological dysfunctions and has extensive work experience interrogating dopaminergic, serotonergic and norepinephrine systems. His research collaborators include basic science researchers as well as clinicians and clinical researchers.
He has published extensively in national and international journals. He served on numerous national and international committees. He is a member of several professional organizations such as Society of Nuclear Medicine and Molecular Imaging, Society of Radiopharmaceutical Sciences, American Chemical Society, and American Association for Cancer Research. He served as Board member and as President of the Radiopharmaceutical Science Council of the Society of Nuclear Medicine and Molecular Imaging. He is on editorial board of several journals and is an active reviewer for a variety of national and international journals.

His research interests include: radiology, imaging, animals, whole, basic mechanisms, clinical trials, immunology, allergy, inflammation, nuclear medicine, reproductive system, animals, cells, membranes, tissue, cancer, oncogenesis, human, adult, technology, technique development, translational research


• Annual Meeting Abstract Reviewer- (2003 – Present)
• Sub-chair Scientific Review Committee- (2002-Present)


Society of Nuclear Medicine
• Radiological Society of North America
• Society of Radiopharmaceutical Chemistry
• American Association of Cancer Research
• American Chemical Society

1. Varma RS, Garg PK. 5-chloro-3-arylthiosemicarbazono-2-indolinoes as antimicrobial agents. Acta Pharm Yugoslavica. 1980; 30:199-204. doi:
2. Varma RS, Garg PK. 3-arylglycylhydrazono-2-indolinones as antibacterial agents. Indian J Pharm Sci. 1981; 43:8-11. doi:
3. Varma RS, Garg PK, Verma HN, Awasthi LP. Synthesis and antiviral activity of some 3-arylthiosemicarbazono-2-indolinones. Arch Pharm (Weinheim) . 1981; 314:918-922. doi:
4. Varma RS, Garg PK. Thin layer chromatography separation of some 3-arylthiosemicarbazono-2-indolinones. Z Ann Chem. 1981; 307:416. doi:
5. Varma RS, Garg PK. Antibacterial and antifungal activity of some new 3-arylglycyl hydrazono-2-indolinones. J Antibact Antifun Agents. 1981; 9:573-576. doi:
6. Varma RS, Garg PK. Reaction of 3-arylimino-2-indolinones with ρ-substituted phenylthiosemicarbazides. J Indian Chem Soc. 1981; 57:980-981. doi:
7. Varma RS, Garg PK. New 5-chloro-3-aryloxyacetylhydrazono-2-indolinones as antibacterial agents. J Antibact Antifun Agents. 1982; 10:195-196. doi:
8. Varma RS, Garg PK, Verma HN, Awasthi LP. Effect of some 5-chloro 3-aryl oxyacetylhydrazono-2-indolinones on Sunnhemp rosette virus. Indian Drugs. 1984; 21:512. doi:
9. Agrawal KC, Larroquette CA, Garg PK. Pharmacokinetic studies of amino acid analogs of 2-nitroimidazole, new hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1984; 10:1301-1305. doi: http://dx.doi.org/10.1016/0360-3016(84)90336-5
10. Lam LKT, Garg PK, Swanson SM, Pezzuto JM. Evaluation of the cytotoxic potential of catechols and quinines structurally related to butylated hydroxyanisole. J Pharm Sci. 1988; 77:393-395. doi:
11. Garg PK, Archer GE, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labeling. Appl Radiat Isot. 1989; 40:485-490. doi:
12. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab)2 fragments with the alpha-particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. ProcNatlAcadSci (U.S.A.) . 1989; 86:7149-7153. doi:
13. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE). Cancer Res. 1989; 49:5543-5549. doi:
14. Garg PK, Friedman H, Slade S, Bigner DD, Zalutsky MR. Astatine-211 labeled monoclonal antibody: a potential agent for radioimmunotherapy. NuclMedizinSuppl. 1989; 25:663-666. doi:
15. Garg PK, Slade S, Zalutsky MR, Harrison C. Labeling proteins using aryl iodide acylating agents: influence of metaversus para substitution on in vivo stability. Nucl Med Biol. 1989; 16:669-673. doi:
16. Garg PK, Harrison C, Zalutsky MR. Comparative tissue distribution of the alpha emitter 211 At and 131I labels of a monoclonal antibody and F(ab)2 fragment. Cancer Res. 1990; 50:3514-3520. doi:
17. Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. ActaRadiolSuppl. 1990; 374, 141-145. doi:
18. Lam LKT, Garg PK. Tumorigenicity of di-tert-butyl-substituted hydroxyl- quinine and hydroxyanisoles in the forestomach of Syrian golden hamsters. Carcinogenesis. 1991; 12:1341-1344. doi: 10.1093/carcin/12.7.1341
19. Garg S, Garg PK, Zalutsky MR. N-succinimidyl-5-(trialkylstannyl)-3-pyridine carboxylates: a new class of reagents for protein radiohalogenation. Bioconjug Chem. 1991; 2:50-56. doi:
20. Garg PK, Garg S, Zalutsky MR. Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. BioconjugChem. 1991; 2:44-49. doi:
21. Schuster JM, Garg PK, Bigner DD, Zalutsky MR. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE). Cancer Res. 1991; 51:4164-4169. doi:
22. Zalutsky MR, Garg PK, Johnson SH, Coleman RE. Fluorine- 18 antimyosin monoclonal antibody fragments: preliminary investigation in a canine myocardial infarct model. J Nucl Med. 1992; 33:575-580. doi:
23. Garg PK, DeGraff W, Garg S, Zalutsky MR, Mitchell JB. 4-Fluorobenzyl amine and phenylalanine methyl ester conjugates of 2-nitromidazole: synthesis and evaluation as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1992; 23:593-596. doi: http://dx.doi.org/10.1016/0360-3016(92)90884-K
24. Garg PK, Garg S, Bigner DD, Zalutsky MR. Selective localization of an 18F-labeled Mel-14 monoclonal antibody F(ab)2 fragment in a subcutaneous human gliomaxenograft model. Cancer Res. 1992; 52:5054-5064. doi:
25. Garg PK, Garg S, Zalutsky MR. N-succinimidyl-4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. Nucl Med Biol. 1993; 20:379-387. doi:
26. Garg S, Garg PK, Zhao XG, et al. Radioiodination of MAb 81C6 and a fragment Mel-14(ab)2 using N-succinimidyl-5-(tri-n-butylstannyl) pyridine carboxylate. Nucl Med Biol. 1993; 20:835-842. doi:
27. Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan GV, Coleman RE. Measuring Astatine-211 distribution with SPECT. Phys Med Biol . 1993; 38:1121-1130. doi: 10.1088/0031-9155/38/8/010
28. Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidines. Nucl Med Biol. 1994; 21:97-103. doi: http://dx.doi.org/10.1016/0969-8051(94)90135-X
29. Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR. Positron emission tomographic images of osteosarcoma in dogs using an 18F-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994; 35:1506-1513. doi:
30. Page RL, Garg PK, Vaidyanathan G, Zalutsky MR. Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab)2 fragment in normal dogs. Nucl Med Biol. 1994; 21:911-919. doi: http://dx.doi.org/10.1016/0969-8051(94)90079-5
31. Zalutsky MR, McLendon R, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994; 54:4719-4725. doi:
32. Garg PK, John CS, Zalutsky MR. Preparation and preliminary evaluations of 4-[211At]astato N-piperidinoethylbenzamide. Nucl Med Biol. 1995; 22:465-473. doi: http://dx.doi.org/10.1016/0969-8051(94)00134-6
33. Garg PK, Alston KL, Zalutsky MR. Catabolism of radioiodinated murine monoclonal antibody F(ab)2 fragment labeled using N-succinimidyl 3-iodobenzoate and iodogen. BioconjugChem. 1995; 6:493-501. doi:
34. Smellie WJB, Dean CJ, Sacks NPM, et al. Radioimmunotherapy of human breast cancer xenograft with monoclonal antibody ICR12 against c-erbB2p185: comparison of iodogen and N-succinimidyl 4-methyl 3-(tri-n-butylstannyl)benzoate. Cancer Res. 1996; 55:5842(s)-5846(s). doi:
35. Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 1996; 56:4970-4979. doi:
36. Berry CR, Garg PK, DeGrado TR, et al. Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J Nucl Cardiology. 1996; 3:119-129. doi:
37. McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered [211At]astatide in B6C3F1 and Balb/c (nu/nu) mice: a long term survival study with histologic analysis. Int J RadiatOncolBiolPhy. 1996; 35:69-80. doi:
38. Zalutsky MR, Archer GE, Garg PK, Batra SK, Bigner DD. Chimeric antitenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol. 1996; 23:449-458. doi: http://dx.doi.org/10.1016/0969-8051(96)00021-2
39. Berry CR, Garg PK, Zalutsky MR, Coleman RE, DeGrado TR. Uptake and retention kinetics of para-[18F]fluorobenzylguanidine in the isolated rat heart. J Nucl Med. 1996; 37:2011-2016. doi:
40. Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of “α-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. BioconjugChem. 1996; 7:233-239. doi: 10.1021/bc960001
41. Tan PZ, Baldwin RM, Soufer R, Garg PK, Charney DS, Innis RB. A complete remote-control system for reliable preparation of [F-18]altanserin. Appl Radiat Isot. 1999; 50:923-927. doi: 10.1016/S0969-8043(98)00150-X
42. McNulty PH, Jagasia D, Ng CK, Garg PK, Whiting JM, Soufer S. Persistent changes in myocardial glucose metabolism during reperfusion of a limited-duration coronary artery occlusion in rats. Circulation. 2000; 101:917-922. doi: 10.1161/01.CIR.101.8.917
43. Van Dyck CH, Tan PZ, Baldwin RM, et al. PET quantification of 5-HT2A receptor in human brain: a constant infusion paradigm with [18F] Altanserin. J Nucl Med. 2000; 41:234-241. doi:
44. Van Dyck CH, Tan PZ, Baldwin RM, et al. Equilibrium modeling of 5-HT2A receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol. 2000; 27:715-722. doi: http://dx.doi.org/10.1016/S0969-8051(00)00160-8
45. Garg PK, Labree DC, Hoyte RM, Hochberg RB. 7-F-18fluoro 17-methyl 5- alphadihydroxytestosterone: a ligand for androgen mediated receptor mediated imaging of prostate cancer. Nucl Med Biol. 2001; 28:85-90. doi: http://dx.doi.org/10.1016/S0969-8051(00)00172-4
46. Staley JK, Van Dyck CH, Tan P, et al. Pharmacological characterization of F-18 deuteroaltanserin: a PET radiotracer for equilibrium imaging of serotonin-2A receptors. Nucl Med Biol. 2001; 28:271-279. doi: http://dx.doi.org/10.1016/S0969-8051(00)00212-2
47. Soares JC, Van Dyck CH, Tan P-Z, et al. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [F18]deuteroaltanserin. Psychiatr Res. 2001; 81-93. doi: http://dx.doi.org/10.1016/S0925-4927(01)00071-3
48. Berry CR, DeGrado TR, Nutter F, et al. Imaging of pheochromocytoma in dogs using para-[F-18]fluorobenzylguanidine. Vet Radiol Ultrasound. 2002; 43:183-186. doi:
49. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in post menopausal women. Am J Psychiatry. 2003; 160:1522-24. doi:
50. Bremner JD, Vythilingam M, Vermetten E, et al. MRI and PET studies of deficit in hippocampal structure and function in women with childhood abuse and posttraumatic stress disorder. Am J Psychiatry. 2003; 160:924-32. doi:
51. Chaley T, Baldwin RM, Neumeyer JL, et al. Radiosynthesis of F-18 N-3-(fluoropropyl)-2-β-(4 bromophenyl) nortropane and the regional brain uptake in non human primate using PET. Nucl Med Biol. 2004; 31:125-131. doi: http://dx.doi.org/10.1016/S0969-8051(03)00110-0
52. Garg S, Thopate SR, Minton RC, Black KW, Lynch A, and Garg PK. 3-Amino-4-(2-((4-[18F]fluorobenzyl)methyl amino)-methyl-phenylsulfanyl)-benzonitrile (FBASB): An F-18 fluorobenzyl analogue of DASB. Synthesis, in-vitro and in vivo biodistribution studies. Bioconjugate Chemistry. 2007; 18: 1612-1618 doi: 10.1021/bc070112g
53. Banks ML, Czoty PW, Gage HD, et al. Effects of Cocaine and MDMA Self-Administration on Serotonin Transporter Availability in Monkeys. Neuropsychopharmacology. 2008; 33: 219-25. doi: 10.1038/sj.npp.1301420
54. Garg S, Doke A, Black KW, and Garg PK. In vivo biodistribution of an androgen receptor avid PET imaging agent 7-α-fluoro-17 -methyl-5-dihydrotestosterone ([18F]FMDHT) in rats pre-treated with cetrorelix, a GnRH antagonist. Eur J Nucl Med Mol Imaging. 2008; 35: 379-85. doi: 10.1007/s00259-007-0610-3
55. Garg S, Lynch A, Minton RC, and Garg PK. A remote controlled system for the preparation of 7-α[18F]fluoro 17-α methyl 5-α dihydrotestosterone ([18F] FMDHT) using microwave. Appl. Rad Isotopes. 2008; 66: 612-618. doi: 10.1016/j.apradiso.2008.01.017.
56. Czoty PW, Riddick NV, Gage DH, et al. Effect of menstrual cycle phase on dopamine D2 receptor availability in female cynomolgus monkeys. Neuropsychopharmacology. 2009;34: 548-554. doi: 10.1038/npp.2008.3.
57. Riddick NV, Czoty PW, Gage HD, et al. Behavioral and neurobiological characteristics influencing social hierarchy formation in female cynomolgus monkeys. Neuroscience. 2009; 158: 1257-65. doi:
58. Garg S, Kothari K, Doke AK, Thopate SR, Garg, PK. Design, synthesis and preliminary evaluation of 4-[18F]fluoro N-(2-diethylaminoethyl)benzamide, [18F]-DAFBA: A novel potential PET imaging probe to image melanoma tumors. Bioconjugate Chemistry. 2009; 20, 583-590.
59. Clark PB, Plaza MJ, Kraas J, et al. Dual radiotracer analysis of cholinergic neuronal changes in prediabetic mouse pancreas. Diabetes TechnolTherap. 2009; 11: 107-111. doi: 10.1089/dia.2008.0024.
60. Clark PB, Kavanagh K, Gage HD, et al. Enhanced cholinergic response in pancreata of non-human primates with impaired glucose tolerance shown on [18F]-fluorobenzyltrozamicol positron emission tomography. Diabetes TechnolTherap. 2009; 11: 451-455. doi: 10.1089/dia.2008.0113.
61. Rose JE, Mukhin AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and non-dependent smokers: a PET study with 11C-nicotine cigarettes. ProcNatlAcad Sci. 2010; 107: 5190 - 5195. doi: 10.1073/pnas.0909184107.
62. Nader MA, Nader SH, Czoty PW, et al. Social Dominance in female monkeys: Dopamine receptor function and cocaine reinforcement. Biological Psychiatry. 2012; 72: 414-421. doi: 10.1016/j.biopsych.2012.03.002.
63. Gould RW, Garg PK, Garg SG, Nader MA. Effects of nicotinic acetylcholine receptor agonist on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology. 2013; 64: 479-488. doi: 10.1016/j.neuropharm.2012.08.004.
64. Czoty PW, Gaze HD, Garg PK, Garg S, Nader MA. Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys. Psychopharmacology (Berl). 2013; doi: 10.1007/s00213-013-3274-7
65. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F-18 AV-45) PET to assess amyloid burden in Alzheimers disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013; 9(0): S72–S83. doi: 10.1016/j.jalz.2012.10.007.
66. Garg PK, Batra SK, Garg S. Role of Molecular Imaging in Oncology. Cancer Stud Mol Med Open J. 2014; 1(1): e1-e7. doi: 10.17140/CSMMOJ-1-e001

Bishoy M. Faltas, MD

Clinical Fellow
Weill Cornell Medical College
435 E 70th Street Apt 9J
NY 10021, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Faltas is a Clinical and a Research Fellow in hematology-oncology at Weill-Cornell Medical College. He is also working in the laboratory of Dr. Mark Rubin and the Weill-Cornell “Precision Medicine” Institute. He is currently focused on the molecular profiling of urothelial bladder carcinoma, a disease with the highest recurrence rate of any malignancy. He is working to generate a detailed molecular profile of platinum-resistant metastatic urothelial carcinoma. His ultimate goal is to identify the driver mutations for metastatic urothelial carcinoma and to identify “druggable” targets for translation of these findings into therapeutic clinical trials.

His research interests include: molecular profiling of urothelial bladder carcinoma, to generate a detailed molecular profile of platinum-resistant metastatic urothelial carcinoma, to identify the driver mutations for metastatic urothelial carcinoma and to identify “druggable” targets for translation of these findings into therapeutic clinical trials.


• 2007-Present, American College of Physicians (ACP)
• 2010-Present, American Association for Cancer Research (AACR)
• 2012-Present, American Society of Clinical Oncology (ASCO)
• 2012-Present, American Society of Hematology (ASH)


• 2009, American Medical Association (AMA) policy promotion grant.
• 2013, Scholarship to attend ASCO- AACR Methods in Clinical Oncology Workshop, Vail, CO
• 2014, Award to attend the Cancer Education Consortium Molecular and Translational Oncology Workshop

Institutional professional responsibilities

7/2013-Present, Elected to Graduate Medical Education Council at Weill-Cornell Medical College


1. Zeidan A, Faltas B, Forde P, Subhawong A, Bello C, Bolanos-Meade J. Sequential Occurrence of a Splenic Marginal Zone Lymphoma, Extranodal MALT Lymphoma, and Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2013 ; 5S2152-2650(13): 00117-1. doi: 10.1016/j.clml.2013.04.004.
2. Zeidan A, Faltas B, Fricke W, Gore S, Ketterling R, Sham R. Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. Leuk Lymphoma. 2013; 54(7): 1534-1537. doi: 10.3109/10428194.2012.742526.
3. Andrei M, Cramer SF, Kramer ZB, Zeidan A, Faltas B. Adult primary pulmonary primitive neuroectodermal tumor: Molecular features and translational opportunities. Cancer BiolTher. 2012; 14(2). doi: 10.4161/cbt.22635.
4. Faltas B, Phatak P, Sham R. Mental nerve neuropathy: Frequently overlookedclinical sign of hematologic malignancies. Am J Med. 2011; 124(1): e1-e2. doi: 10.1016/j.amjmed.2010.05.006.
5. Faltas B. Targeting hematogenous spread of circulating tumor cells by achemotactic drug-eluting IVC filter to prevent pulmonary and systemic metastasis. Med Hypotheses. 2010; 74(4): 668-669. doi: 10.1016/j.mehy.2009.11.008.
6. Faltas B, Kramer ZB. Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori. Leuk Lymphoma. 2009; 50(9): 1538-1539. doi: 10.1080/10428190903085969.
7. Zeidan A, Tariq S, Faltas B, Urban M, McGrody K. A case of primarymeningococcal pericarditis caused by Neisseria meningitidis serotype Y with rapidevolution into cardiac tamponade. J Gen Intern Med. 2008; 23(9):1532-1535. doi: 10.1007/s11606-008-0685-y.
8. NigwekerS, Faltas B, Hix J. Sarcoidosis unmasked. American Journal of Kidney Diseases. 2008; 51(4): B74-B74.
9. Faltas B, Chow MY. Cant catch a breath. Am J Med. 2007; 120(9): 778-780. doi: http://dx.doi.org/10.1016/j.amjmed.2007.05.002

Alexandros Charalabopoulos, MD, PhD, FRCS

Consultant Upper GI and General Surgeon
Mid Essex Hospital Services NHS Trust
Broomfield Hospital
Broomfield, Chelmsford
Essex CM1 7ET, UK

BiographyResearch InterestScientific ActivitiesPublications
Consultant Upper GI & General Surgeon with an interest in Minimally Invasive Oesophagogastric Cancer Surgery.

Broomfield Hospital, Mid Essex Hospital Services NHS Trust

Permanent full time post from December 2013

As an Upper GI & General Surgery Consultant with a major interest in oesophagogastric cancer resection surgery, Dr. Charalabopoulos performs all the operations in the spectrum of upper gastrointestinal surgery and mainly in the field of upper GI cancer surgery and its minimally invasive treatment. Broomfield Hospital is a high volume and the regional oesophagogastric cancer center in which more than 100 oesophagogastric resections per year are performed. He perform all types of oesophagectomies with the majority being laparoscopic assisted Ivor-Lewis oesophagogastrectomies and all the types of gastrectomies. Most of the elective operations he perform are laparoscopic. He perform upper GI and general surgical operations like laparoscopic incisional and inguinal (TEP and TAPP) hernia repair, laparoscopic cholecystectomy and CBD exploration, laparoscopic fundoplication, and laparoscopic Heller’s myotomy. He perform robotic upper GI surgery and especially robotic assisted Heller’s myotomy, robotic gastric resections and robotic gastric pacing. He is also have a special interest in the treatment of gastroparesis and he is one of the two surgeons in the region who specializes in gastric pacing. He does general surgical on calls in a 1 in 8 rota. He perform upper GI diagnostic and therapeutic endoscopy and do upper GI and general surgical clinics. He is also a key member of the upper GI cancer MDT meetings.
As an Upper GI Surgeon, he have been extensively trained in all types of oesophagectomies (Ivor-Lewis, McKeown, transhiatal, thoracoabdominal, minimal invasive), gastrectomies with extensive lymph node dissections (D1, D2 and even D3), bariatric surgery (gastric bypass, sleeve gastrectomy, gastric band, intragastric balloon) and laparoscopic benign upper GI disease. He have received expert training in Upper GI surgery from internationally renowned units. Specifically, cancer resections through fellowships from Broomfield Hospital in Chelmsford, National Cancer Centre Hospital in Tokyo, St Thomas’ Hospital in London and upper GI advanced laparoscopic procedures including bariatric surgery from St Thomas’ and St George’s Hospitals in London. He have also had advanced training in general surgery (mainly HPB, colorectal, endocrine, vascular) and was awarded an MSc and a PhD for his research in experimental acute pancreatitis and gastrointestinal carcinogenesis respectively. So far he have participated in about 3000 operations, the great majority of which is in the field of Upper GI surgery, having performed more than 1800 of those.

His research interests include: oesophagogastric cancer resection surgery, treatment of gastroparesis


1. Bariatric surgery. Operations and pitfalls. Chairman: Mr A Botha. FY2/CT/SHO Surgical Education Day. Guy?s and St Thomas? Education Centre, London, UK. 07 Feb 2013
2. Complications of bariatric surgery. Round table. Chairman: Dr S Chong. South Thames Gut Club Meeting. Post Grad Lecture Theatre, St Helier Hospital. London, UK. 24 Nov 2011.
3. Round Table: The role of adhesion molecules in cancer. New useful tools. Topic: Cadherins. 15th Scientific Congress of Greek Medical School Students & 3rd International Forum of Medical Students and Young Doctors of Greece. Thessaloniki, Greece, 8-10 May 2009.
4. Surgical anatomy of the liver and types of hepatectomies. Higher Surgical Training Meeting of University of Athens. Attikon University Hospital, Athens, Greece. June 2009.

5. Respiratory failure and its prevention in the surgical patient. Higher Surgical Training Meeting of University of Athens. Attikon University Hospital, Athens, Greece. Feb 2008.
6. Oesophageal resection with colonic interposition. Round table. Chairman: Prof Liakakos. 1st Joined Meeting of the Travelling Surgical Society of Great Britain and Northern Ireland and the Third Academic Department of Surgery of the University of Athens. Attikon University Hospital, Athens, Greece. Sept 2008.
7. Spontaneous kidney rupture. A&E East Anglia Meeting. Peterborough Hospital, Peterborough, UK. April 2006.
8. Surgical pathology of liver and spleen. Basic Surgical Training Meeting. Post graduate center, Peterborough Hospital, Peterborough, UK. July 2005.

8. Surgical pathology of liver and spleen. Basic Surgical Training Meeting. Post graduate center, Peterborough Hospital, Peterborough, UK. July 2005.
9. Sore throat. ENT East Anglia Meeting. Peterborough Hospital, Peterborough, UK. Oct 2005.
10. Sensorineural hearing loss. ENT East Anglia Meeting. Peterborough Hospital, Peterborough, UK. Jan 2006.
11. Management of surgical infection. Basic Surgical Training Meeting. Post graduate center, Peterborough Hospital, Peterborough, UK. July 2005.


• Member of AUGIS - Association of Upper Gastrointestinal Surgeons of Great Britain & Ireland
• Member of BOMMS- British Obesity & Metabolic Surgery Society
• Member and Fellow of RCSEng - The Royal College of Surgeons of England
• Member of EA-HPB-A - European-African Hepato-Pancreato-Biliary Association
• Member of HPB-HS - The Hepato-Pancreato-Biliary Hellenic Society


1. Charalabopoulos A, Golias C. E-cadherin expression in Barretts esophagus and esophageal carcinoma. Esophagus. 2014.
2. Charalabopoulos A, Lambropoulou M, Papalois A, Papachristou F, Simopoulos C, Tsaroucha A. Does apigenin exert a prophylactic effect in acute pancreatitis An experimental study evaluating pancreatic TNF- expression. J Surg Res. 2013.
3. Charalabopoulos A, Botha AJ. Laparoscopic cholecystectomy in the presence of lumboperitoneal shunt. Case Rep Surg. 2013; doi: 10.1155/2013/929082.
4. Machairas A, Tsapralis D, Samaras VD, et al. Basaloid squamous cell carcinoma of the rectum. A rare entity. J Med Cases. 2013; 4(8): 535-539.
5. Machairas A, Petropoulos K, Machairas N, Charalabopoulos A, Misiakos EP. Image of the month. Choledochocele. Arch Surg. 2011; 146(10): 1213-1214. doi: 10.1001/archsurg.2011.263-a.
6. Golias C, Batistatou A, Bablekos G, et al. Physiology and pathophysiology of selectins, integrins, and IgSF cell adhesion molecules focusing on inflammation. A paradigm model on infectious endocarditis. Cell Commun Adhes. 2011; 18(3): 19-32. doi: 10.3109/15419061.2011.606381.
7. Misiakos EP, Siama E, Schizas D, et al. Massive Uterine Leiomyoma in a Patient with Friedreichs Ataxia: Is There a Possible Association. Case Report Med. 2011; 2011: 648217. doi: 10.1155/2011/648217.
8. Charalabopoulos K, Makris G, Charalabopoulos A, Golias C, Athanasiou K. Public knowledge, beliefs and practices in Greece about cancer etiology and prevention. East Mediterr Health J. 2011; 17(5): 392-397.
9. Charalabopoulos K, Krivan S, Machairas N, Machairas M. Endopancreatic bile duct cholangiocarcinoma in a patient with Peutz-Jeghers syndrome. HPB Surgery. 2011; 2011: 364570. doi: 10.1155/2011/364570.
10. Charalabopoulos , Macheras , Krivan S, Petropoulos K, Misiakos , Macheras A. Arteriovenous malformation of the pancreas. Case Reports Med. 2011; 2011: 612657.
11. Charalabopoulos A, Misiakos E, Macheras A. Colocutaneous fistula complicating sigmoid diverticulitis. Int J Surg Case Rep. 2011; 2: 68-70.
12. Batistatou A, Charalabopoulos A, Charalabopoulos K. Molecular basis of colorectal cancer. N Engl J Med. 2010; 362(13): 1246.
13. Tsapralis D, Charalabopoulos A, Karamitopoulou E, et al. Pancreatic intraductal papillary mucinous neoplasm with concomitant heterotopic pancreatic cystic neoplasia of the stomach: a case report and review of the literature. Diagn Pathol. 010; 5: 4. doi: 10.1186/1746-1596-5-4.
14. Charalampopoulos A, Charalabopoulos A, Batistatou A, et al. Parathormone and 1,25(OH)2D3 but not 25(OH)D3 serum levels, in an inverse correlation, reveal an association with advanced stages of colorectal cancer. Clin Exp Med. 2010; 10(1): 69-72. doi: 10.1007/s10238-009-0069-6.
15. Charalabopoulos A, Misiakos EP, Foukas P, et al. Localized peripancreatic plasma cell Castleman disease. Am J Surg. 2010; 199(5): 51-53. doi: 10.1016/j.amjsurg.2009.05.020.
16. Yiotakis I, Georgolios A, Charalabopoulos A, et al. Primary localized laryngeal amyloidosis presenting with hoarseness and dysphagia: A case report. J Med Case Reports. 2009; 3: 9049. doi: 10.4076/1752-1947-3-9049
17. Charalabopoulos K, Kotsalos A, Batistatou A, et al. Serum and tissue selenium levels in gastric cancer patients and correlation with CEA. Anticancer Res. 2009; 29(8): 3465-3467.
18. Batistatou A, Charalabopoulos A, Charalabopoulos K. Molecular basis of metastasis. N Engl J Med. 2009; 360(16): 1679. doi: 10.1056/NEJMra0805239.
19. Charalampopoulos A, Macheras A, Charalabopoulos A, Fotiadis C, Charalabopoulos K. Iliopsoas bscesses: diagnostic, aetiologic and therapeutic approach in five patients with a literature review. Scand J Gastroenterol. 2009; 44(5): 594-599. doi: 10.1080/00365520902745054.

Daniel Dennis Taub, PhD, MT (ASCP) SH

Senior Scientist and Director
Center for Translational Studies, VA Medical Center
Department of Veteran Affairs, Veterans Health Administration
Medical Services, Bldg. 4, Room 1F-123A
50 Irving Street, NW
Washington, DC 20422, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Dennis D. Taub received his PhD from the Department of Microbiology and Immunology at Temple University School of Medicine in Philadelphia in 1991. He subsequently entered the laboratory of Dr. Joost J. Oppenheim as a staff fellow at the National Cancer Institute in Frederick, Maryland. From 1994-1997, he headed the vaccine monitoring laboratory within the Clinical Services Program at the National Cancer Institute. In early 1997, he moved to the National Institute on Aging and started the Laboratory of Immunology as its Chief as well as the Senior Investigator and Chief of Clinical Immunology Section. Dr. Taub also served as the Director of Clinical Core Laboratory and the NIA Bio-Repository, National Institute on Aging, National Institutes of Health from 1998-2010. In 2013, Dr. Taub moved to the Veterans Affairs Medical Center in Washington DC, Department of Veterans Affairs as the Director of Hematology and Immunology Research, Hematology Section.
Dr. Taub has wide interests in many areas of biology and medicine, both basic and clinical. His current researches focus on chemokine biology, age-associated changes in immune function, the role of cholesterol and lipid rafts in T lymphocyte signaling and trafficking, novel connections between the immune and endocrine systems, the molecular and biological mechanisms of age-associated thymic involution and the role of homocysteine in immunoregulation. He has published over 240 articles as an author or co-author in peer-reviewed journals, reviews and book chapters. Dr. Taub has rich experience in journal editorial services, including past experience as an Associate Editor for Journal of Clinical Investigation (2000-2002), Journal of Immunology (1995-2001), and Blood (2000-2005). He currently sits on the editorial board of numerous journals including Ageing Research Reviews, Brain, Behavior and Immunity, Cellular Immunology, Current Immunology Reviews, Journal of Gerontology (Medical Sciences), Journal of Immune Based Therapies and Vaccines, Journal of Neuroinflammation, Mechanisms of Ageing and Development, and several others. Dr. Taub is also the current Editor-in-Chief of the Journal of Inflammation, International Journal of Medical Sciences and the Journal of Immune-Based Therapies, Vaccines and Antimicrobials. He also serves as a member of Faculty 1000, and serves on many Committees/Advisory Boards within NIH or external.

His research interests include many areas of biology and medicine, in both basic and clinical research with a focus on translational studies. His function, the role of cholesterol and lipid rafts in T lymphocyte signaling and trafficking, novel connections between the immune and endocrine systems, the molecular and biological mechanisms of age-associated thymic involution and the role of homocysteine in immunoregulation.


• American Association for the Advancement of Science (AAAS)
• American Association of Blood Banking (AABB)
• American Association of Clinical Chemistry (AACC)
• American Association of Immunologists (AAI)
• Association of Clinical Scientists
• Association of Directors of Anatomic and Surgical Pathology
• Association for Pathology Informatics
• American Geriatric Society (AGS)
• American Society of Clinical Laboratory Science (ASCLS)
• American Society of Clinical Pathologists (ASCP)
• American Society of Medical Technologists (ASMT)
• American Society of Microbiology (ASM)
• British Society of Immunology (BSI)
• Clinical Immunology Society (CIS)
• Clinical Laboratory Management Association (CLMA)
• Council of Science Editors (CSE)
• Federation of Clinical Immunology Societies (FOCIS)
• Gerontology Society of America (GSA)
• Human Proteome Organization (HUPO)
• Inflammation Research Association (IRA)
• International Society for Biological and Environmental Repositories (ISBER)
• Leukocyte Biology Society (LBS)
• National Association on HIV Over Fifty (NAHOF)
• Psychoneuroimmunology Research Society (PNIRS)
• Society for Applied Research in Aging (SARA)
• Society for Hematopathology
• Society of Neuro-Immune Pharmacology (SNIP)
The Endocrine Society


• 1977-1981 National Honor Society (GPA >4.0)
• 1980-1981 Mentally Gifted Program
• 1981 Scholarship for Excellence in Languages (Latin), Penn State scholarship
• 1980-1982 Alpha Lambda Delta Honor Society (GPA 3.9) and monetary award • for Academic Excellence
• 1989-1992 National Research Service Awards (NRSA) for Performance, graduate stipend
• 1993 Clinical Immunology Society Science Recognition Award for New Investigators at AAI/CIS meeting, Denver
• 1997 EEO Award for Special Achievement
• 1997 NIA On the Spot Award
• 1997 BSI Young Investigator of Year
• 1998 EEO Award for Special Achievement
• 1999 NIA Staff Recognition Award
• 1999 NIA Special Achievement
• 2000 NIA Sustained High Quality Work Performance
• 2000 NIA Staff Recognition Award
• 2001 NIA Staff Recognition Award
• 2002 NIA Special Act or Service Award- Leadership in Direction of the Clinical Core Laboratory
• 2002 NIA Staff Recognition Award
• 2002 NIA, On the Spot Award
• 2003-2009 NIA Staff Recognition Award (Annual award)
• 2007 NIH Ten-Year Service Award


Total publications: 263 (manuscripts, chapters and reviews)
Total Citations: 14,427 (since 1987), 5843 (since 2007) – checked Jan 2013
H-index (Google Scholar): 66 (from 1987), 47 (since 2007) – checked Jan 2013
[Note – selected search necessary under Taub DD, Taub D and one Taub DT paper]
i10 Index (Google Scholar): 168 (since 1987), 128 (since 2007) – checked Jan 2013
G-index (Microsoft Academic Search): 60 (not based on all published papers and chapters) – checked Jan 2013

Joshua A. Bauer, PhD

Research Assistant Professor
Department of Biochemistry
Vanderbilt Institute of Chemical Biology
High-Throughput Screening Facility
824 Robinson Research Building
2200 Pierce Avenue
Nashville, TN 37232, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Bauer is currently leading the high-throughput screening team to facilitate the development and implementation of technologies to enable the discovery of chemical modulators of a variety of molecular targets and pathways in cancer cell biology. He also helps in developing pharmacological discoveries for anti-cancer agents and identifies new lead compounds that benefit both mechanistic studies and drug discovery/development.

His research interests are focused on bioinformatic and chemical genomic approaches to identify novel cancer targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics.


• 2006 – Present American Association for the Advancement of Science (AAAS)
• 2002 – Present American Association for Cancer Research (AACR)


• Journal of Clinical Investigation
• Cancer Research
• Clinical Cancer Research
• Carcinogenesis
• Oncogene
• Molecular Cancer Therapeutics
• Chemical Research in Toxicology


• March 2012: NIH study section (NCI)- “Provocative Questions” in Cancer
• April 2011: AACR-Susan G. Komen Scholar-in-Training Award- Annual International Meeting
• June 2009: Vanderbilt Breast SPORE Pilot Project Grant
• May 2009: 1st Place Poster Presentation- 2009 Vanderbilt-Ingram Cancer Center Retreat
• April 2007: 2006 University of Michigan Distinguished Dissertation Award
• November 2005: AACR Scholars-in-Training Award- Molecular Targets and Cancer Therapeutic International Meeting
• July 2004: AACR- Pathobiology of Cancer Workshop Trainee
• May 2002: Undergraduate Research Opportunity Program (UROP) Recognition Award for Outstanding Research Mentorship


1. Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014; 4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286
2. Guo Y, Sheng Q, Samuels DC, et al. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int. 2013; 915636. doi: 10.1155/2013/915636.
3. Xie J, Wang C, Virostko J, et al. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. Chembiochem. 2013; 14(12): 1494-503. doi: 10.1002/cbic.201300142
4. Ye F, Bauer JA, Pietenpol JA, Shyr Y. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. BMC Genomics. 2012; 13(Suppl 8): S3. doi: 10.1186/1471-2164-13-S8-S3
5. Chen X, Li J, Gray WH, et al. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform. 2012; 11: 147-56. doi: 10.4137/CIN.S9983
6. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7). doi: 10.1172/JCI45014.
7. Adams S, Chakravarthy AB, Donach M, et al. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 2010; 124(3): 723-32. doi: 10.1007/s10549-010-1181-8.
8. Bauer JA, Ye F, Marshall CB, et al. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010; 12(3): R41. doi: 10.1186/bcr2595
9. Bauer JA, Chak BA, Rosenbluth J, et al. Identification of Markers of Taxane-Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation. Clin Cancer Res. 2010; 16(2): 681-90. doi: 10.1158/1078-0432.CCR-09-1091.
10. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, gender and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J ClinOncol. 2008; 26(19): 3128-37. doi: 10.1200/JCO.2007.12.7662.
11. Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008; 7(6): 1533-42. doi: 10.1158/1535-7163.MCT-08-0140.
12. Sikora MJ, Bauer JA, Verhaegen M, et al. Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. Cancer BiolTher. 2008; 7(5): 767-76. doi: 10.4161/cbt.7.5.5767
13. Bauer JA, Kumar B, Cordell K, et al. Targeting apoptosis to overcome cisplatin resistance: A translational study in head and neck cancer. Int J RadiatOncolBiol Phys. 2007; 69(2 Suppl): S106-8. doi: http://dx.doi.org/10.1016/j.ijrobp.2007.05.080
14. Verhaegen M, Bauer JA, De La Vega CM, et al. A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell maintenance controlled by p53 and reactive oxygen species. Cancer Res. 2006; 66 (23). doi: 10.1158/0008-5472.CAN-06-1748
15. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL. Mol Cancer Ther. 2005; 4(7): 1096-104. doi: 10.1158/1535-7163.MCT-05-0081
16. Oliver CL, Bauer JA, Ubell ML, et al. The BH3-mimetic BL-193, (-)-gossypol, exhibits potent In vitro activity against head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004; 10(22): 7757-63.
17. Bauer JA, Thompson TA, Church DR, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate. 2003; 55(3): 159-67. doi: 10.1002/pros.10219

Kailash C. Chadha, PhD

Associate Professor of Oncology
Department of Molecular and Cellular Biology
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr.Chadha is the Associate Member and Associate Professor of Oncology in the Department of Molecular and Cellular Biology at Roswell Park Cancer Institute, and Department of Medicine, State University of New York at Buffalo, NY, USA. He got his Ph.D. degree in Virology from the University of Guelph, Guelph, Ontario, Canada. After two years of postdoctoral work he joined Roswell Park Cancer Institute in Buffalo, New York as a Cancer Research Scientist in the Department of Medical Viral Oncology. His research interests are in the area of cell and molecular biology of Herpes viruses, interferons and prostate cancer. He has published well over 125 publications, written several book chapters, edited a book on Interferon and currently holds four U.S. patents. He is currently on the editorial board of several journals. He is member of several professional organizations including New York Academy of Sciences; American Association for the Advancement of Science; Society for Experimental Biology & Medicine; American Association for Cancer Research; International Society for Interferon & Cytokine research and The Society of Basic Urologic Research etc.

His research interests include: The physiological role of PSA in prostate tissue microenvironment, in prostate tumor growth and progression, and in prostate cancer metastasis is not known. Attenuation of PSA levels with age, disease progression, or during androgen deprivation therapy, however, removes this important regulator of angiogenesis, and by extension results in tumor progression. Re-introduction of human PSA into the prostate tissue microenvironment may suppress tumor angiogenesis through either the inhibition of expression of pro-angiogenic genes or induction of expression of anti-angiogenic genes, or via inhibition of signaling mechanisms associated with angiogenesis that are independent of gene transcription. Validation of an anti-angiogenic effect of PSA on the human tissue vasculature in a pre-clinical model of primary xenografts of human prostate and prostate cancer tissue will provide compelling evidence that PSA has therapeutic potential against prostate cancer.


1. Chadha K, Armosina M, Kane C, Grob P. Characterization of human leukocyte interferon. I. Affinity chromatography on poly(I) agarose. I-A590/l, June, 1978.
2. Miller L, Chadha KC, Carter WA. Characterization of bovine fibroblast interferon on affinity chromatography ligands. I-A569/l, June, 1978.
3. Chadha K, Armosina M, Kane C, Grob P, Sulkowksi E. Copper chelate chromatography of human leukocyte interferon. A-607/l, July, 1978.
4. Grob P, Chadha K, Sclair M. Characterization of human leukocyte interferon. II. Chromatography on aromatic ligands. Ia622, August, 1978.
5. Chadha KC, Grob PM, Hamill R, Sulkowski, E. Effects of tunicamycin on properties of human leukocyte interferon. February, 1979.
6. Grob PM, Chadha KC. Separation and characterization of human leukocyte interferon components by concanavalin A-sepharose chromatography. I-A723, April, 1979.
7. Chadha KC. Thermal stability of human leukocyte interferon produced in the presence of tunicamycin. I-A828, Nov., 1979.
8. Chadha KC, Sulkowski E. New sorbent for hydrophobic chromatography of human leukocyte interferon. I-A856, 1980.
9. Duigou R, Grob PM, Dinolfo E, Chadha KC. In vitro antiviral and anti-cell growth activities of the three molecular components of human leukocyte interferon: lung adenocarcinoma cells. I-A873/l, Feb., 1980.
10. Brown JR, Chadha KC. Studies on human interferon produced in a lymphoblastoid cell line apparently free from EBV genome (DG-75 cell line). June, 1980.
11. Thacore HR, Chadha KC, Mount D. Marked resistance of herpes simplex virus type l (HSV-l) to human interferon in human cornea cells in culture. I-A948, August, 1980.
12. Chadha KC, Sulkowski E. CPG chromatography of HuIFN-alpha. July, 1981.
13. Bonaccio E, Pawlik L, Hossenlopp D, Chadha KC. Human cells treated with adriamycin are less sensitive to interferon. September, 1982.
14. Chadha KC, Sulkowski E. Adsorption of leukocyte derived human interferon on glass: contribution of electrostatic and hydrophobic forces. I-A1127, January, 1982. 15. Landgraf S, Chadha KC. Acid-labile human leukocyte interferon. September, 1983.

1. Chadha KC, Raychaudhuri SP. Deodar fruit extract-inhibitor of Chilli mosaic virus. Indian Phytopath. 1965; 18: 93.
2. Chadha KC, Raychaudhuri SP. Interaction between sterility virus and Fusarium udum, Butl, in pigeon pea. Indian J Agri Science. 1966; 36(3): 133.
3. Chadha KC, Raychaudhuri SP. Interaction between Chilli mosaic virus and powdery mildew (Erysiphe chichoacearum). Indian Phytopath. 1968; 21: 171.
4. Chadha KC, MacNeill BH. An antiviral principle from tomato plants systemically infected with tobacco mosaic virus. Canadian J Botany. 1968; 47: 513.
5. Chadha KC, MacNeill BH. Influence of temperature upon level of virus and an antiviral principle in tomato plants systemically infected with tobacco mosaic virus. Can J Microbiology. 1969; 15(12): 1469.
6. Srivastava BIS, Chadha KC. Liberation of Agrobacterium tumifaciens DNA from tumor DNA by shearing. Biochem Biophys Res Comm. 1970; 40: 968.
7. Chadha KC, Srivastava BIS. Evidence for the presence of bacteria specific proteins in sterile crown gall tumor tissue. Plant Physiology. 1971; 48: 125. doi: http://dx.doi.org/10.1104/pp.48.2.125
8. Srivastava BIS, Matsumoto H, Chadha KC. Studies on chromatin-associated nucleases from barley leaves. Plant and Cell Physiology. 1971; 12: 609.
9. Reyes AA, Chadha KC. Interaction between Fusarium oxysporum f. sp. conglutinans and turnip mosaic virus in Brassica comperstris var. Chiensis seedling. Phytopathology. 1972; 62(12): 1424.
10. Chadha KC, Brown SA. Biosynthesis of phenolic acids in tomato plants infected with Agrobacterium tumifaciens. Canadian J Botany. 1974; 52: 2041-2047.
11. Chadha KC, Davey MW, Byrd DM, Carter WA. Differential production of interferon and refractoriness inducing principle in L cells. Infect Immun. 1974; 10(5): 1057-1061.
12. Chadha KC, Munyon W. Presence of herpes simplex virus antigens in transformed L cells. J Virol. 1975; 15(6): 1475.
13. Allen WR, Chadha KC. Fruit disorder of glasshouse tomatoes caused by a tobacco form of tobacco mosaic virus. Canadian J Plant Science. 1975; 55: 597-604.
14. Thouless ME, Chadha KC, Munyon WH. Serological specificity of thymidine kinase activity in herpes simplex virus transformed L cells. Virology. 1976; 60(l): 350. doi: 10.1016/0042-6822(76)90225-7
15. Hardi R, Hughes Jr RG, Ho YK, Chadha KC, Bardos TJ. Differential effects of 5-methylmercapto-2-deoxyuridine on the replication of herpes simplex virus type l in two cell systems. Antimicrob Agents Chemother. 1976; 10(4): 682-686. doi: 10.1128/AAC.10.4.682
16. Chadha KC, Munyon WH, Zeigel RF. Expression of type specific virion structural antigen(s) in L cells transformed by herpes simplex virus. Virology. 1977; 76: 433-436.
17. Cheng Y-C, Chadha KC, Hughes Jr RG. Biochemical and immunological characterization of deoxythymidine kinase of thymidine kinaseless HeLa cells biochemically transformed by herpes simplex virus type l. Infec Immun. 1977; 16(2): 486-492.
18. Chadha KC, Munyon WH, Hughes Jr RG. Thymidine kinaseless revertants of Ltk- cells transformed by HSV-1 are resistant to retransformation by homologous virus. Infec Immun. 1971; 16(2): 655-661.
19. Surgino WM, Chadha KC, Kingsbury DT. Quantitation of HSV-DNA present in biochemically transformed mouse cells and their revertants. J Gen Virol. 1977; 36: 111-122.
20. Chadha KC, Sclair M, Sulkowski E, Carter WA. Molecular size heterogeneity of human leukocyte interferon. Biochemistry. 1978; 17: 196-200.
21. Carter WA, Davis LR, Chadha KC, Johnson Jr FH. Porcine leukocyte interferon and antiviral activity in human cells. Molec Pharmacol. 1979; 15: 685-690.
22. Chadha KC, Grob PM. Affinity of human leukocyte interferon for immobilized polyribonucleotides. Cell Biology: International Reports. 1979; 3: 663-669.
23. Chadha KC, Grob PM, Mikulski AJ, Davis LR, Sulkowski E. Copper chelate affinity chromatography of human fibroblast and leukocyte interferons. J Gen Virol. 1979; 43: 701-706. doi: 10.1099/0022-1317-43-3-701
24. Grob PM, Chadha KC. Separation of human leukocyte interferon components by Con A-Sepharose chromatography and their characterization. Biochemistry. 1979; 18: 5782-5786.
25. Chadha KC, Grob PM, Hamill R, Sulkowski E. Arch Virol. 1980; 64: 109-117.
26. Dicioccio RA, Chadha KC, Srivastava BIS. Aphidicolin: inhibition of herpes simplex virus-induced DNA polymerase, cellular DNA polymerase alpha and virus production. Biochim Biophys Acta. 1980; 609: 224-231.
27. Chadha KC, Srivastava BIS. Comparison of the antiproliferative effects of human fibroblast and leukocyte interferons on various leukemic cell lines. J Clin Hematol Oncol. 1981; 11(2): 55-60.
28. Srivastava BIS, Dicioccio RA, Chadha KC, Rinehart Jr KL. Preferential inhibition of some cellular and virus associated nucleotide polymerases and anti herpes simplex virus activity of streptovaricin derivatives. Antimicrob Agents Chemother. 1981; 20(5): 653-659.
29. Chadha KC, Sulkowski E. Chromatography of human leukocyte interferon on controlled pore glass. Prep Biochem. 1981; ll(4): 467-482.
30. Van Oss CJ, Bronson PM, Dinolfo EA, Chadha KC. Two methods for the removal of erythrocytes from buffy coats for the production of human leukocyte interferon. Immunol Commun. 1981; 10(6): 549-555.
31. Ikossi-OConnor M, Goldrosen MH, Chadha KC. Identification of target cell(s) responsible for production of human leukocyte interferon. Surgical Forum. 1981; 32: 74.
32. Orsini F, Fitzpatrick J, Cohen E, et al. The effects of long term leukapheresis on the immune system. Vox Sanguinis. 1982; 43: 11-19, 1982.
33. Chadha KC, Sulkowski E. Adsorption of human leukocyte interferon on glass: contribution of electrostatic and hydrophobic forces. J Interferon Res. 1982; 2: 229-234.
34. Thacore HR, Mount DT, Chadha KC. Interferon system of human cornea cells: interferon production, characterization and development of antiviral state. J Interferon Res. 1982; 2(3): 401-408.
35. Baglioni C, Branca AA, DAlessandro S, Hossenlopp D, Chadha KC. Low interferon binding activity of two human cell lines which respond poorly to the antiviral and antiproliferative action of interferon. Virology. 1982; 122: 1982.
36. Dinolfo E, Chadha KC. Antiviral and antiproliferative activities of three molecular components of leukocyte-derived human interferon. Microbiol Immunol. 1983; 27(7): 589-599.
37. Ikossi-OConnor MG, Chadha KC. The effect of malignant epithelial tumors, surgical therapy and bacterial sepsis upon various parameters of interferon system. J Surg Oncol. 1984; 26(1): 27-34.
38. Ikossi-OConnor MG, Chadha KC. Effect of splenectomy on interferon production. Surgical Forum. 1984; 57-81V.
39. Ikossi-OConnor MG, Ambrus J, West T, Lillie MA, Milgrom H, Chadha KC. Interferon and interferon inactivators in patients with acquired immune deficiency syndrome and Kaposis sarcoma. J Res Chem Pathol Pharmacol. 1984; 45(2): 271-277. doi: http://dx.doi.org/10.1016/0002-9343(86)90345-1
40. Yarvin M, Thacore H, Chadha KC. Modulation of the interferon response by adriamycin in normal and malignant human cells. Antiviral Res. 1986; 6: 113-122.
41. Davis PJ, Thacore HR, Chadha KC, Lawrence WD, Kite JH. Calmodulin in interferon preparations: effect of interferon on calmodulin in bioactivity. Biochem Biophys Res Comm. 1985; 133(1): 113-119. doi: 10.1016/0006-291X(85)91848-0
42. OConnor MGI, Chadha KC, Lillie MA, Zucker-Franklin D, Bernstein Z, Ambrus JL. Interferon inhibitors in Patients with AIDS and AIDS unrelated Kaposis sarcoma. American J Med. 1986; 81: 783-785. doi: http://dx.doi.org/10.1016/0002-9343(86)90345-1
43. Ikossi MG, Ambrus JL, Chadha KC. Regulation of in vitro human leukocyte interferon production. Effect of prostaglandin synthetase and phosphodiesterase inhibition. Res Commun Chem Path Pharmacol. 1986; 54(3): 379-393.
44. Ikossi MG, Chadha KC, Ozer H. Characterization of Non-T effector cell subpopulations involved in production of human alpha interferon. Immunol Inves. 1986; 15(6): 559-574.
45. Ambrus JL, Ambrus JL Jr, Chadha KC. Interferon inhibitors in lupus erythematosus. New Eng J Med. 1988; 319(9): 582.
46. Stoll HL III, Chadha KC. Effect of splenectomy upon the growth of B16-F10 melanoma and its relation to the interferon system. J Surgical Oncol. 1989; 40: 79-84.
47. Ambrus JL, Poiesz BJ, Lillie MA, Stadler S, DiBerardino L, Chadha KC. Interferon and interferon inhibitors in patients infected with varicella-zoster virus, AIDS, ARC, Kaposis sarcoma and normal individuals. The American J Medicine. 1989; 87: 405-407.
48. Mahafzah M, Stadler S, Ambrus JL, Chadha KC. Effect of meclomen on production and action of human interferon alpha. Acta Virologica. 1990; 34: 26-34.
49. Lin H-Y, Davis PJ, Davis FB, Chadha KC, Thacore HR. Effect of calmodulin antagonists on the interferon system: induction and action of interferons. J Interferon Res. 1990; 10: 39-46.
50. Chadha KC, Ambrus JL, Halpern J, et al. The interferon system in gnyecological cancer: effect of radiation and chemotherapy. Cancer. 1991; 67: 87.
51. Chadha KC, Ambrus JL, Stadler I, Ambrus Jr JL. Interferon inhibitor in the blood of patients with systemic lupus erythrematosus. J Biol Regulators and Homeostatic Agents. 1991; 5: 1-9.
52. Aszalos A, Grimley PM, Balint E, Chadha KC, Ambrus JL. On the mechanism of action of interferons: interaction with nonsteroidal anti-inflammatory agents pentoxifylline (Trentol) and cGMP inducers. J Medicine. 1991; 22: 255-271.
53. Stadler I, Hammad A, Ambrus J, Chadha KC. Effect of maclofenamate on natural killer cell activity. Res Commun Chem Pathol Pharmacol. 1991; 73: 65-74.
54. Aszalos A, Chadha KC, Stadler I, Ambrus JL Jr, Ambrus J. Effect of an interferon inhibitor on the antiproliferative signal of interferon-alpha. Biochem. Medicine and Metabolic Biol. 1991; 46: 267-270.
55. Chadha KC, Stadler I, Albini B, Nabeeb S, Thacore HR. Effect of alcohol on spleen cells and their functions in C57BL/6 mice. Alcohol. 1991; 8: 481-485.
56. Ambrus JL, Chadha KC, Ambrus JL Jr. Interfreon inhibitors in Wegners granulomatosis. Ann Internal Medicine. 1991; 114: 606-607.
57. Chadha, KC, Ambrus, JL, Halpern, J, et al. The interferon system in carcinoma of the cervix: Effect of radiation and Chemotherapy. Cancer. 1991; 67(1): 87-90.
58. Windle M, Mondul T, Whitney RB, Cummins MK, Stadler I, Chadha KC. A multivariate analysis of various interferon parameters among alcoholics and heavy smokers. Drug and Alcohol Dependence. 1993; 31: 139-147. doi: http://dx.doi.org/10.1016/0376-8716(93)90066-Y
59. Ambrus JL, Chadha KC, Anthone S, Anthone R, Sayyid S. The alpha-interferon system in patients undergoing renal transplantation and treated with cyclosporin and prednisone. Surgery, Gynecology and Obstetrics. 1993; 176: 588-590.
60. Sayyid S, Chadha KC, Anthone S, Anthone R, Halpern J, Ambrus JL. The alpha-interferon system in cyclosporin and prednisone treated renal transplant patients. Surgery Gynecology and Obstetrics. 1993; 176: 588-590.
61. Stadler I, Chadha KC, Nakeeb S, et al. Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. J Pharmacol Expt Therapeutics. 1994; 268: 10-13.
62. Nair MPN, Kronfol ZA, Greden JF, et al. Selective inhibition by alcohol and cortisol of natural killer cell activity of lymphocytes from cord blood. Prog Neuro-psychopharmacol and Biol Psychiatry. 1994; 18: 1293-1305. doi: 10.1016/0278-5846(94)90094-9
63. Nanak E, Vijayalakshmi MA, Chadha KC. Segregation of normal and pathological human red blood cells, lymphocytes, and fibroblasts by immobilized metal ion affinity chromatography. J Mol Recognition. 1995; 8: 77-84.
64. Nair MPN, Chadha KC, Stadler I, Sweet A, Schwartz SA. Differential effects of human immunodeficiency virus type I envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. Clinical and Diagnostic Laboratory Immunology. 1995; 2: 434-438.
65. Chadha KC, Kazim AL, Parthasarathy R, Sulkowski E, Tomasi TB. Heparin binding sites on prions. International J Biochromatography. 1997; 2: 211-223.
66. Nair MPN, Hou J, Sweet A, Schwartz SA, Chadha KC. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunology. 1997; 4: 127-132.
67. Ambrus JL, Ambrus JL Jr, Chadha S, ed al. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with Lupus erythrematosus with vasculitis. Res Commun Mole Path Pharmaco. 1997; 96: 255-265.
68. Nair MPN, Mahajan S, Chadha KC, Hewitt RG, Schwartz SA. Immunopathogenesis of HIV infection. Role of Recreational Drugs. Recent Res Devel Immunology. 1999; 1: 597-606.
69. Chadha KC, Stadler I, Ambrus JL, Nair MPN. Effect of alcohol and MAIDS virus infection upon immunological status in C57BL/6 mice. Recent Res Devel Immunol. 2000; 2: 41-51.
70. Nair MPN, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz S. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and HIV 1 infected patients. Clin Diagn Lab Immunol. 2000; 7: 96-100. doi: 10.1128/CDLI.7.1.96-100.2000
71. Payne J, Nair MPN, Ambrus JL, Chadha KC. Mild hyperthermia modulates biological activities of interferons. Int J Hyperthermia. 2000; 16: 492-507, 2000.
72. Nair MPN, Mahajan S, Chadha K, et al. Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients. In “Neuroimmune Circuits, Drugs of Abuse and Infectious Diseases.” Adv Exp Med Biol. 2001; 493: 235-40. doi: 10.1007/0-306-47611-8_28
73. Chadha KC, Kawinski E, Sulkowski E. Thiophilic interaction chromatography of prostate-specific antigen. J Chromatog. B. 2001; 754(2): 521-525.
74. Kawinski E, Levine E, Chadha K. Thiophilic interaction chromatography facilities detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate. 2002; 50(3): 145-153.
75. Nair MPN, Kaudaswami C, Mahajan S, et al. The flavonoid, Quecertin, differentially regulates Th-1 (IFN-y) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochem Biophys Acta. 2002; 1593(1): 29-36. doi: 10.1016/S0167-4889(02)00328-2
76. Aalinkeel RK, Nair MPN, Sufrin G, Mahajan SD, Chadha KC, Schwartz, SA. Antisense inhibition of the cyclo-oxygenase-2 gene modulates the expression of pro-angiogenic molecules in prostate cancer cell lines. J Urol. 2003; 169: 220.
77. Ambrus JL Sr, Dembinski W, Ambrus JL Jr, et al. Free interferon -alpha/beta receptors in the circulation of patients with adenocarcinomas. Cancer. 2003; 98: 2730-2733. doi: 10.1002/cncr.11843
78. Chadha KC, Schwartz SA, Nair MPN, Demeter LR, Hewitt RG. Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy. Immunol Invest. 2003; 32: 299-312.
79. Ambrus JL Sr, Dembinski W, Ambrus JL Jr, et al. Free interferon -alpha/beta receptors in the circulation of patients with adenocarcinomas. Cancer. 2003; 98: 2730-2733. doi: 10.1002/cncr.11843
80. Chadha KC, Ambrus JL Jr, Dembinski W, Ambrus JL Sr. Interferon and interferon inhibitory activity in disease and therapy. Mini Review. Exp Biol Med. 2004; 229(4): 285-290.
81. Aalinkeel R, Nair MPN, Sufrin G, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res. 2004; 64: 5311-5321. doi: 10.1158/0008-5472.CAN-2506-2
82. Chadha KC, Dembinski WE, Dunn CB, et al. Effect of increasing thiolation of the polycytidylic acid strand of poly I: poly C on the alpha, beta and gamma interferon inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004; 64: 171-177. doi: 10.1016/j.antiviral.2004.08.002
83. Bindukumar B, Kawinski E, Cherrin C, et al. Two-step procedure for purification and characterization of enzymatically active prostate-specific antigen from seminal plasma. J Chromatogr B. 2004; 813: 113-120. doi: 10.1016/j.jchromb.2004.09.014
84. Ambrus JL Sr, Dembinski WD, Chadha Kunal, Ambrus JL Jr, Chadha KC. Resistance to interferons. Discovery Medicine. 2004; 4: 310-314.
85. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7: 241-252.
86. Ambrus JL, Ambrus CM, Kulaylat MN, Dembinski W, Akhter S and Chadha KC. Effect of nutritional status and of a carcinogenic Pox virus infection on interferon producing capacity and mortality. J Medicine. 2005; 36: 107-119.
87. Ambrus JL, Dembinski W, Chadha KC, Ambrus CM, Ambrus JL Jr, Akhter S. Interferon resistance in lung cancer patients. J Medicine. 2005; 36: 33-39.
88. Chadha K, Weinstock-Guttman B, Zivadinov R, et al. Interferon Inhibitory Activity in Multiple Sclerosis Patients. Arch Neurology. 2006; 63: 1579-1584. doi: 10.1001/archneur.63.11.1579.
89. Ambrus JL Sr, Chadha KC, Islam A, Akhter S, Ambrus JL Jr. Treatment of Viral and Neoplastic Diseases with Double-Stranded RNA Derivatives and Other New Agents. Mini Review: Soc Expt Biology and Medicine. 2006; 231: 1283-1286.
90. Ambrus CM, Kulaylat, Lillie DB, et al. Interferons and Interferon Inhibitory Activity in Disease and Therapeutic Implications. J Medicine. 2006; 3-38: 53-71.
91. Sternberg Z, Weinstock-Guttman B, Hojnaki D, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential biomarker of disease severity. Mult Scler. 2008; 14: 759-763. doi: 10.1177/1352458507088105
92. Aalinkeel R, Bindukumar B, Reynolds JL, et al. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate. 2008; 68(16): 1773-89. doi: 10.1002/pros.20845.
93. Bindukumar B, Schwartz S, Aalinkeel R, Mahajan S, Lieberman A, Chadha K. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells. Prostate. 2008; 68(14): 1531-45. doi: 10.1002/pros.20811.
94. Satheesh Babu AK, Vijayalakshmi MA, Smith GJ, Chadha KC. Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 861(2): 227-35. doi: 10.1016/j.jchromb.2007.11.039
95. Sternberg Z, Chadha K, Lieberman A, et al. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol. 2008; 205 (1-2): 142-7. doi: 10.1016/j.jneuroim.2008.09.008.
96. Nicotera TM, Schuster DP, Bourhim M, Chadha K, Klaich G, Corral DA. Regulation of PSA secretion and survival signaling by calcium-independent phospholipase A2 β in prostate cancer cells. The Prostate. 2009; 69: 1270-1280. doi: 10.1002/pros.20968.
97. Sternberg Z, Chadha K, Lieberman A, et al. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. J Neuroinflammation. 2009; 6: 28. doi: 10.1186/1742-2094-6-28.
98. Sternberg Z, Hennies C, Sternberg D, et al. Plasma Pentosidine: A potential Biomarker in the management of Multiple Sclerosis. Multiple Sclerosis. 2011; 17(2): 157-163. doi: 10.1177/1352458510384123.
99. Aalinkeel R, Bindukumar B, Reyonld JL, et al. Over expression of MMP-9 contributes to invasiveness in Prostate Cancer cells. Immunological Investigations. 2011; 40(5): 447-464. doi: 10.1093/jnci/djn214.
100. Chadha K, Nair B, Chakravarthi S, et al. Enzymatic activity of free-prostate specific antigen is not required for its physiological activities. The Prostate. 2011; 71: 1680-1690. doi: 10.1002/pros.21385
101. Sternberg Z, Christopher L, Daniel S, et al. The Prevalence of Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients. CNS and Neurological Disorders-Drug Target. 2013; 12(1): 104-111. doi: 10.2174/1871527311312010016
102. Chadha KC, Miller A, Nair BK, Schwartz SA, Trump DL, Underwood W III. New Serum Biomarkers for Prostate Cancer Diagnosis. Clinical Cancer Investigation Journal. 2014; 3(1): 72-79.

Li Chen, PhD

Assistant Professor
Division of Cancer Biostatistics
Department of Biostatistics
College of Public Health and Biostatistics and Bioinformatics Shared Resource Facility
Markey Cancer Center
University of Kentucky, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Chen is an Assistant Professor of the Division of Cancer Biostatistics in the Department of Biostatistics and the Biostatistics and Bioinformatics Shared Resource Facility at the Markey Cancer Center, University of Kentucky. She received her PhD in Biostatistics from the University of North Carolina at Chapel Hill in 2009.

Her research interests includes: Development and application of novel statistical methods for medical and epidemiological studies especially in cancer research. Semiparametric and Nonparametric Methods, Survival Analysis, Longitudinal Data Analysis and Prediction Models.


• (2011)- Larry Kupper Dissertation Publication Award, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2010 )- Barry H. Margolin Dissertation Award, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2005)- Pass with Special Commendations in Qualifying Exams, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2004 - 2005)- Merit Assistantship of University of North Carolina at Chapel Hill
• (2004)- Title of Outstanding Graduate of Peking University
• (2001 - 2003)- Canon Special Scholarship of Peking University
• (1999 – 2000)- NKK Scholarship of Peking University


• American Statistical Association
• Chinese Statistical Association

1. Chen L, Lin DY, Zeng D. Attributable fraction functions for censored event times. Biometrika. 2010; 97: 713-726. doi: 10.1093/biomet/asq023
2. Davison BA, Cotter G, Sun H, et al. Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. Clin Res Cardiol. 2011; 100(9): 745-753. doi: 10.1007/s00392-011-0304-5.
3. Chen L, Lin DY, Zeng D. Predictive accuracy of covariates for event times. Biometrika. 2012; 99(3): 615-630. doi: 10.1093/biomet/ass018
4. Chen L, Lin DY, Zeng D. Checking transformation models with censored data. Biostatistics. 2012; 13(1): 18-31. doi: 10.1093/biostatistics/kxr017
5. Chen L, Romond E, Chokshi S, et al. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Res Treat. 2012; 136(2): 565-572. doi: 10.1007/s10549-012-2265-4.
6. Feddock J, Arnold SM, Shelton BJ, et al. Stereotactic body radiotherapy (SBRT) can be used safely to boost residual disease in locally advanced non-small cell lung cancer (NSCLC): a prospective study. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1325-1331. doi: 10.1016/j.ijrobp.2012.11.011.
7. Sui X, Li H, Zhang J, Chen L, Zhu L, Blair SN. Percentage of Deaths Attributable to Poor Cardiovascular Health Lifestyle Factors: Findings from the Aerobics Center Longitudinal Study. Epidemiology Research International. 2013; 2013. Article ID 437465. doi: 10.1155/2013/437465
8. Shang Y, Lin Y, Henry BA, et al. Noninvasive evaluation of electrical stimulation impacts on muscle hemodynamics via integrating diffuse optical spectroscopies with muscle stimulator. Journal of biomedical optics. 2013; 18(10): 105002-105002. doi: 10.1117/1.JBO.18.10.105002.
9. Feddock J, Cleary R, Arnold S, et al. McGarry RC. Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Non-Small Cell Lung Cancer. Journal of Radiosurgery and SBRT. 2013; 2(3): 235-242.
10. McGarry RC, Feddock J, Sinha P, et al. Early postchemoradiation PET/CT for assessing responses of stage II-III non-small cell lung cancer to treatment. Journal of Radiosurgery and SBRT. 2013; 2(4): 315-323.
11. Chen L, Voronovich Z, Clark K, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology. 2014; 16(11):1478-1483. doi: 10.1093/neuonc/nou097.
12. Chen A, Chen L, Al-Qaisi A, et al. Everolimus-induced hematologic changes in patients with metastatic breast cancer. Clinical Breast Cancer. 2014. doi: 10.1016/j.clbc.2014.07.002.
13. Alqaisi A, Chen L, Romond E, Stevens M, Pasley G, Massarweh S. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: Implications for tumor biology and research. Breast Cancer Res Treat. 2014; 148(2):437-444. doi: 10.1007/s10549-014-3145-x.

Jennifer Sims-Mourtada, PhD

Senior Clinical Scientist
Center for Translational Cancer Research
Helen F. Graham Cancer Center
Christiana Care Health System
Newark, DE, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Sims-Mourtada is the Director of Translational Breast Cancer Research in the Center for Translational Research at the Helen F Graham Cancer Center and Research Institute, Christiana Care Health Services, Inc, located in Newark, DE. She is also an appointment as a adjunct Associate Professor in the Department of Medical Laboratory Sciences, College of Health Sciences at the University of Delaware. She received her PhD in Immunology in 2004 from the University of Texas Graduate School of Biomedical Sciences and completed her post-doctoral training in Radiation Biology at The University of Texas MD Anderson Cancer Center. Prior to joining the HFGCCRI, she served as Director of Molecular Research and Development for RadioMedix, Inc. located in Houston TX.

Her research seeks to provide insight as to what drives growth and treatment resistance in aggressive breast cancers, particularly factors which influence cancer stem cell growth and plasticity.


• (1993)-Present) Member of National Golden Key Honor Society
• (1998-2004) Recipient of R.E. Smith Predoctoral Fellowship for research in the field of Cancer Immunology
• (2005-2006) Recipient of Postdoctoral Traineeship Award - Department of Defense Prostate Cancer Research Program
• (2006) Travel award, 3rd Annual Gastrointestinal Oncology Conference, International Society of Gastrointestinal Oncology, Arlington, VA


• Radiation Research Society, (2006)
• International Society of Gastrointestinal Oncology, (2006)
• American Association of Cancer Researchers (AACR) (2007-present)
• Society of Nuclear Medicine (SNM) (2007-present)
• American Society for Therapeutic Radiation and Oncology (ASTRO) (2007-present)
• Society of Molecular Imaging (SMI) (2009-present)

1. Sims MJ, Davis OL, Arnold J, Flynn KD. Taxane induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Molecular Carcinogenesis. doi: 10.1002/mc.22225.
2. Smith DL, Yang KF, Larson RD, Sims MJ, Woodward W. Hedgehog targeting peptides for imaging and therapy of breast cancer. Biomed Research International .
3. Sims MJ, Niamat RA, Samuel S, Eskridge C, Kmiec EB. Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds. International Journal of Nanotechnology. 2014; 9(1): 995-1003. doi: 10.2147/IJN.S55720.
4. Smith DL, Breeman WAP, Sims MJ. The untapped potential of 68-Gallium-PET: the next wave of 68-gallium agents. Journal of Applied Radiation and Isotopes. 2012; 29(12): 537-544. doi: 10.1016/j.apradiso.2012.10.014
5. SimsMJ, Yang D, Tworowka I, et al. Detection of canonical hedgehog signaling in breast cancer by 131-Iodine-labeled derivatives of the sonic hedgehog protein. Journal of Biomedicine and Biotechnology. 2012; 2012: 639562 doi: 10.1155/2012/639562.
6. Delpassand E, Samarghandi A, Sims MJ, et al. Long-term survival and toxicity profile of patients with progressive neuroendocrine tumors following Peptide Receptor Radionuclide Therapy with high activity 111In pentetreotide. Theranostics. 2012; 2(5):472-480 doi: 10.7150/thno.3739.
7. McKeller MR, Herrera RS, Ma W, et al. Vital function of PRELI and essential requirement of its LEA motif. Cell Death and Disease. 2010; (1): 1-13. doi: 10.1038/cddis.2009.19.
8. Delpassand ES, Sims MJ, Saso H, et al. Safety and efficacy of radionuclide therapy with multiple 500 mCi doses of In-111 Pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biotherapy and Radiopharmaceuticals. 2008; 23(3): 292-300. doi: 10.1089/cbr.2007.0448.
9. Sims MJ, Azhdarinia A, Yang DJ, Mourtada F. Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer Current Molecular Imaging Reviews: 2008; 4(1): 28-33.
10. Yang DY, Chandra M, Sims MJ, Azhdarinia A, Oh CS, Kim E. Challenges and Opportunities in Molecular Imaging. Current Molecular Imaging Reviews. 2008; 4(1): 46-50.
11. Izzo JG, Luthra R, Sims MJ, et al. Emerging Molecular Targets in Esophageal Cancer. GastroIntestinal Cancer Research. 2007; 1(4): S3-S6.
12. Chen YJ, Sims MJ, Izzo JG, Chao KSC. Targeting the Hedgehog Pathway to mitigate treatment resistance. Cell Cycle. 2007: 6(15): 1826-1830. doi: 10.4161/cc.6.15.4545
13. Sims MJ, Izzo JG, Ajani JA, Chao KSC. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007; 26(38): 5674-5679. doi: 10.1038/sj.onc.1210356
14. Sims MJ, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clinical Cancer Research. 2006; 12(21): 6565-6572. doi: 10.1158/1078-0432.CCR-06-0176
15. Sims MJ, McKellarMR, Martinez VH, et al. The human AKNA gene maps to chromosome 9q32.1, expresses alternatively spliced transcripts and translates into overlapping protein isoforms . DNA Cell Biol. 2005; 24(5): 325-338.
16. Rangel R, McKeller MR, Sims MJC, et al. Assemble of the k PreB receptor requires the Vk- like protein encoded by germline transcripts. J Biol Chem. 2005; 280(18): 17807-17814.
17. Sims MJC, Guzman RL, Rangel R, et al. In vivo expression of interleukin-8, and RANTES by human germinal centre B lymphocytes. Immunology. 2003; 110(3): 296-303. doi: 10.1046/j.1365-2567.2003.01745.x
18. Guzman RL, Sims MJC, Rangel R, Martinez VH. Life and death within germinal centers: a double-edged sword. Immunology. 2002; 107: 167-175. doi: 10.1046/j.1365-2567.2002.01494.x
19. Siddiqa A, Sims MJ, Guzman RL, et al. Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA. Nature. 2001; 41: 383-387. doi: 10.1038/35066602
20. Guzman RL, Sims JC, Rangel R, et al. PRELI, the human homologue of the avian px19, is expressed by germinal center B lymphocytes. Int Immunol. 2000; 12: 607-612. doi: 10.1093/intimm/12.5.607
21. Sims-Mourtada J, Opdenaker LM, Davis J, Wu C. Long term, low dose Genistein decreases stem cell populations and sensitizes inflammatory breast cancer cell lines to radiation. Cancer Stud Mol Med Open J. 2015; 2(1): 60-65.
21. Mourtada F, Sims-Mourtada J. Boosting response: the impact of immune checkpoint inhibitors on radiation treatment schedules. Cancer Stud Mol Med Open J. 2015; 2(2): e8-e10. doi: < a href= http://openventio.org/Volume2_Issue2/Boosting_Response_The_Impact_of_Immune_Checkpoint_Inhibitors_on_Radiation_Treatment_Schedules_CSMMOJ_2_e002.pdf target=_blank>10.17140/CSMMOJ-2-e002
22. Sims-Mourtada J, Opdenaker LM, Davis J, Wu C. Long term, low dose Genistein decreases stem cell populations and sensitizes inflammatory breast cancer cell lines to radiation. Cancer Stud Mol Med Open J. 2015; 2(1): 60-65. doi: 10.17140/ CSMMOJ-2-107
23. Mourtada F, Sims-Mourtada J. Boosting response: the impact of immune checkpoint inhibitors on radiation treatment schedules. Cancer Stud Mol Med Open J. 2015; 2(2): e8-e10. doi: 10.17140/CSMMOJ-2-e002
24. Arnold KM, Flynn NJ, Sims-Mourtada J. Activation of inflammatory responses correlate with hedgehog activation and precede expansion of cancer stem-like cells in an animal model of residual triple negative breast cancer after neoadjuvant chemotherapy. Cancer Stud Mol Med Open J. 2015; 2(2): 80-86. doi: 10.17140/CSMMOJ-2-112

Huey-Jen Lin, PhD, MT(ASCP)

Associate Professor
Department of Medical Laboratory Sciences
College of Health Sciences
University of Delaware
Room 305, Willard Hall Education Building
16 West Main Street, Newark, Delaware 19716, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Lin laboratory is examining the aberrant epigenomes in breast and pancreatic cancers. The long-term objectives are to study how carcinoma-associated fibroblasts convey aberrant signaling molecules that subsequently influence epigenome profiles particularly promoter DNA hypermethylation. Upon methylation at promoter DNA, the target genes frequently undergo expressional silencing, an event that could potentially lead to a wide spectrum of malignant phenotypes. The ultimate goals for her research are: identify the microenvironmental cause(s) leading to tumorigenesis, study how carcinoma-associated fibroblasts influence signaling pathways that subsequently lead to epigenetic alternations mainly by DNA methylation; decipher how dysregulated signaling pathways contribute to neoplasm by altering epigenomes; discover potential diagnostic bio-markers; and develop specific therapeutic strategies by correcting the aberrant signaling molecules influenced by carcinoma-associated fibroblasts. They are currently investigating how epigenetically silenced tumor suppressor molecules govern cancer cell migration, invasion, metastasis, susceptibility to chemotherapeutic agents as well as other malignant features.

Her research interests include: Examine how epigenetically silenced tumor suppressor genes influence tumor initiation, progression and metastasis in breast and pancreatic cancers. Her long-term research objective is to examine how aberrant signaling molecules regulate epigenomes and lead to a wide spectrum of malignant phenotypes, primarily in breast and pancreatic cancers. The ultimate goals are: to identify the microenvironmental cause (s) leading to tumorigenesis, decipher how dysregulated signaling pathways contribute to neoplasm by altering epigenomes, discover potential diagnostic bio-markers, and develop specific therapeutic strategies by correcting signaling molecules.


• 1984 Graduate Student Science and Technology Scholarship, Taiwan
• 1991 Block Fellowship, University of Delaware, Newark, Delaware
• Outstanding Young Investigator Awarded from Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
• 2009 Faculty Research Award, School of Allied Medical Profession, The Ohio State University, Columbus, Ohio


• American Association of Cancer Research (AACR)
• Woman in Cancer Research (WICR)
• American Society of Clinical Laboratory Sciences (ASCLS)
• American Society of Clinical Pathology (ASCP)


1. Wang F-F, Wang Y-J, Lee H-J, Fong J-C. Identification of erythropoietin receptors of erythroleukemic cells. Biochemistry International. 1989; 18: 163-171.
2. Lin H-J, Upson RH, Simmons DT. Nonspecific DNA binding activity of simian virus 40 large T antigen: evidence for the cooperation of two regions for full activity. Journal of Virology. 1992; 66: 5443-5452.
3. Lin H-J, Eviner V, Prendergast GC, White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol Cell Biol. 1995; 15: 4536-4544.
4. Page C, Lin H-J, Jing Y, Castle VP, Nuñez G, Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Research. 2000; 20: 407-16.
5. Lin H-J, Flint SJ. Identification of a cellular repressor of transcription of the adenoviral late Iva2 gene that is unaltered in activity in infected cells. Virology. 2000; 277: 397-410. doi: 10.1006/viro.2000.0598
6. Lin H-J, Holman P, Lu J, Finniss S, Dickinson C, Castle VP. Functional activity of chimeric molecules containing a death signal against neuroblastoma. Clinical Cancer Research. 2001; 5(11/99 suppl): 427.
7. Jasty R, Van Golen C, Lin H-J, et al. Bcl-2 and N-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia. 2001; 3: 304-313.
8. Burke W, Jin X, Lin H-J, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001; 20: 7925-7934.
9. Lin J, Jin X, Rothman K, Lin H-J, Tang H and Burke W. Modulation of signal transducer and activator of transcription 3 activates by p53 tumor suppressor in breast cancer cells. Cancer Research. 2002; 62: 376-380.
10. Bian X, Giordano TD, Lin H-J, Solomon G, Castle VP, Opipari AW Jr. hemotherapyinduced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. Journal of Biological Chemistry. 2004; 279: 4663-4669. doi: 10.1074/jbc.M306905200
11. Lin H-J, Hsieh FC, Song H and Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. British Journal of Cancer. 2005; 93: 1372-1381. doi: 10.1038/sj.bjc.6602862
12. Cen L, Arnoczky KJ, Hsieh FC, et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Modern Pathology. 2007; 20: 936-946. doi: 10.1038/modpathol.3800834
13. Cen L, Hsieh FC, Lin H-J, Chen CS, Qualman SJ and Lin J. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcom cells using OSU-03012 compound. British Journal of Cancer. 2007; 97, 785-791. doi: 10.1038/sj.bjc.6603952
14. Chan MW, Huang YW, Hartman-Frey C, et al. Aberrant Transforming Growth Factor-beta 1 Signaling and SMAD4 Nuclear Translocation Confer Epigenetic Repression of ADAM19 in Ovarian Cancer. Neoplasia. 2008; 10: 908-919.
15. Lin H-J, Zuo T, Lin C-H, et al. Breast cancerassociated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Research. 2008; 68: 10257-10266. doi: 10.1158/0008-5472.CAN-08-0288
16. Chan C, Lin H-J and Lin J. Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane. International Journal of Oncology. 2008; 33: 415-419. doi: 10.3892/ijo_00000023
17. Lieblein JC, Ball S, Hutzen B, et al. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer. 2008; 21; 8(1): 302. doi: 10.1186/1471-2407-8-302.
18. Qin H, Chan MW, Liyanarachchi S, et al. An Integrative ChIP-chip and Gene Expression Profiling to Model SMAD Regulatory Modules. BMC Systems Biology. 2009; 3: 73. doi: 10.1186/1752-0509-3-73.
19. Huang Y-W, Jansen RA, Fabbri E, et al. Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncology Reports. 2009; 22: 853-861. doi: 10.3892/or_00000509
20. Chou J-L, Su H-Y, Chen L-Y, et al. Promoter hypermethylation of novel tumor suppressor FBXO32 predict survival in ovarian cancer patients. Lab Invest. 2010; 90(3): 414-425. doi: 10.1038/labinvest.2009.138
21. Pichiorri F, Suh SS, Rocci A, et al. Down-regulation of p53-inducible microRNAs 192, 194 and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010; 18: 367-381. doi: 10.1016/j.ccr.2010.09.005.
22. Zuo T, Liu TM, Lan X, et al. Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer. Cancer Research. 2011; 71(5): 1752-1762. doi: 10.1158/0008-5472.CAN-10-3573.
23. Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Research. 2011; 71(23): 7226-7237. doi: 10.1158/0008-5472.CAN-10-4660
24. Peng Z, Weber JC, Han Z, et al. Dichotomy Effects of Akt/PKB signaling in breast cancer. Molecular Cancer . 2012; 11: 61. doi: 10.1186/1476-4598-11-61.
25. Peng Z, Shen R, Li Y, Teng K-Y and Lin, H-J. Epigenetic Repression of RARRES1 Is Mediated by Methylation of a Critical Proximal Promoter Region Along with a Loss of CTCF Binding. PLoS One. 2012; 7(5): e36891. doi: 10.1371/journal.pone.0036891.
26. Lin L, Hutzen B, Lee HF, et al. Evaluation of STAT3 Signaling in ALDH+ and LDH+/CD44+/CD24- Subpopulations of Breast Cancer Cells. PLoS One. 2013; 8(12): e82821. doi: 10.1371/journal.pone.0082821

Francis V. James, MD

Additional Professor
Department of Radiotherapy and Oncology
Regional Cancer Centre
Trivandrum, Kerala, India

BiographyResearch InterestScientific ActivitiesPublications

• (1983) MBBS, University of Kerala, India
• (1989) MD, University of Kerala, India


• (June-December 1992) Fellowship of Leeds University, UK
• (1996-1997) Fellowship of Institute of Cancer Research, London and Honorary Senior Registrar in Uro-Oncology, Royal Marsden Hospital, London
• (February 2002-April 2003) Clinical Research Fellowship of Institute of Cancer Research in Uro-oncology, Royal Marsden Hospital, UK
• (Sept-Oct 2012) AROI Kirloskar Fellowship, Mount Vernon Hospital, Middlesex, UK


• (Since July 2004) Additional Professor of Radiotherapy and Oncology, Regional Cancer centre, Trivandrum
• (April 2003-June 2004) Associate Professor of Radiotherapy and Oncology, Regional Cancer Centre Trivandrum, India
• (February 2002-April 2003) Clinical Research Fellow, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
• (March 1998-January 2002) Associate Professor of Radiotherapy & Oncology, Regional Cancer Centre, Trivandrum, India
• (March 1997-March 1998) Assistant Professor of Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (March 1996-February 1997) Clinical Research Fellow, Institute of Cancer Research & Honorary Senior Registrar, Royal Marsden Hospital, Sutton, UK
• (March 1995-February 1996) Assistant Professor of Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (Dec 1992-March 1995) Lecturer in Radiotherapy ,Regional Cancer Centre, Trivandrum
• (June 1992-Dec 1992) Clinical Research Fellow, Cookridge Hospital, University of Leeds, UK
• (Aug. 1990-May 1992) Lecturer in Radiotherapy, Regional Cancer Centre, Trivandrum, India
• (Feb 1990-Aug 1990) Tutor in Radiotherapy, Medical College, Trichur, India
• (Dec 1988-Jan 1990) Tutor in Radiotherapy, Medical College, Trivandrum, India
• (June 1986-Apr 1989) Resident in Radiotherapy, Medical College, Trivandrum, India
• (Jan 1985-June 1986) Junior Medical Officer, Department of Medicine, Bishop Vayalil Medical Centre, Moolamattom, Kerala, India

His research interests include: Urological cancers and Gynecological cancers.


• (1976-1982) National Merit Scholarship of India
• (July 1992-Dec 1992) Visiting Research Fellow-University of Leeds, UK
• (March 1996-Feb1997) Clinical Research Fellow-Institute of Cancer Research and Honorary Senior Registrar, Royal Marsden Hospital, Sutton, Surrey, UK
• (Feb 2002-April 2003) Clinical Research Fellow-Institute of Cancer Research, Sutton, UK
• (Sept-Oct 2012) AROI Kirloskar Fellowship , Mount Vernon Hospital, Middlesex, UK


• Member, Indian Medical Association
• Member, Association of Radiation Oncologists of India
• Member , European Society of Medical Oncology
• Member , American Society of Radiation Oncology
• Member, Indian Co-operative Oncology Network
• Member, Indian Oxford Cancer Research Network
• Member, International Society of Gynecological Oncology
• Member, ESTRO
• Member, ICRO


1. James FV, lijeesh AL, Koshy SM, Kumar A. Choriocarcinoma with brain involvement. J Cancer Res Ther. 2011; 7(3): 383-384. doi: 10.4103/0973-1482.87025
2. James FV. PET scan for prostate cancer. Indian J Cancer. 2011; 48(3): 372.
3. James FV. Specialist training in oncology. J Cancer Res Ther. 2010; 6: 594.
4. James FV, Kumar A, Jayaprakash PG, Mathews A. Metachronous bilateral testicular germ cell tumours: Report of two cases. J Cancer Res Ther. 2009; 3(5): 206-207. doi: 10.4103/0973-1482.57128
5. Venkitaraman R, Coffey J, Norman AR, et al. Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial. Clin Oncol (R Coll Radiol). 2008; 20(4): 288-292. doi: 10.1016/j.clon.2008.01.012
6. Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol. 2006; 101(3): 411-417. doi: 10.1016/j.ygyno.2005.10.033
7. Chitrathara K, Namratha D, Francis V, Gangadharan VP. Spontaneous rectovaginal fistula and repair using bulbocavernosus muscle flap. Tech Coloproctol. 2001; 5(1): 47-49.
8. Kusumakumary P, James FV. Permanent Disabilities in childhood survivors of LCH. Paed Heamatol Oncol. 2000; 17(5): 375-381. doi: 10.1080/08880010050034300
9. Ajithkumar TV, Nileena N, Abraham EK, James FV, Nair MK. Bone marrow relapse in primary mucinous adenocarcinoma of skin. Am. J. Clin Oncol-CCT. 1999; 22(3): 303-304.
10. Geetha N, James FV, Ramachandran K, Ajithkumar TV, Nair MK. Ovarian carcinoma relapsing as CP Angle tumor. Australasian Radiology. 1999; 43(3): 388-390. doi: 10.1046/j.1440-1673.1999.433676.x
11. KusumaKumary P, Priyakumari T, Chellam VG, James FV, Nair MK. Langerhans cell histiocytosis in children less than 2 years of age. Indian Pediatr. 1999; 36(1): 29-36.
12. Kusumakumary P, James FV, Chellam VG, Ratheesan K, Nair MK. Disseminated LCH in children-treatment outcome. Am. J. Clin Oncol-CCT. 1999; 22(2): 180-183.
13. Kusumakumary P, Mathews A, James FV, et al. Clear cell sarcoma of kidney-clinical features & outcome. Pead. Heamat. Oncol. 1999; 16(2): 169-174.
14. Ankathil R, Bhattathiri VN, James FV, Ratheesan K, et al. Mutagen sensitivity as a predisposing factor in familial oral cancer. International Journal of Cancer (Pred. Oncol.). 1996; 69: 265-267.


1. Nair MK, Bhattathiri VN, Ratheesan K, et al. Treatment results with mould therapy in epidermoid carcinoma of hard palate. Journal of Clinical Radiotherapy & Oncology. 1992; 7(1): 21-23.
2. Kusumakumary P, Kumar SR, James FV, Chellam VG, Nair MK, Warrier RP. Langerhans cell histiocytosis in children-patterns of disease and treatment results in Kerala. International Journal of Paediatric Hematology Oncology. 1996; 3(4): 297-303.
3. Kusumakumary P, Ajithkumar TV, James FV. Brain parenchymal involvement in neuroblastoma-a review. Ind. J. Med. Ped. Oncol. 1997; 18: 33-38.
4. James FV, Sivanandan CD. Advanced renal cancer- promising changes. JIPMER journal of Cancer. 2013; 2(1): 5-8.
5. Anjanappa M, Kainickal CT, James FV. Treatment of Stage I Seminoma. Cancer Stud Mol Med Open J. 2015; 2(2): 75-79. doi: 10.17140/CSMMOJ-2-111


1. James FV. Urgent Issues for Research on Oral Cancer in India. In: Verma AK. Oral Oncology. 3rd ed. McMillan, India; 1994: 32-34.
2. Ratheesan K, Bhattathiri VN, Davis CA, James FV, Nair MK. Pattern of lymph node recurrence in epidermoid cancers of tongue after interstitial implant. In: Verma AK. Oral Oncology. 3rd ed. McMillian, India, 1994: 473-477.

Masahiko Tanabe, MD, PhD

Associate Professor
Department of Breast Oncology
Juntendo University School of Medicine
2-1-1 Hongo Bunkyo-ku
Tokyo 113-8421, Japan

BiographyResearch InterestScientific ActivitiesPublications

Dr. Tanabe, Medicine Doctor (PhD-medicine), now is an Associate professor of the Department of Breast Oncology at Juntendo University School of Medicine. He is a surgical oncologist for breast cancer as well as a certified specialist in medical genetics. He got his Medicine Doctors degree (PhD) at the University of Tokyo. Currently. Dr. Tanabe is delighted to collaborate with the Cancer Studies and Molecular Medicine -Open Journal (CSMMOJ). He can contribute to review manuscripts on epigenetic biology and clinical field of breast cancer.

His research interest includes: Treatment of metastatic breast cancer which is resistant after multiple treatment, and he is continuously exploring epigenetic marks on estrogen receptor target genes which are associated with progression of breast cancer.

1. Himuro T, Horimoto Y, Arakawa A, Tanabe M, Saito M. Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?. Int J Surg Pathol. 2015.
2. Fukuda T, Tanabe M, Kobayashi K, et al. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus. 2015; 4: 376. doi: 10.1186/s40064-015-1159-4
3. Horimoto Y, Arakawa A, Tanabe M, et al. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. J Clin Pathol. 2015. doi: 10.1136/jclinpath-2015-203085
4. Sakai T, Nishimura S, Ogiya A, et al. Four types of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: classification of IBTR based on precise pathological examination. Pat-hol Int. 2015; 65(3): 113-118. doi: 10.1111/pin.12253
5. Horimoto Y, Arakawa A, Tanabe M, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. 2014; 14: 550. doi: :10.1186/1471-2407-14-550
6. Nakayama Y, Ito Y, Tanabe M, Takahashi S, Hatake K. A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study. Breast Cancer. 2015; 22(2): 177-184. doi: 10.1007/s12282-013-0472-4
7. Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society et al. Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. Breast Cancer. 2014; 21(6): 754-760. doi: 10.1007/s12282-013-0454-6
8. Nakayama Y, Ito Y, Tanabe M, Takahashi S. Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer. Case Rep Oncol. 2013; 6(1): 50-54. doi: 10.1159/000346839
9. Nishimura S, Tanabe M, Morizono H, et al. Clear cell sarcoma of the neck which metastasized to the mammary gland. Case Rep Oncol. 2013; 6(1): 55-61. doi: 10.1159/000345843
10. Uehiro N, Horii R, Iwase T, et al. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer. Breast Cancer. 2014; 21(6): 748-753. doi: 10.1007/s12282-013-0453-7
11. Ishitobi M, Okumura Y, Arima N, et al. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. Ann Surg Oncol. 2013; 20(6): 1886-1892. doi: 10.1245/s10434-012-2825-1.
12. Ito S, Nakamura S, Kimura S, et al. Epigenetic Silencing of Core Histone Genes by HERS in Drosophila. WI Cell. 2012; 45(4): 494-504. doi: 10.1016/j.molcel.2011.12.02
13. Sawatsubashi S, Murata T, Lim J, et al. A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev. 2010; 24(2): 159-170. doi: 10.1101/gad.185741
14. Nakamura S, Ito S, Sawatsubashi S, et al. BTB protein, dKLHL18/CG3571, serves as an adaptor subunit for a dCul3 ubiquitin ligase complex. Genes Cells. 2009; 14(8): 965-973. doi: 10.1111/j.1365-2443.2009.01323.x
15. Suzuki E, Zhao Y, Ito S, et al. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neu rotoxi city. Proc Natl Aced Sci USA. 2009; 106(143): 818-822. doi: 10.1073/pnas.0809819106
16. Tanabe M, Ito Y, Tokudome N, et al. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer. 2009; 16(4): 301-306. doi: 10.1007/s12282-009-0093-0
17. Zhao Y, Takeyama K, Sawatsubashi S, et al. Corepressive action of CBP on androgen receptor transactivation in pericentric heterochromatin in a Drosophila experimental model system. Mal Cell Biol. 2009; 29(4): 1017-1034. doi:
18. Murata T, Suzuki E, Ito S, et al. RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila. Biosci Biotechnol Biochem. 2008; 72(9): 2255-2261.
19. Kimura S, Sawatsubashi S, lto S, et al. Drosophila arginine methyltransferase 1 (DART1) is an ecdysone receptor co-repressor. Biochem Biophys Res Commun. 2008; 371(4): 889-893. doi: 10.1016/j.bbrc.2008.05.00
20. Tokudome N, Sakamoto G, Sakai T, et al. A case of carcinosarcoma of the breast. Breast Cancer. 2005; 12(2): 149-153.
21. Yoshimoto M, Tada K, Hori H, et al .Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001--an institutional review. Jpn J Clin Oncol. 2004; 34(8): 457-462.
22. Tamura M, Tada T, Tsuji H, et al. Clinical study on the metastasis to the eyes from breast cancer. Breast Cancer. 2004; 11(1): 65-68.

Sandeep Kumar Kar, MD

Assistant Professor
Department of Cardiac Anaesthesiology
Institute of Postgraduate Medical Education and Research (IPGMER)
Kolkata, West Bengal 700020, India

BiographyResearch InterestScientific ActivitiesPublications

Dr. Kar is presently working as Assistant Professor, Super Specialty Department of Cardiac Anaesthesiology, Institute of Postgraduate Medical Education and Research, Kolkata, India. He has represented India in several world congresses in Anaesthesiology and Critical Care. He has published more than eighty research articles and reviews in high impact international journals including Anaesthesiology (Journal of American Society of Anaesthesiology). He is in the Editorial board of several journals and Editor of Translational Biomedicine, Journal of drug designing, Journal of Bioequivalence and Bioavailability, Journal of Bioanalysis and Medicine, World journal of pharmaceutical Sciences, EJPMR journal and Experimental Cardiology Insight of Blood Pressure, Journal of Neurosurgery, and Interventional Cardiology. He is also a Poet and Writer of international repute with poetry published in several international Journals.

His research interests include: Cardiopulmonary bypass, Heart failure, Anaesthetics, Cardiac surgery, Anaesthesiology, Critical appraisal of research, Poetry writing, Anesthesiology, Pain, Fictional works, Percussionist, Music therapist, Cardiac anesthesiology, Crirical care, Neuro anesthesiology, Literature, Writing, Anesthesia, Echocardiography, Arrhythmias, Pain measurement, Catheter ablation, Valvular heart disease, Cardiovascular system, Cardiothoracic surgery, Pain perception, Critical care, Pain management, Critical care medicine, Atrial fibrillation, Acute pain, Cardiovascular, Bronchiectasis, Ventilation, ICU, Cardiology, Intensive care medicine, Pharmacology, Pain Research, Pain medicine, Cardiac arrhythmias, Pain assessment, General anesthesia and Cardiac function.


• (May 2014) Elected as Executive Committee member in WBACTA for 2 years
• (Apr 2013) Scholarship: ESOP scholarship to attend NWAC world anesthesia Convention Bangkok 2013
• (Apr 2013) EACCME 24 credit points to provide SME to medical specialists
• (Jun 2012) Scholarship: B Braun Scholar of the year scholarship 2012
• (Apr 2011) EACCME Awarded 30 credit points for providing CME to medical specialists in NWAC world congress 2011 Rome Italy
• (Feb 2011) Janak Mehta National Award
• (Feb 2011) Janak Mehta National Award For Best Paper In Cardiac Anaesthesia
• (Feb 2011) Best Poster Award In Cardiac Anaesthesia IACTA 2011


• ISA, Indian Society of Anesthesiologists
• IACTA, Indian Association of Cardiothoracic and Vascular Anaesthesiologist
• IARS, International Anesthesia Research Society
• Poetry Society India
• Poem Hunter
• Red Room
• Poetry.com
• Konark Natya Mandap


1. Kar SK, Das A, Choudhuri R, Mayur N. Association between churg strauss syndrome and vitamin d deficiency: A myth or truth? A rare case report. Journal of Anesthesia and Clinical Research. 2016; 7(5): 1-3. doi: 10.4172/2155-6148.1000625
2. Kar SK, Ganguly T, Dasgupta S. Variability of presentation and surgical approach in patients with congenital cystic adenomatoid malformation: Report of two cases. Journal of Bioanalysis and Biomedicine. 2016; 8(3): 134-140.
3. Mitra M, Basu D, Ganguly T, Kar SK, Chaterjee S. Comparison of the hemodynamic alterations in normotensive and preeclamptic pregnant woman posted for cesarean section under subarachnoid block. Cardiovasc Dis Diagn. 2016; 4: 242. doi: 10.4172/2329-9517.1000242
4. Kar SK, Dipanwita Das, Dasgupta CS. Post balloon stent right coronary artery aneurysm: cardiologists nightmare. J Cardiovasc Dis Diagn. 2016; S1: 002. doi: 10.4172/2329-9517.S1-002
5. Kar SK. Post-operative delirium after cardiac surgery: Can it be prevented? Journal of Epilepsy. 2016; 2(2).
6. Ganguly T, Kar SK, Bhattacharyya R, Mitra M, Kamat SS, Goswami A. Peripheral Nerve Sheath Tumour of Neck: A Rare Presentation. Journal of Molecular Biomarkers & Diagnosis. 2016; 7: 3.
7. Mitra M, Abhishek Nag, Ganguly T, Kar SK, Lahiri S. Quality of laryngoscopic view and rapidity of development of intubating conditions after atracurium, vecuronium and rocuronium: A randomized controlled study. Journal of Bioequivalence & Bioavailability. 2016; 8( 3): 128-133.
8. Kar SK. Atrial Fibrillation: Paradigm Shift in Concept Leading to Change in Treatment Strategies in the Developing World. Anatomy & Physiology: Current Research. 2016; 6: 212.
9. Kar SK. The Human Microbiome Concept of Disease Prevention and Treatment. A Giant Leap in Medical Genetics. 2016; 5: e114.
10. Kar SK, Deepanwita Das, Dasgupta CS. Complication of Coronary Angioplasty; leading to Surgical Emergency: A Case Report. International Cardiovascular Research Journal. 2016; 5( 2): 1-4.
11. Kar SK. Social Conditions and Compromises done by Anesthesiologists in India. Diversity and Equality in Health and Care. 2016; 13(2): 206.
12. Kar SK. Faecal Incontinence in Gullain-Barre Syndrome with Bulbar Palsy-A Case Report with Review of Literature. Journal of Clinical and Experimental Cardiology. 2016; 7(2): 1-4.
13. Kar SK. The Analgesic Efficacy of Preoperative Lornoxicam in Prevention of Postoperative Pain after Septoplasty. Journal of Neurophysiology. 2016; 7(1): 1-5.
14. Kar SK. Current Trends in Preliminary Cerebral Protection after Traumatic Brain Injury. Neurosurg. 2016, 2: 1. doi: http://neurosurgery.imedpub.com/current-trends-in-preliminary-cerebral-protection-after-traumatic-brain-injury.php?aid=8367
15. Kar SK. Challenges of Percutaneous Balloon Mitral Valvuloplasty in Paediatric Patients with Mitral Stenosis: A Case Report. Translational Biomedicine. 2016; 7(1): 42. doi: http://www.transbiomedicine.com/translational-biomedicine/challenges-of-percutaneous-balloon-mitral-valvuloplasty-in-paediatric-patients-with-rheumatic-mitral-stenosis-a-case-report.php?aid=8543
16. Kar SK, Ganguly T, Dasgupta S, Mitra M, Bhattacharya R. Pericardial Cyst: A Review of Historical Perspecive and Current Concept of Diagnosis and Management. Interventional Cardiology. 2015; 1( 8): 1-8. doi: http://interventional-cardiology.imedpub.com/pericardial-cyst-a-review-of-historical-perspective-and-current-concept-of-diagnosis-and-management.php?aid=8111
17. Kar SK, dipanwita das, Dasgupta CS. Recurrent Fibrosarcoma Protuberans of Anterior Chest and Abdominal Wall. A Rare Case Report. Archives of Medicine. 2015; 8(1): 1-6. doi: http://www.archivesofmedicine.com/medicine/recurrent-fibrosarcoma-protuberans-of-anterior-chest-and-abdominal-wall-a-rare-case-report.pdf
18. Kar SK, Ganguly T, Dasgupta CS, Goswami A. Preoperaive Anxiety in Pediatric Populaion: Anesthesiologist"s Nightmare. Translational Biomedicine. 2015; 6(4): 30. doi: http://www.transbiomedicine.com/translational-biomedicine/preoperative-anxiety-in-pediatric-populationanesthesiologists-nightmare.php?aid=8003
19. Kar SK. Translaional Biomedicine: The Future of Modern Internal Medicine. Translational Biomedicine. 2015; 6(4): 36. doi: http://www.transbiomedicine.com/translational-biomedicine/translational-biomedicine-the-future-of-modern-internal-medicine.php?aid=8009
20. Kar SK, Choudhuri R, Adhikari D, Nandi G, Basu R. Atypical Associaion of Japanese Encephaliis with Sixth and Seventh Cranial Nerve Palsy during Outbreaks: Does it Require a Second Thought? A Case Report. Translational Biomedicine. 2015; 6(4): 1-4. doi: http://www.transbiomedicine.com/translational-biomedicine/atypical-association-of-japanese-encephalitis-with-sixth-and-seventh-cranial-nerve-palsy-during-outbreaks--does-it-require-a-secon.pdf
21. Kar SK, Chakraborty B, Ghosh S, Sarkar M, Ray R. HIV in Intensive Care Unit: Concerns and Constraints of Intensivists. Transl Biomed. 2015; 6(4): 1-6. doi: 10.21767/2172-0479.100028
22. Kar SK, Das D, Dasgupta CS, Bhattacharya R, Munsi A. Inhalation of Pin: A Rare Case Report. Annals of Clinical and Laboratory Research. 2015; 1(1): 22-26.
23. Kar SK, Ganguly T, SenDasgupta C, Khurana HS. Cardiovascular consideration of bilateral carotid body tumour: A rare case report. International Archives of Medicine. 2015; 8(227): 1-6.
24. Kar SK, Ganguly T, Dutta S. Incidental Diagnosis of a Giant Pericardial Cyst and Surgical Management: a Rare Case Report. International Archives of Medicine. 2015; 8(198): 1-7.
25. Banerjee A, Kar SK, Dasgupta CS, Goswami A. Renal Cell Carcinoma Extending through Inferior Vena Cava into Right Atrium Removed with Cardiopulmonary Bypass Support. Archives of Medicine. 2015; 7(3:2): 1-4.
26. Kar SK, Ganguly T, Nayek J. Robotic Cardiac Surgery: A Systematic Review of the Past and Present. Prensa médica argentina. 2015; 101(6): 1-6.
27. Kar SK, Ganguly T, Nayek J. La Prensa Medica Argentina. Prensa médica argentina. 2015; 101(6): 1-5.
28. Kar SK. Laparoscopic bilateral adrenalectomy in a patient of cushing disease due to pituitary microadenoma: A challenge for the anaesthesiologist. Prensa médica argentina. 2015; 101( 6): 1-4.
29. Kar SK, Ganguly T, Dasgupta CS, Bhattacharya C, Mitra M. Thoracic Gunshot Wound: A Report of 3 Cases and Review of Management. Prensa médica argentin. 2015; 101(6): 1-5.
30. Choudhuri R, Kar SK, Samui S, Mayur N. Perioperative Management of a Child having Ovarian Dysgerminoma with Para Neoplastic Syndrome: Case Report of Stormy Events. Prensa médica argentina. 2015; 101(6): 1-3.
31. Kar SK, Mitra M, Ganguly T, Gupta CS, Sarkar M, Goswami A. Hereditary Hemorrhagic Telangiectasia: Presening with Epistaxis. Journal of Universal Surgery. 2016.
32. Kar SK, Ganguly T, Sendasgupta C, Goswami A, Bhattacharya C. Comparison of Postoperative Analgesia in Thoracotomy versus paravertebral block Patients by Thoracic Epidural versus Paravertebral Block with Ropivacaine and Clonidine. Journal of Universal Surgery. 2016. doi: http://www.jusurgery.com/universalsurgery/comparison-of-postoperativeanalgesia-in-thoracotomypatients-by-thoracic-epiduralversus-paravertebral-block-withropivacaine-and-clonidine.php?aid=6025
33. Kar SK, Ganguly T. Postoperative Pneumoscrotum in a Cardiac Surgery Patient: A Case Report. Prensa médica argentina. 2015; 101(6): 1-5.
34. Kar SK, Ganguly T, Dasgupta C, Goswami A. Surgical Management of Congenital Cysic Adenomatoid Malformaion in a 2 Month Old Paient: A Case Report. Archives of Medicine. 2015; 7(1:5): 1-4. doi: http://www.archivesofmedicine.com/medicine/surgical-management-of-congenital-cystic-adenomatoidmalformation-in-a-2-month-old-patient-a-case-report.pdf
35. Kar SK, Ganguly T, Dasgupta CS, Goswami A. Comparison of Low Venilaion, No Venilaion and Coninuous Posiive Pressure Venilaion as Pulmonary Protecion Strategy during Cardiopulmonary Bypass. Archives of Medicine. 2015; 7(1:2). doi: http://www.archivesofmedicine.com/medicine/comparison-of-low-ventilationno-ventilation-and-continuous-positive-pressure-ventilation-as-pulmonary-protection-strategy-during-cardiopulmonary-bypass.pdf
36. Ganguly T, Kar SK, Dasgupta CS, Goswami A. Surgical Management of Congenital Cystic Adenomatoid Malformation in a 2 Month Old Patient: A Case Report. Archives of Medicine. 2015; 7(1): 1-4.
37. Choudhuri R, Kar SK, Adhikari D, Dasgupta CS, Saha A. Can undiagnosed Parkinsons disease become uncovered in perioperative phase? A case report of stormy postoperative event. International Publisher of Science, Technology and Medicine. 2014; 100: 3. doi: 10.4172/lpma.1000129
38. Kar SK, Ganguly T, Santa Saha Roy, Goswami A. Effect of Indian Classical Music (Raga Therapy) on Fentanyl, Vecuronium, Propofol Requirements and Cortisol levels in Cardiopulmonary Bypass. J Anesth Crit Care Open Access. 2015; 2(2): 00047. doi: 10.15406/jaccoa.2015.02.00047
39. Kar SK. Cardiovascular and Airway Considerations in Mediastinal Mass during Thoracic Surgery. Experimental and clinical cardiology. 2014; 5(12): 1-8.
40. Ganguly T, Kar SK, Dasgupta CS, Goswami A, Mandal A. Penetrating Arrow Wound of the Chest -A Case Report. Del Med J. 1972; 44(1): 7.
41. Kar SK. Comparison of the additive effects of intravenous methyl prednisolone with that of intravenous pentoxyfylline on low tidal normal frequency ventilation as a lung protection strategy during cardiopulmonary bypass that improves immediate postoperative outcome. Journal of Cardiology & Current Research. 2014; 1: 6. doi: http://medcraveonline.com/JCCR/JCCR-01-00034.pdf
42. Kar SK, Rajat C, Chaitali SD, Dhiman A, Tanmoy G. Influence of Speed of Fentanyl Citrate Injection before Induction of Anesthesia on Fentanyl-Induced Cough: A Prospective, Randomized, Double Blinded Study. Prensa Med Argent. 2014; 100( 4): 1-5. doi: 10.4172/lpma.1000141
43. Kar SK, Chowdhury R, Adhikari D. Thyrotoxic Periodic Paralysis: A Case Report and Review of Literature.
44. Kar SK, Kar R, Choudhuri D, Adhikari A, Kar M. Acute Necrotising Pneumonia with Bronchiectatic Changes and Transaminitis following Kerosene Ingestion: An Unusual Acute Presentation. Prensa Med Argent. 2014; 100(4): 1-4.
45. Kar SK. Fat Embolism Syndrome and Role of Immunomodulation: A Case Report. Experimental and Clinical Cardiology. 2014; 5(8): 1-4.
46. Kar SK. A Discussion about Modalities of Smoking Cessation in Perioperative Phase for Addicts.
47. Choudhuri R, Kar SK, Adhikari D, Dasgupta CS, Som A. Effect of paracetamol intravenous infusion on duration and quality of spinal blockade in patients undergoing major gynaecological surgeries: A prospective, randomised, double-blinded, placebo-controlled study. La Prensa Medica. Prensa Med Argent. 2014; 100: 3.
48. Kar SK. Unusual Variant of Guillain-Barré Syndrome Following Hepato-biliary Surgery- A Rare Case Report. Journal of Case Reports and Studies. 2014; 2: 5.
49. Kar SK. Can Undiagnosed Parkinsons Disease become Uncovered in Perioperative Phase? A Case Report of Stormy Postoperative Event. Prensa médica argentina. 2014; 100(3): 5.
50. Kar SK. Anaesthetic Management of a Dwarf with Hypopituitarism Presenting for Epigastric Hernioplasty. J Metabolic Synd. 2014, 3: 154.
51. Kar SK. Epilepsy Treatment in Developing Countries: Constraints and Possibilities Editorial. Neurorehabilitation. 2014; 3(2).
52. Kumar Kar S, Choudhuri R, Bhunia P, Chakrabarti S, Santra S: Recurrent Hypoglycaemia in a Case of Phyllodes Tumour of the Breast: A Rare Case Report. Carcinogenesis. 2014; 7( 2): 1-4.
53. Dasgupta CS, Kar SK, Goswami A, Dutta S, Sarkar UN. Effect of low ventilation during cardiopulmonary bypass on oxygenation and postoperative pulmonary outcome. Indian Journal of Thoracic and Cardiovascular Surgery. 2013; 28(4).
54. Kar SK. Cardiac Anesthesiologist. Anesthesiology. 2012; 117(2): 420-421.
55. Kar SK. Comparison of low ventilation, no ventilation and continuous positive airway pressure during cardiopulmonary bypass on immediate postoperative outcome.
56. Kar SK, Dasgupta CS, Goswami A. Effect of prophylactic amiodarone in patients with rheumatic valve disease undergoing valve replacement surgery. Annals of Cardiac Anaesthesia. 2011; 14(3): 176-182.


1. Kar SK, Ganguly T, Dasgupta CS. Epidural and Paravertebral Block in Thoracotomy as Multimodal Analgesia. Saarbrücken, Germany: Lambert Academic Publishing; 2015.
2. Kar SK, Majhi B. Cardiology of Systemic Sclerosis With Pulmonry Hypertension. Saarbrücken, Germany: Lambert Academic Publishing; 2015.
3. Kar SK, Dasgupta CS, Goswami A. Amiodarone in Rheumatic Valve Disease Undergoing Valve replacement. Saarbrücken, Germany: Lambert Academic Publishing; 2013.

Dilyara Kaidarova, MD

Kazakh Institute of Oncology and Radiology
Abay ave. 91, 050022
Almaty, Kazakhstan

BiographyResearch InterestScientific ActivitiesPublications

(1984-1990) Alma-ata State Medical Institute (ASMI), medical business
(1990-1992) Residency in Obstetrics and Gynecology, ASMI
(2008-2010) Kazakh University “Alatau”, Bachelor of Economics

• (1992-1999) Oncologist,gynecological department, City Oncology Center(COC), Almaty city
• (1999-2006) Head of the gynecological department, COC, Almaty city • (2006-2016) Head of Almaty Cancer Center
• (2006-Present) Mainoncologist,Health Department of Almaty
• (2013-Present) Professor, Department of Oncology of the Kazakh National Medical University (KazNMU)
• (2009-Present) Member of the European Association of Gynaecologists (ESGO)
• (2009-Present) Member of the International Society of GynecologicalCancer, UICC
• (2010-Present) Member of the American Society of ClinicalOncology, ASCO
• (2013-Present) The head of the International community clinical studies on gastric cancer and breast cancer
• (2016) Memberof the dissertationcouncil at KazNMU, Ministry of Health and Social Development of the Republic of Kazakhstan,on specialty: Oncology
• (2016) Director, Kazakh Institute of Oncology and Radiology

More than 80 publications on cancer, including 5 articles in scientific journals with IMPACT-factor, andarticlespublished in LANCET(Challenges to effective cancer control in China, India, and Russia)andSPRINGER(Screening the APC, MLH1, MSH2 and TP53 Mutations in Patients with Early Onset of Colorectal Cancer;K-ras codon 12 and not TP53 mutations are predominant in advanced colorectal cancers; G39179T DNMT3B Gene Variants in Relation to Colorectal Cancer Risk in Kazakhstan Population)